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SUMMARY.
The clinical value of high sensitivity assay methods for determining 
the levels of therapeutic drugs in biological fluids is now widely accepted 
both for monitoring treatment and for accurate pharmacokinetic studies. 
Radioimmunoassay has recently been applied to this area of clinical 
biochemistry.
This thesis describes the development of radioimmunoassays for 
phenytoin and etorphine and discusses problems encountered in the 
developmental work of an assay for sulthiame. It also examines some of the 
critical factors in antibody and label production in general.
A sensitive and specific radioimmunoassay for phenytoin has been 
developed and can be used to determine the amount of drug in micro-samples 
of blood. Sufficient serum for this assay can be collected from a finger- 
prick, an important factor when the patient is an infant epileptic or if 
vene-puncture is difficult. The radioimmunoassay has been applied to the 
study of the disappearance of phenytoin-from the blood of volunteers 
following a single oral dose, and has shown pharmacokinetic phenomena that 
have been undetected by other workers using less sensitive methods.
Although the development of a radioimmunoassay for sulthiame was 
unsuccessful, it has exemplified many of the problems encountered in the 
raising of antibodies to, and the radioactive labelling of, small molecules.
Using a morphine radioimmunoassay as a model, factors affecting the
for increasing the immunogenicity of the drug-carrier conjugates and for 
influencing the specificity of the resulting antibodies. These principles 
have been applied to the development of a radioimmunoassay for etorphine 
to produce the first method for measuring the low levels of this drug 
present in biological fluids.
A high specific activity radioactive label is essential for the
development of a sensitive assay. For many drugs this can only be achieved
3effectively by using a H- label; radioiodine, the other isotope frequently 
used in radioiminunoassays has not proved suitable for labelling these small 
compounds.
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NUN-STANDARD ABBHCJVlATIOWb
BSA Bovine Serum Albumin.
CMC 1-cyclohexyl-3-(2-morpholynoethyl)carbodiimide metho-p-toluene
DCC Dextran-Coated Charcoal. /sulphonate.
DHM Dihydro-morphine.
DPH Diphenylhydantoin (phenytoin).
EDC 1-ethyl-3-(3-<iiniethylaminopropyl)carbodiimide hydrochloride,
Et Etorphine.
Et-HS Etorphine hemisuccinate.
ppp Factor VIII-.Fibrinogen-Free plasma
GLC Gas-Liquid Chromatography.
Glut. Glutaraldehyde (&).
HFHS 3-(p-hydroxyphenyl)propionic acid N-hydroxysuecinimide seter.
HPHi p -hy dr oxypheny 1-ph e nylhy dant o in.
id. intra-dermal.
im.. ‘ intra-muscular.
I.R. Infra-red.
Man Mannich reaction (Mann)
MB Maximum binding (bound)
MBS A Methylated Bovine Serum Albumin.
NM Normorphine.
NSB Non-Specific Binding (bound).
PBSG Phosphate-Buffered Saline with 1 % Gelatin.
S Sulthiame.
sc, sub-cutaneous.
Sulph Sulphanilamide.
TLC Thin-Layer Chromatography. %
TMAH Tetramethylammonium hydfoxide.
©.IE Tyrosine Methyl Ester.
TMPAH Trimethyl-phenyl ammonium hydroxide.
U.V. Ultra-violet.
ANIMAL CODE AND ABBREVIATIONS.
D Dutch rabbit.
G Goat.
NZW New Zealand White rabbit.
R Rabbit.
S Sheep.
Code; G/S/3-Vc means that the animal, a sheep (s) is housed in Guildford 
and is sheep number 3» The roman numeral indicates the number of
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booster immunisations, in this case the fifth, and the letter the bleed 
after the the booster, here it is bleed"c"- the third serum sample collected 
following boost V and before boost yi.
STANDARD ABBREVIATIONS.
cm centimetre,
d days.
g grams (also mg, jxg, ng, pg).
h hours.
L litres.
M Moles, (also mole).
m milli-.
n nano-,
nm nanometer,
p pico-.
sec seconds.
S.E. of mean Standard Error of mean, 
u micro,
y years.
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INTRODUCTION.
The value of precise, sensitive and specific methods for measuring 
the concentrations of drugs in blood and other tissues for
a) research into distribution, metabolism and pharmacokinetics,
b) monitoring treatment,
has been discussed by Marks, Lindup and Baylis (1973^ Blood level determ­
inations can be used to delineate the distribution of a drug in the body, 
certain areas acting as reservoirs because of selective accumulation of the 
drug. In such cases the drug is in a state of equilibrium between the 
plasma and these storage sites, and as a result may not reach its 
therapeutic level until these sites are filled. Alternatively, the 
therapeutic effect may be prolonged once the reservoirs are filled. Many of 
the methods developed for blood level determinations are also applicable to 
other tissues after minor alterations in the extraction procedures.
The number of drugs available, uncertainties about their mode of 
action, and the success or failure of a particular therapeutic trial have 
provided the impetus for the continuing development of quantitative assay 
techniques. The value of blood level determinations in the monitoring of 
therapy has been clearly demonstrated by Buchthal and Svensmark (1959), Kutt, 
Winters, Kokenge and McDowell and Lund, Jorgensen and Kuhl (1964),
in cases of patients developing signs of intoxication when on multiple 
drugs/or totally failing-to respond to normally therapeutic doses ,of the 
drugs. ‘
3
stressed the importance of the possible effects of one drug on the 
metabolism of another. Conney stated that the nature and extent of these 
interactions must be defined and that plasma determinations would help to 
define them. "It is important, and I think probable, that routine methods 
for the rapid, analysis if drug levels in a drop of blood will be developed” 
Conney concluded. Indeed the biochemical monitoring of anticonvulsant 
therapy is regarded as routine in the clinical management of patients with 
epilepsy.
The classical analytical methods are not sensitive enough to permit 
accurate measurements to be made under clinical conditions. In addition 
the techniques are often time consuming, employing long extraction 
procedures, and may require relatively large volumes of serum or plasma. A 
suitable assay method would be one that was both sensitive and rapid 
while being reliable, specific, capable of being carried out on a small 
amount of blood, with the possibility of being automated for the handling 
of large numbers of samples. Radioimmunoassay represents such a technique 
-and since its introduction, has made a vast impact in areas of medicine 
in which the accurate measurement of small concentrations of biologically 
potent compounds is vital. The method has already been applied to a great 
many substances as is indicated in fig. 1.1.
This thesis describes the development of a radioimmunoassay for 
the anticonvulsant drug phenytoin for use in clinical studies on its 
pharmacokinetics, and for routine laboratory use in the monitoring of 
blood levels of patients receiving this drug. The problems encountered in
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HORMONES SUBSTANCES ■
Pituitary hormones Steroids Drugs
G-rowth hormone Aldosterone Digoxin
Adrenocorticotrophic Testosterone Digitoxin
hormone (ACTH) Dihydrotestosterone Morphine
Glycoproteins Estradiol LSD
Thyroid stimulating Estrone Barbiturates
hormone (TSH.) Estriol ' Cyclic nucleotides
Follicle stimulating 2-Hydroxyestrone cAMP
hormone (FSH) Medroxyproges terone cGMP
Luteinising hormone{n) 17-Hydro:yprogest- cBIP
Prolactin erone cUMP
Lipotropin (LEH) Pros taglandins Enzymes
Vasopressin Thyroidal hoimones C-j esterase
Oxytocin Triiodothyronine Fructose-1,6-diphosphs-
Chorionic hormones Thyroxine tase
HCG Virus
HC3 Australia antigen
Pancreatic hormones Tumour antigens
Insulin ■ Carcinoembryonic antigen
Proinsulin ©<-fetoprotein
C-peptide Serum proteins
Glucagon Thyroxin binding globulin
Calcitropic hormones IgG, IgE
Parathyroid hormone Properdin
Calcitonin Anti-Rh antibodies
Gastrointestinal hormones Others
Gastrin Intrinsic factor
Secretin Rheumatoid factor
Enteroglucagon Folic acid
Vasoactive tissue hormones * Neurophysin
Angiotensins Staphylococcal
Bradykinins 
Hypothalamic releasing
ft-Enterotoxin
factors 
Thyrotropin releasing 
factor (TRF)
Fig 1.1 : Some of the substances for which radioimmunoassaysi^ave been 
developed.
(from Radioimmunoassay Methodology, Yalow,R.S. (1973) Pharmacol. 
Rev. 2£; 161).
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label for a radioimmunoassay for sulthiame are also presented and 
discussed. Some of the factors influencing the immunogenicity of drug 
molecules are examined using morphine as a model. The conclusions drawn 
from this study are then applied to the development of a radioimmunoassay 
for etorphine, a powerful analgesic drug.
1a. Phenytoin.
Phenytoin (diphenylhydantoin, DPH) was first synthesised in 1908 by 
Biltz, screened for hypnotic effect at the Parke-Davis laboratories and 
then examined for toxicity by G-ruhzit (1939). Merritt and Putnam (l938a) 
tested the efficacy of the drug against electroshock induced seizures in 
cats and found its activity to be surprisingly high. The first trials in 
humans demonstrated the anticonvulsant activity of phenytoin (Merritt and 
Putnam, 1938h). Today phenytoin is probably the drug of choice in the 
treatment of most forms of epilepsy, with the exception of petit mal. The 
mode of action of the drug appears to be by virtue of its ability to 
stabilise the excitable cellular membranes. The rapid absorption of the 
drug is limited by its low solubility in gastrointestinal fluids. In the 
blood phenytoin becomes readily bound to the serum proteins, but the free 
form soon enters the tissues, including the brain, where it becomes 
firmly bound , probably to the nucleoproteins. Phenytoin is metabolised 
in the liver, mainly to a para-hydroxylated derivative 5-(p-hydroxyphenyl) 
-5-phehylhydantoin (HPPH), and is excreted in the urine as a conjugate with 
glucuronic acid (Parsonage, 1973). A me ta-hydroxy la ted derivative is known
6
1970) but has not been fo\jnd in man. 
i. Chemistry.
-C -
c = o
Fig. 1.2 : Molecular structure of phenytoin.
Phenytoin (5,5-&iphenylhydantoin)(M.W. = 252*26, m.p. = 295*-298°C) 
is a weak acid with reported pKa values of 8*3-9*2 (Agarwal & Blake, 1968; 
Dill, Kazenko, Wolf & G-lazko, 195&)* Phenytoin is poorly soluble in water 
but dissolves readily in alkaline solutions. Solubility studies indicate 
that the apparent solubility in blood plasma is approximately 75pg/nil at 
37°C, due to the protein binding of excess drug (l2*pg/ral in aqueous solutions 
at pH 1-7 (Dill et al., 1956)).
Structurally the phenytoin molecule appears to be quite rigid, 
having the molecular configuration indicated in fig.1.2. It is the sodium 
salt of phenytoin that is most commonly used, leading to activation of a 
nitrogen atom when in alkaline solutions (fig.1.3).
7
C— ONa. kC=0
Fig. 1*3 • Dissociation of phenytoin sodium.
1b. Sulthiame.
Sulthiame is the most potent analogue of a series of N-aryl-butane- 
sultams synthesised, by Helferich and Kleb in 1260, and is now produced 
commercially by Bayer Pharmaceuticals as Ospolot* It has been 
.widely used in the treatment of temp oral lobe epilepsy, and is also of 
value in case's of grand mal and critical seizures other than those of 
temporal lobe origin, particularly when these occur in children (Bray & 
Bower, 1963). The use of sulthiame tends to be associated with a rather 
high incidence of dose-dependent side effects such as head-ache, paraes- 
thesia and hyperprioea. Hence , there is a tendency to combine its use in 
comparatively low dosage with that of other anticonvulsants,in 
intractable cases (Parsonage, 1973)•
Sulthiame acts as a powerful inhibitor of carbonic anhydrase, 
blocking both brain and erythrocytic forms. However, a dose which blocks 
12$  of the red blood cell enzyme will block of the cerebral enzyme 
(Green & Kupferberg, 1972). The erythrocytes appear to accumulate the 
drug preferentially, with less accumulation in the liver, kidney and bone 
marro?/. The brain levels of sulthiame in rats are equivalent to those
to parallel the time course of the protection afforded against maximal electro­
shock induced seizures (Nishimura,1963).
When used in conjunction with phenytoin, Houghton and Richens (1974) 
concluded that sulthiame inhibits the para-hydroxylation of phenytoin, so 
increasing the serum concentration, a view previously held by Hansen, Kristen- 
sen and Skovsted (1968). Olsen and Jensen (19&9) suggetsed that the increased 
phenytoin levels may be due to the sulthiame being adsorbed to the erythrocytes 
in preference to phenytoin. In experiments in dogs, the half-life of intra­
venous .phenytoin was found to be doubled by pretreatment with sulthiame 
(G-reen & Kupferberg, 1972) and it was suggested that this may be due to the 
reduced rate of metabolism and increased serum levels.
Duhm, Maul, Medenwald, Patzschke and Weger (19^3) have shown that 
sulthiame is readily absorbed from the rat gastrointestinal tract, and it 
appears that both rats and humans metabolise the drug in the same way. The 
metabolite of suthiame has been identified as a hydroxylated form that does 
not have anticonvulsant activity (Duhm et al., 19^3)•
i. Chemistry.
M.W. = 290.4, and a structure (fig. 1.4) somewhat similar to that of 
sulphanilamide. The therapeutic index ( LD^/ ED^q) for sulthiame was found 
to be four or five times that of phenytoin.
Fig 1.4 : Molecular structure of sulthiame
Sulthiame is a white powdery substance with a m.p. = 185-188°C
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conformations. It seems likely that the preferred conformation would be 
one in which the two rings are in the same plane, although only the phenyl 
ring will present a planar structure, the other ring resonating between 
chair and boat conformations with the former being slightly more stable:-
S-
cf V0
H
H. Hv
Y  >A c\
Vo )
H
cx
V  ^*
Chair
V
H
•N
Boat
H'c C"H 
' \
V II II O
H ^
1H
0- iPc H
Morphine is found only in opium ?diere it occurs in amounts varying 
from 5. to 20p, It was the first plant base to be isolated, by Derosne in 
1803 an& its basic properties were discovered by Sertruner also in 1803 
(Soine & Willette, 1971)* The chemical formula of morphine was postulated 
by Gulland and Robinson (1925) but was not confirmed until 1952 by Gates 
and Tschudi (1952).
Morphine acts principally on the central nervous system where it is 
both a stimulant and a depressant. Clinically the latter is its most 
useful property, resulting in increased tolerance to pain, drowsiness, 
lessened perception of external stimuli and euphoria. Its major use is to 
control severe pain such as that caused by serious injury, neoplasms and 
migraine, but it is also often administered as a preoperative sedative 
together with atropine. In addition to its tendency to cause addiction, 
nausea and respiratory depression are the major side effects of the drug. 
The normal dose range by parenteral administration is 5 to 75mg/day, with 
an estimated minimum lethal dose of 200mg, although this may be higher in 
addicts and lower in infants.
Following parenteral administration morphine rapidly enters the 
blood stream and peak levels are reached after one hour (Clarke, i9^9)5 
gastrointestinal absorption however is poor. Unconjugated moiphine has 
been found in the blood of terminal cancer patients receiving therapeutic
f
doses as long as four hours after ah oral administraion (Aheme, Piall, 
Robinson, Morris & Marks, in press).
The major metabolic pathway of morphine is conjugation with
11
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ation and O-methylation may also occur to a small extent (Clarke, 19&9; 
B&rner & Abbott, 1973 )•
i. Chemistry,
CH
HO OH
Fig. 1.5 : Molecular structure of morphine.
Anhydrous morphine base (M.W. = 285*3; m*P* = 254*0°C) consists of 
short rhombic prisms. Structurally, morphine is a phenanthrene derivative 
(fig. 1.5) with a phenolic hydroxyl group at position 3, an alcoholic 
hydroxyl group at position 6 and a methyl group attached to the cyclic 
nitrogen atom of the piperidine ring. The anhydrous base is poorly soluble 
in water (1:5000 or 1:4Q0 in boiling water) and is only slightly more 
soluble in ethanol (1:250).
Morphine hydrochloride is prepared by neutralising a hot aqueous 
suspension of morphine with dilute hydrochloric acid and concentrating 
the resulting solution to crystallisation. This compound occurs as silky, 
white glistening needles or as a crystalline powder and is soluble in 
water (1:17*5 or 1:0*5 at boiling point). Aqueous solutions of this salt 
have a pH of approximately 4*7.
12
na. ja-corpnine,
Etorphine hydrochloride is one of a number of derivatives of 6,14-
endoethenotetrahydro-oripavine synthesised by Bentley and Hardy (1963) a^d
> '
reported by Lister (1964) to possess powerful narcotic properties, acting 
as a depressant on the respiratory centres in the brain. Y/hen given sub- 
cutaneously etorphine is 1000 to 80000 times more potent than morphine and 
its ability to cause catonia at very low dose levels has resulted in its 
use for the immobilisation of game animals (Blane, Boura, Fitzgerald & 
Lister, 1967). The drug was found to be a, clinically efficacious analgesic 
at doses of 1pg/Kg, having a rapid onset (less than ten minutes after intra­
muscular injection) and moderately short duration of action (approximately 
two hours).
In a pilot study on safety and efficacy, etorphine 7/as given intra­
muscularly to twenty-seven patients for relief of pain’ in terminal malignant 
disease (Blane & Robbie, 1970). From trials involving more than 5000 
subjects it has been shown that many patients were more satisfactorily 
stabilised during their last weeks on etorphine plus heroin than they had 
been on heroin alone (Jordan, personal communication). Since etorphine 
does not cause vomiting, it was especially useful in patients suffering from 
nausea or vomiting with their regular oral analgesic. The use of etorphine 
made it possible for these patients to be maintained on oral medication.
i. Chemistry.
Etorphine hydrochloride is a colourless white ciystalline powder 
with M.W, = 448*0 and m.p. = 266-267°C. It is slightly soluble in water at 
20°C and a little more soluble in 93/o ethanol. The molecular formula of
Fig. 1.6 : Molecular structure of etorphine.
1e. METHODS OF DETERMINATION.
A wide number of analytical procedure for the determination of anti­
convulsant drugs in biological fluids have been developed. Many of these 
techniques are applicable to the determination of the blood levels of other 
therapeutic drugs; the methods will be discussed with reference only to 
those used for the determination of phenytoin, sulthiame and etorphine.
Prior to the early 1940's, very few analytical procedures for drugs
in biological fluids were available. The advent of sulphonamides and the
development of the colorimetric procedure of Bratton and Marshall (1939)
for primary aromatic amines marked the start of a quantitative approach
to chemotherapy based on drug concentrations in the plasma and drug
elimination in the urina. Kozelka and Hine (1941) attempted to chlorinate
phenytoin quantitatively on the hydantion ring by traetment v/ith sodium
hypochlorite,removing the excess reagent, adding potassium iodide and titrating
14
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phenobarbital. The method also required large samples (Plaa & Hine, 1956), 
being useful only for milligram quantities of phenytoin, and it failed as 
a micromethod (Dill, Kazenko, Wolf & Glazko, 1956). Numerous other assay 
procedures for phenytoin have been devised, all based on the separation of 
phenytoin from phenobarbital by ion exchange chromatography or solvent 
extraction followed by non-aqueous titration or spectrophotometiy. The 
methods were all designed for the estimation.of milligram quantities of 
drug and so were not suitable for clinical applications.
i. Spectrophotometry.
The first published spectrophotometric determination of a hydantoin 
level was probably that of Butler (1933)» w^o determined the plasma level 
of 5-ethyl-9-phenylhydantoin. This was followed in 1956 by two reports, a 
spectrophotometric method by Plaa and Hine (1956) and a colorimetric method 
by Dill et al. (1956). The problem of interference from phenobarbital 
was recognised in both these methods but they have been criticised for 
their difficult and time consuming procedures (Svensmark ar^ d TCristensen,
1963; Wallace, Biggs & Dahl, 1965) - Plaa and Hine extracted plasma at 
pH 8*6 with a mixture of cyclohexane and n-butanol, and then washed the 
organic phase by shaking with hydrochloric acid to estimate phenobarbital. 
Svensmark and Kristensen (1963) stated that this method does not give 
complete separation. The phenytoin was finally transferred from the organic 
solvent to a carbonate buffer for measurement of the ultra-violet (U.V.) 
absorbance. The method of Dill et al. (1956) involved an initial extraction 
with chloroform from acidified plasma. The plasma was then subjected to the
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resulted in a more complete separation of phenytoin from phenobarbital and 
increased the specificity of the procedure. Subsequent to this step the 
Dill procedure involves quantitative nitration, reduction of the nitro- 
group with stannous chloride to give an aromatic amine, diazotisation and 
coupling with the Bratton-llarshall reagent to form a highly coloured azo- 
dye. Several slight modifications of this technique are being used by Dill, 
Baukema, Chang & Glazko (1971). This procedure has a high degree of 
specificity when the counter-current extraction step is employed 
(Kristensen, Hansen, Hansen & Lund, 1967), hut is time consuming.
Follovong these developments, various combinations and modifications 
of techniques were tried. Schiller and Buchthal (1958) combined the three- 
plate counter-current extraction of Dill et al. (195?) with the spectro­
photometric assay of Plaa and Hine (1956). This was further modified by 
Svensmark, Schiller and Buchthal (1960) to give simultaneous assays for 
phenytoin and phenobarbital, and later appeared as the procedure of 
Svensmark and Kristensen (i 9^3)• Olsen (1967a) has since suggested minor 
modifications to this method, and in 1968 described a spectrophotometric 
method for the estimation of sulthiame (Olsen, 1968). In this method 
sulthiame was initially separated from other anticonvulsants by thin- 
layer chromatography (TLC). The sulthiame spots were then located under a 
U.V. lamp, scraped off, extracted into methanol and the extinction 
measured against the corresponding blank at 243 and 280nm.
ii. Thin-Layer Chromatography.
Olsen (1965) described a phenytoin assay by TLC which was followed
16
by the formation of a yellow copper complex of piperidene and phenytoin. 
Huisman (1966) used the procedure of Dill et al. (1956) to nitrate a 
mixture of anticonvulsant drugs, which was then subjected to TLC in an 
isobutanol:chloroform:ammonia system. The spots, .visualised under U.V., 
were scraped off, the nitro compounds reduced to amines, diazotised and 
coupled with the Bratton-Karshall reagent for determination by colorimetry. 
Pippenger,Scott and Gillen (1969) described a semi-quantitative procedure 
based on the visual observation of the spots on a TLC plate. Vesdo, Rud 
and Place (19&9) also described a TLC procedure for the assay of both 
phenytoin and sulthiame involving the use of staining procedures to 
visualise the spot.
Simon, Jaylow, Seligson and Seligson (i 971) carried out most exacting 
TLC studies in which phenytoin was extracted from the plasma, concentrated 
by evaporation and then subjected to TLC on silica gel plates. After the 
phenytoin spot had been scraped off, the colorimetric procedure of Dill et 
al. (1956) was applied directly to the scrapings. Phenytoin levels of 
5Ms/m1 an& greater could be recognised by visual inspection of the plates 
under U.V., and serum levels of 1^ ig/ml detected by the colorimetric 
procedure. A comparison of gas-liquid chromatography (&LC) and TLC methods 
on the same specimens showed a good agreement and the recovery of phenytoin 
averaged 99-106^. The efficiency of this procedure as determined by isotope
17
dilution techniques using C-DPH was found to be 97/'°*
iii. Benzophenone-Extraction Procedure.
The approach of Wallace et al. (19&5) was based on the formation of 
benzophenone from phenytoin by heating with alkali, followed by treatment
17
benzophenone extracted from the distillate with organic solvent. This was 
followed by measurement of the U.V. absorption. The advantage of the 
'procedure is that phenobarbital and most other drugs do not interfere with 
the measurements and normal plasma blanks are low. The original procedure 
required large volumes of blood and a great many modifications have been 
made to provide a method that is suitable for clinical applications. In 
1966 Wallace modified the original procedure by using potassium permanganate 
for the oxidation step and refluxing with n-heptane during oxidation of the 
sample (Wallace,1968; 'Wallace, 1969). However, large volumes of blood plasma 
(5**10ml) were still required for these assays. Lee and Bass (1970) 
succeeded in scaling down the Wallace procedure by using 1-2ml of blood 
and steam distilling the benzophenone in a micro Kjeldahl apparatus. The 
sensitivity of the procedure was 1-^ig/ml with 2ml of plasma. Morselli (1970) 
also scaled down the Wallace procedure, using benzene for the extraction 
and eliminating the distillation step by refluxing with n-heptane during 
the oxidation step. With this modification it v?as possible to assay forty 
samples in four hours. The Wallace method has again been modified by Dill, 
Chucot, Chang and G-lazko (1971), by use of first ethylene dichloride and 
then iso-octane for the initial extraction.
iv. Fluorimetry.
Dill and G-lazko (1972.) modified the benzophenone extraction procedure 
by extracting the benzophenone with heptane and allowing this to react 
with concentrated sulphuric acid. Under these conditions fluorescence 
occurs and can be used for the measurement of phenytoin. The benzophenone
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procedure is nigniy specinc ror pnenycoxn, ana tnese autnors nave confirmed 
that neither phenobarbital nor HPPPI interfere with the fluorimetiy.
v. Gas-Liquid Chromatography,
Another major development in the assay of phenytoin involves the 
application of gas-liquid chromatography (GLC) to clinical samples.
Sandberg, Resnick and Bacallao (19&8) prepared a methylated derivative of 
phenytoin using diazomethane; hor/ever this presents an explosion hazard 
and is not suitable for routine use. Chang and G-lazko (1968; 1970) prepared 
a trimethylsilyl derivative of phenytoin which proved to be unstable in 
the presence of moisture. A p-tolyl analogue of phenytoin was developed 
as an internal marker for GLC assays by Chang and Glazko (1968), so 
eliminating the need for accurate volumetric measurements in the steps 
subsequent to the addition of the internal marker. The method was also 
found to be suitable for the assay of the 5-bydroxy metabolite of phenytoin.
Further improvement in GLC procedures came with the development of 
’on-column" methylation techniques. MacGee (1970) reported the ude of tetra- 
methyl-ammonium hydroxide ’(TMAH) asa methylating agent, using the internal 
marker of Chang and Glazko in the extracting solvent (toluene). The 
product measured was identified as 1,3-dime thyl-5,5-diphenylhydantoin. 
Kupferberg (1970) reported a similar procedure using trimethylanalinium 
hydroxide (triraethyl-phenylammonium hydroxide, TMPAH) as the methylating 
agent. TMPAH appears to be stable for methylating phenytoin quantitatively 
in a flash heater; it does not require anhydrous conditions and produces a 
lower GLC base-line than TMAH. Barratt (1971) combined the best features 
of a number of methods using chloroform, with the internal marker of
of the plasma, and TMPAH as the methylating agent.
Many of the more recent procedures involve the direct chromatography 
of phenytoin at higher temperatures without the use of derivative 
formation. Pippenger and Gillen (1969) achieved good separation and 
identification of phenytoin, mephenytoin, 5**©thyl-5-phenylliydantoin,pheno­
barbital and primidone using this technique. However, the peak heights were 
found not to be proportional to the concentration (Kupferberg, 1970).
Other procedures (Sabih & Sabih, 1969; Svenson, Jones and Darcey, 1970) 
lack a " clean-up! step to eliminate the plasma lipids which produce a high 
blank (Sampson, Harasymiv & Hensley, 1971) • This problem has been overcome 
by Papadopoulos, Baylis, Fry & Marks (1973) by the use of a carrier gas 
saturated with formic acid ( a method used by Ackman and Burgher (19^3) 
for the determination of fatty acids). Under these conditions no interfering 
lipid peaks are detected and the analysis time for a single sample is short 
(approximately one hour) although the column must be equilibrated overnight 
with formic acid vapour.
Friel, Green and Kupferberg (1972) tried three different techniques 
for the determination of sulthiame. These were a) the direct GLC of 
sulthiame in methanol, b) methylation of sulthiame with TMPAH, and
c) methylation with TMAH. The first and second alternatives proved unsucce­
ssful, and finally an adaptation of MacGee*s method, using TMAH both as an 
extraction medium and a methylating agent was employed. Friel and co­
workers also modified the technique further for the simultaneous 
determination of sulthiame and phenytoin levels.
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In general, the direct GLC methods without derivative formation tend 
to produce, assymetric peaks, which increase the difficulty of quantification 
by measurement of peak heights. The "on-column" methylation techniques 
appear just as convenient to use, with sharper peaks being obtained at 
lower temperatures, and many of the technical difficulties of GLC operation 
eliminated.
vi. Radioassay.
Radioassay is an in vivo method involving the administration of a 
radioactively labelled form of the drug, and has been used effectively to 
determine the drug binding in plasma, its distribution, metabolism and 
elimination. Because of the health hazards accompanying the use of radio­
activity, radioassay has been limited primarily to research in-animals.
1 h.
Firemark, Barlow & Roth (19&3) used diphenylhydantoin-2- C to investigate
the binding of the drug to plasma proteins, its distribution and its
metabolism. Duhm, Maul, Medenwald, Patzschke and Weger (19^3) developed a
radioassay technique for experimental investigations on sulthiame using 
35a S-labelled molecule. Blane and Dobbs carried out distribution
studies on etorphine using this technique and a tritium label prepared by 
Lane, McCoubrey and Peaker( 19^6).
1f. radioiieunoassay:
The term "radioimmunoassay was first introduced by Yalow and Berson 
(1959) to describe their assay for plasma insulin levels, using specific 
insulin antibodies as the main reagent. Ekins (i960) described an assay 
system for thyroxin based on identical principles but using the naturally 
occuring thyroxin^ binding globulin as a specific reagent. Ekins named his
meiaioa savaraxion anu-Lysis • xiie i'«JLav,xuii5xu.p ueween xxiwse ana uuxxex 
similar techniques is indicated in fig. 1.7*
The essential requirements for a radioimmunoassay include a radio- 
actively labelled antigen, a pure fora of the antigen,. a specific anti­
body, and a method for separating the antibody-bound from free antigen.
Radioimmunoassay exploits the ability of an unlabelled antigen to 
compete with a fixed amount of radioactively-labelled antigen for a limited 
number of specific antibody binding sites. Thus conditions are chosen such 
that there is a relative excess of antigen and as the amount of unlabelled 
antigen increases, the amount of labelled antigen bound (b ) to the anti­
body is reduced while the rest remains free (F) or unbound. Radioimmuno­
assays are based on the deteraination of the amount of labelled antigen 
present in the antibody, bound fraction and/or in the free fraction. The
reaction taking place can be represented mathematically as :-
k,
Ag + Ab v- =r" -  AgAb
2
where Ag, Ab, and AgAb represent antigen, antibody and antigen-antibody 
complex respectively, and k^  and k^ are the association and dissociation 
constants for the reaction (Landon, 1 9 7 1 ®
Applying the Lav/ of Mass Action to this system :-
K = N  = fAg.Ab] 
k2 [AgJ[AbJ
where the equilibrium constant K is a measure of the binding avidity of the
antibody and the square brackets denote molar concentrations of the
reactants. The greater the value of K the higher v/ill be the percentage of
antigen in the bound fraction. This approach assumes that there are single
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reached equilibrium, and that there is no difference in the reactivities 
of the labelled and unlabelled antigen in the assay system (Chard, 1971)
Under these conditions the percentage of antigen bound is directly 
proportional to the concentration of antibody present and will decrease as 
the concentration of antigen increases. The concentration of unlabelled 
antigen in an unknown sample is obtained by comparing the percentage of 
label bound by the antibody in that sample, with that found in standard 
solutions containing known amounts of antigen, expressed in the form of a 
standard curve.
* The first stage in the development of a radioimmunoassay is to 
determine, by means of an antiserum dilution curve, the amount of antibody 
that will bind 90 to 6q£ of a fixed amount of labelled antigen. The 
constant amount of labelled antigen, dependent on its specific activity, is 
incubated with decreasing amounts of the antiserum. The percentage of the 
radioactivity bound to the antibody is determined and plotted against the 
antibody dilution.
• **
The assay is then set up by adding these amounts of antiserum and 
labelled antigen to assay tubes containing unknown samples or known amounts 
of standards. After an appropriate incubation time the antibody bound and 
free fractions are separated by one of the many separation methods available 
(fig. 1.8). The amount of radioactivity in one or both fractions is determined 
by liquid scintillation or gamma counting techniques and the distribution
of radioactivity expressed in terms of either the ratio of the counts in the
S IP
two fractions ( or ), or as the percentage of total counts bound or
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MATERIAL USED
Differential migration of 
bound and free fractions 
Migration caused by diff­
erence in charge.
Migration caused by mol­
ecular weight difference
Paper chromatography 
chromatoelectrophoresis 
Electrophoresis on 
starch gel 
Wick chromatography
Gel filtration
Berson, Yalow, Bduman, 
Rothschild & IIewerly(l 95 6) 
Hunter & Greenwood (19&4)
J2frskov (1967)
Chao, Karam &Grodsky (1965)
Adsorption methods 
Free fraction Coated charcoal
Silicates, eg. Quso, 
talcum powder. 
Anion-exchange.resin
Herbert, Lau, Gottlieb & 
Bleicher (19&5) 
Rosselin, Assan, YalOw & 
Berson (1966)
Lazarus & Young (1966)
Fractional precipitaion of 
bound fraction using : 
Organic solvent
Salt
Ethanol-NaCl
Ethanol
Dioxan
Sodium sulphate 
Ammonium sulphate
Odell, Wilbur & Paul(1965) 
Heding (1966)
Thomas«& Ferin (1968) 
Grodsky & Forsham (i960) 
Chard, Martin & Landon
(1971)
Immunological precipitation 
of bound fraction (double­
antibody method)
Precipitation after 
first antibody incub­
ation
Preincubation of first 
and second antibody 
prior to assay 
Second antibody link­
ed to solid matrix
Morgan & Lazarow (19°2)
* N
Hales & Randle (1963) 
den Hollander & Schuurs
(1971)
Solid-phase methods 
First antibody
| Antigen
Antibody coated discs 
and tubes
Antibody linked to 
finely divided solid 
phase
Catt & Tregear (19^7) 
Wide & Porath (1966)
Miles & Hales (1963)
Pig 1.8 : Some of the methods used for separating bound from free tracer.
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unlabelled standard in the system, produce a standard curve from which the 
concentration of unlabelled antigen in the unknown sample can be derived.
An assay in which the reactants are all added to the reaction tubes 
as soon as possible after one another is known as an "equilibrium" assay. A 
second type of assay is one in which the antiserum and unlabelled antigen 
are preincubated together before the addition of •the labelled antigen.
After a further incubation period, phase separation and measurement of the 
radioactivity are carried out as before. This system is known as a 
"disequilibrium" assay and is more sensitive than the equilibrium system.
Since its development radioimmunoassay has been applied to the assay 
of a variety of substances in biological fluids, as has already been shown 
Xfig.1.1), and has recently been applied to the measurement of drugs (fig. 
1.9). The determination of blood drug levels by radioimmunoassay has been 
reviewed by several authors, Brattin and Sunshine (1973), Butler (1973), 
Spector (1973 a- & b), Spector, Berkowitz, Flynn and Peskar, (1973) aad Marks 
Morris and Teale (i974).
One of the main problems encountered in drug radioimmunoassays is 
the production of specific antibodies against the drugs. Most drugs are
relatively small molecules having a molecular weight of less than 1000, 
and usually less than 500. Such compounds are not naturally immunogenic but 
can be made so by coupling them to a large carrier protein that is itself 
immunogenic. Because of this lack of immunogenicity, antibodies having 
titres of the same order as those produced against peptide hormone immuno­
gens (ie. at least 1:100,000) are not generally produced against drug-
26
1963 Digitoxin Oliver, Parker, Brasfield & Parker 
(1968)
1970 Morphine Spector & Parker (1970)
1971 Barbital & 
Pentobarbital
Flynn & Spector (1972)
1972 Gentamicin 
Lysergic acid 
diethylamide 
Phenytoin
Tubocurarine
Lewis, Nelson & Elder (1972)
Taunt on-Rigby, Sher & Kelley (1973)
Tigelaar, Rapport, Inman & Kupferberg
(1973)
Horowitz & Spector (1973)
1973 Amphetamines
Cotinine
Diazepam
Nicotine
Pentazocine
Phenobarbital
Prednisolone
Serotonin
Cheng, Kim, Chung & Castro (1973) 
Langone, G-jika & Van Vunakis (1973) 
Peskar & Spector (1973a)
Langone, Gjika & Van Vunakis (1973) 
Williams & Pittman (1974)
Chung, Kim, Cheng & Castro (1973) 
Colburn & Buller (1973)
Peskar & Spector (1973b)
1974 Codeine
Fenatyl
Tetrahydro­
cannabinol
Prednisone
Aherne, Piall, Robinson, Morris & 
Marks (in press)
Henderson, Frincke, Leung, Torten 
& Benjamini (1974)
Teale, Forman, King & Marks (1974)
Colburn (1974)
\ "*
Fig, 1.9 : Some drugs for which radioimmunoassays have been reported.
carrierconjugates. With the lower molecular weight drug immunogens, titres 
in the region of 1:500 to 1:1000 are normally achieved, although in many cases 
the antiserum is used at dilutions of 1:10 or 1:50. Higher titres have 
been reported, eg. 1:40,000 against digoxin conjugates (Smith,Butler &
Haber, 1970), 1:500,000 against lysergic acid diethylamide (Taunton-Rigby,
Sher & Kelley, 1 973)» hut are not common.
Since the start of work on the development of a radioimmunoassay for
27
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The first was by Tigelaar, Rapport, Inman and Kupferberg (1 973) an<i the 
other by Cook, Kepler and Dix Christensen ('i 973) • Tigelaar* s assay, using 
a low titre (1:8 final dilution)antiserum raised in guinea-pigs, could not 
distinguish between phenytoin and its major metabolite, HPFH. The assay of 
Cook et al. (1973) using antisera raised in rabbits with a titre of 1:14,000, 
had similar characteristics to those described later in this thesis, in 
that it showed no cross reaction with HPPH.
To clarify some of the terms used in radioimmunoassay: an "antigen" 
is used to describe a compound that will combine with its specific anti­
body; an "immunogen" describes a substance that invokes an immune response. 
This may be the antigen itself or the antigen attached to a large immuno­
genic carrier molecule, when the antigen is termed a "hapten". "Avidity" 
is the term applied to the strength of the binding of an antibody to its 
antigen and is a property of the antibody, vrhile "affinity" describes the same 
strength of binding but as a property of the antigen.
1g. Conjugation Techniques.
Landsteiner (19^5) found that when small molecules, such as drugs, 
were linked as haptens to protein or polypeptide carriers^ antibodies Y/ere 
produced that were capable of reacting specifically with the hapten used.
The protein carriers that have been used in various laboratories include 
globulin fractions, serum albumin, haemocyanin, ovalbumin, thyroglobulin 
and poly-l-2ysine. In general hapten-protein conjugates to serum albumin 
have been found to be more soluble than conjugates to gamma-globulins or 
ovalbumin (Erlanger, 1973)* There is^  hov/ever, no clear evidence to
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although Mitchison (19&7) has suggested that conjugates to ovalbumin are 
more immunogenic.
The specific role of the carrier is evident in the secondary immune 
response; an animal primed with a hapten-carrier conjugate will generally 
produce an effective secondary response to the hapten only if, for 
secondary stimulation, the hapten is coupled to the same carrier as was used 
for sensitisation. This is known as the "carrier effect" (Roitt, Greaves, 
Torrigiani, Brostoff & Playfair, 19&9; Mitchison, Rajewsky & Taylor, 1970; 
Klinman, 1971).
Although there is some disagreement, it has been suggested that there 
is an optimum density of conjugation for the induction of antihapten anti­
bodies, an increase beyond this optimum substitution leading to an impaired 
immune response (Haurowits, 193&; Kantor, Ojeda & Benacerraf, 19&3). 
effects of this "degree of derivatisation" are examined later in this 
thesis.
It has been pointedout (Rajewsky, 1971) that for induction, the hapten 
must be chemically linked to the carrier molecule. However, electrostatic 
complexes of methylated bovine serum albumin and negatively charged 
molecules, as well as phosphorylated bovine serum albumin and positively 
charged molecules,, have been successfully used for antibody production 
(Plescia, Braun & Palezuk, 19^4; Seaman, Levine & Van Vunakis, 19^5;
Maurer, 19^4).
Many techniques have been used to couple haptens to a carrier molecule. 
These have been extensively reviewed (Beiser, Butler & Erlanger, 19^8;
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the course of this project will be discussed here.
i. Carbodiimides.
Carbodiiraides are derived from the compound HN=C=NH which probably 
exists mainly in the tautomeric form, H^NCHN (Khorana, 1953) a^d can be 
used to couple compounds containing many types of functional groups 
including carboxylic acids, amines, phosphates, alcohols and thiols. The 
coupling reaction probably takes place in two stages
eg. PROTEIN—  C
0
OH
R-N=C=N-R*
(carbodiimide)
H
I
,0 N— R
/  i
PROTEIN-Cv ,CVv v,
+ HAPTEN-NH
.0
PROTEIN— HAPTEN 
N
H
Rearrangement
PROTEIN— 0
\  B / H  
nN—  C— It?
I \ R.
R
0
li
R-*N— C-N— R* 
I I
H H
(N-protein-substituted urea)
(Adapted from Goodfriend, Levine & Fasman; Science, 144: 1344, 19^ 4-)•
In addition to coupling haptens to proteins by peptide bond formation, 
carbodiimides can also add to carboxylic acids to produce, by molecular 
rearrangement, N-substituted ureas (Goodfriend, Levine & Fasman, 19&4)*
NH^ groups and have been used to conjugate to the £ -amino groups of the 
lysine residues of bovine serum albumin (BSA) (Erlanger, 1973)*
Of the drug radioimmunoassays already published, have used a carbo* 
diimide condensation reaction to couple the hapten to carrier proteins.
Two wqter soluble carbodiimides have been used during the course of this 
work : 1-cyclohe^l-3-(2-morpholynoethyl)carbodiimide metho-p-toluene- 
sulphonate (CMC or Morpho CDl) and 1-ethyl-3-(3-3iraethylaininopropyl)carbo- 
diimide hydrochloride (EDC), The structural formulae of these compounds 
are
■N=C=N-CH,r-CH-N
CH.
CMC
H
!f/CH3 • =C =N-CH „— CH 0-CH D Cl
CH,
EDC.
The chemical structure of two water soluble carbodiimides.
In the coupling reaction the carrier protein, hapten and carbodi- 
iraide are stirred togetherin aqueous solution for a time varying from 
thirty minutes to several days. Unconjugated hapten and carbodiimide are 
removed by dialysis against distilled water or buffer and the product 
recovered by lyophilisation.
ii. Clutaraldehyde.
Glutaraldehyde is a bifunctional reagent that is thought to react.
Avrameas & Ternynk, 19^9)« The most important reaction (fig.1.10) occurs 
with free primary amino groups, but glutaraldehyde will react with phenolic 
hydroxyl and other chemical groups (Avrameas & Ternynk, 19&9). During the 
course of the work presented here glutaraldehyde has been used to couple 
secondary amino and sulphonamide groups to a carrier protein.
o 9 
h-c-(ch2),~c-h h h
R'-NHg + R“-KH2 — ----- -2--- ► 1. R*-N=C-(CH2)^-C=K-R"
H H
2. R ,-N=C-(CH2)^-*C=N-Rt
H IJ
3. R'^NsC-CCHgJ^-CsN-R"
Fig. 1.10 : Reaction of glutaraldehyde with primary amino 
groups (from Abraham & Grover, 1971)..
By-products of the reaction include hapten-hapten and carrier-carrier 
polymers in addition to hapten-earrier complexes. The production of these 
by-products can be minimised by carrying out pilot experiments in which 
only the amount of glutaraldehyde is varied. It has been suggested 
(Abraham & Grover, 1971) that the number of haptenic amino groups should be 
the same as the number of free amino groups on the carrier and the amount 
of glutaraldehyde varied to give a glutaraldehyde:h&pten ratio from 1:1 to 1:10. 
The pH of the mixture also affects the coupling reaction (Abraham & Grover,
197 *), with the best results being obtained with a pH near the isoelectric 
poin^as uncharged amino groups are more reactive with glutaraldehyde than 
are charged amino groups.
A typical conjugation by this method involves the incubation of
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Van Vunakis, Bradvica, Benda & Levine, 19&9) for up to one hour before the 
addition of the carrier (Crookall-G-reening, personal communication). After a 
further incubation of 3-4 h at room temperature, during which the solution 
becomes a pale yellow colour, cysteamine or lysine are added to react with 
the excess glutaraldehyde. The free hapten is then removed by dialysis 
against distilled water and the product lyophilised.
iii. Mannich Reaction.
The Mannich (1917) reaction is a condensation reaction between 
formaldehyde, ammonia or a primary or secondary amine (preferably as the 
hydrochloride), and a compound containing at least one active hydrogen atom 
(Blicke, 1942; Fraenkel-Conrat & Olcott, 194S). The exact mechanism of the 
reaction is not known (Finar, 19^7)• An "active" hydrogen atom is one 
attached to oxygen, nitrogen or sulphur.
This conjugation method has been used by Ranadive and Sehon (19&7) 
to conjugate serotonin to BSA, and by Taunt on-Rigby, Sher & Kelley (1973) 
to couple lysergic acid diethylamide to carrier. ^
1h. ANTIBODY PRODUCTION.
The production of a specific antibody is one of the most important 
steps in the development of a radioimmunoassay, but is unfortunately one 
that cannot be closely controlled. Although several factors are known to 
influence the titre of the resultant antiserum, such as the immunogenicity 
of the conjugate and the use of an adjuvant, no particular immunisation 
schedule can be said to be ideal. Some however, are more successful than 
others.
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Most investigators have raised antibodies to drug-carrier conjugates 
by conventional methods, which involve emulsifying a solution of the drug- 
carrier conjugate with an adjuvant and injecting it into experimental animals 
by intra-muscular (im) or sub-cutaneous (sc) routes. A recent development 
is the low dose, multi-site, intrademial technique described by Vaitukaitis, 
Robbins, Nieschlag and Ross (i97i) in which the animals are injected intra­
de rmally (id) at forty or more sites on the back and flanks. This method 
uses low doses of antigen and booster immunisations do not appear to 
influence the antibody titre (Playfair, Hurn & bchulster, 1974). However, 
this technique is no more capable of stimulating antibodies than 
conventional methods (Playfair et al., 1974) • The intra lymph nodal route 
(Boyd & Peart, 1968) has also been used , in which separate lymph nodes 
are injected under open surgery. Although producing better antisera in 
experiments comparing intranodal with conventional routes (Hurn & Landon,
1971), the former served no useful advantage since fe?/er animals responded.
Most antisera for use in radioimmunoassays have been raised in guinea- 
pigs and rabbits although goats, sheep and donkeys are becoming more widely 
used. There is no clear evidence that the species of animal used is 
important, except for the need to use guinea-pigs for the production of 
insulin antiserum (Playfair et al., 1974). Individual animals vary in their 
response to different Immunogens. This variation may be a reflection of the 
genetic constitution of the animals (Green, Paul & Benecerraf, 19&9), an<* 
random-bred animals are more satisfactory.
i. Adjuvants.
The antibody response to injected immunogen can be increased by the
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specifically enhance the antibody production to unrelated antigens. Some 
adjuvants are- large molecules and so are themselves immunogenic, others are 
small organic compounds, and some employ physical adsorption of the antigen 
onto the surface of a particle, eg, adsorption onto aluminium hydroxide 
(alhydrogel) or carbon particles. The use of an adjuvant allows a reduction 
in the amount of immunogen necessary to induce a large quantity of anti­
body.
several processes in the immune response may be affected by the use 
of an adjuvant including antigen processing and distribution. Less than 
5/S of the administered antigen is effective in stimulating antibody 
formation (Freund, 1951)# If this proportion can be increased without 
increasing the total amount of antigen injected, the effective antigen 
dose will be increased. One method of doing this is to make the antigen 
particulate by, for example, mixing it with aluminium compounds to produce 
a precipitate of immunogen adsorbed onto aluminium.- The resulting antibody 
response is usually higher and more prolonged than that following the 
injection of soluble antigen. It seems likely that the particulate antigens 
are phagocytosed more readily than soluble antigens. The increased phago­
cytosis and/or digestion of particulate antigens could result in an 
enhanced immune response by increasing the antigenic stimulation.
It is known that the antibody response to the second injection of 
antigen is usually higher than that to the first injection of the same 
antigen (Rajewsky, 1.971')* Some adjuvants may help antibody production by 
inducing both primary and secondary immune responses after a single
35
in this way to render the antigen relatively insoluble. "Complete" Freund's 
adjuvant consists of a neutral detergent (Arlacel A), a mineral oil (Bayol 
F) and killed Mycobacterium butyricum; the "incomplete" adjuvant lacks the 
bacterial fraction.
The detergent, because of its high content of hydrophylic and lipo- 
phylic groups, binds both the oil and aqueous solution of the antigen, 
allowing the formation of a stable emulsion with the antigen in the water 
phase. By this means, small droplets of antigen are slowly released from 
the emulsion, resulting in antigenic stimulation over long periods of 
time and avoiding the rapid degradation of the immunogen by circulating 
proteolytic enzymes. Support for this hypothesis comes from the fact that 
excision of the injection site a short time after injection, results in a 
reduction of the adjuvant effect (Freund, '1.951)* In addition, antigen in 
a biologically active form has been found persisting at the sites of 
injection for long periods after the actual injection (Halbert, Mudd & 
Smolens, 191+6).
■ • %
The Mycobacterium in the adjuvant increases the immune response
through an effect on the antibody forming cells (Herbert, 1973)* Increased 
numbers of cells have been observed after the administration of antigen 
and adjuvant (Braun & Firschein, 19&7). Increased mitosis has also been 
demonstrated in the spleens of animals receiving adjuvant (Ward, Johnson 
& Abell, 1959)* Some adjuvants,therefore, may increase antibody production 
by increasing the rate of proliferation of either the precursors or the 
antibody forming cells themselves. The end result is an increase in the
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response. Such a response would also be obtained in the absence of an 
increase in antibody-forming cells if the adjuvant increased the amount of 
antibody produced per cell, though this has yet to be demonstrated.
ii. Antibodies.
Antibodies comprise a group of proteins known as the immunoglobulins, 
and are divided into five classes : IgA, IgB, IgE, IgG, and IgM (World 
Health Organisation, 19&4). 0? these, the IgA, IgG- and IgM groups are the 
ones involved in the immune response. The antibodies of the IgM class are 
the largest with a molecular weight approaching 1,000,000 (Abramoff & LaVia, 
1970;Dorrington and Tanford, 1970). In most mammalian species the IgG 
group is quantitatively and qualitatively the most important and is the one 
usually involved in a radioimmunoassay reaction (Hurn & Landon, 1971)* The 
antibodies of this group are made up of four polypeptide chains; tv/o heavy 
(H) chains of some k50 amino acids, and two light (L) chains of 200 amino 
acids (Cohen & Porter, 19&4 ) (fig.1.11).
Tissue fixation
complement fixation
Antibody
combining
sites
F fragmentsF , fragments
Site of pepsin 
digestion
Site of papain digestion
Fig. 1.11: Representation of rabbit IgG antibody molecule.
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antigen and each is located near the N-terminal region of the molecule. 
Immunoglobulins of the same class and sub-class have large regions with 
identical amino acid sequences (constant region, c) and other areas in which 
the sequence varies with antibody specificity (variable region, v)
(Edelman & Gill, 1969). There appear to be variable regions in both chains 
contributing to the antibody combining sites. Preliminary- evidence has 
suggested that antibodies to positively or negatively charged 
antigens have one or more oppositely charged amino acid residues in their 
combining region (Singer and Doolittle, 19&6). The differences in charge 
between the antibody and the antigen contribute coulombic energy to the 
antigen-antibody interaction. Further evidence suggests that amino acids 
with extended hydrophylic side chains are heavily represented in the 
combining regions of the antibodies to hydrophobic antigenic determinants 
(Koshland & Englberger, 19&3).
For any individual antibody^ the energy of binding (avidity) is 
determined by the complementary relationship between the antigenic deter­
minants and the combining site of the antibody. It seems likely that no 
single type of bond predominates, though relatively long range electrostatic 
interactions may be responsible for the initial binding between the 
molecules, followed by secondary interactions when the range is of the 
order of a few A (Chard, 1971).
iii. Antibody Formation.
One of the first theories of antibody formation was that of Ehrlich 
(1900) Y/hich stated that antigen interactions accelerate a regeneration of
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responsible for antibody production. This theory was revived by Jerne (1935) 
in his natural selection theory which postulated the phagocytosis of the 
antigen-antibody complex by cells in which replicates of the antibody were 
formed without further involvement of the antigen.
Burnett (1959) adopted a cellular basis for replication of anti­
body with the additional concept of clonal selection. That is, clones of 
c.eils are established during embryonic differentiation by a genetic "random­
isation" process, resulting in the mesenchymal cells-carrying reactive 
sites equivalent to those of the globulin molecules they produce. In the 
early stages of development all possible variants of gamma-globulin molecule 
are represented by the individual cells. Subsequently clones of cells 
carrying reactive sites corresponding to the body determinants are 
eliminated.
A more recent theory suggests that the cells of the reticulo-endo- 
thelial system have the ability to phagocytose a variety of materials. 
Following-an injection, the immunogen is trapped by these cells and appears 
to be broken down by high concentrations of proteolytic enzymes, so 
releasing fragments which may represent the antigenic determinants.
While the immunogen is initially taken up by the phagocytes it is 
the cells of the lymphoid series that actually synthesise the antibody. It 
is thought that immunologically competent small lymphocytes receive 
material from adjacent macrophages which enables them to synthesise a 
specific antibody. The small lymphocytes then convert to plasma cells 
which are the main antibody producers and have a life-time of only a few
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As antibody is formed, it neutralises a portion of the immunogen so 
reducing the stimulus to further antibody formation. The already formed 
antibody cells continue to replicate for a short time and then die. When 
this happens antibody synthesis decreases and the antibody titre falls.
At this point the re-introduction of immunogen will normally produce a 
dramatic increase in titre, The booster effect occurs rapidly, apparently 
reflecting the persistence of relatively long-lived antigen sensitive cells 
which rapidly give rise to antibody producing cells (Parker & Vavra, 19&9)*
Serum antibody avidity is both a function of the time after immun­
isation and the dose of immunogen given (Eisen & Siskind, 1964) • The 
avidity is likely to increase with time after immunisation and is greater if 
moderate amounts of immunogen are given. At low doses, cells with high 
avidity sites form complexes with the antigen, are stimulated and will produce 
high avidity antibodies. At high concentrations of antigen these cells are 
inhibited by the excess antigen, but other cells producing low avidity anti- 
bodies are stimulated (Parker & Vavra, 1969; Paul, Siskind & Benacerraf, 1S68) , 
Once a critical level of immunogen is achieved there is a reciprocal relatio­
nship between the avidity of the antibody and the dose of the imminogen.
After most immunisations the antibody population is heterogeneous in its 
binding properties, suggesting that both low and high avidity antibody 
producing cells are being stimulated simultaneously, and reflecting the 
immunological heterogeneity of the antigen.
The factors determining the specificity of the antibodies are not 
fully understood, but may be due to changes in the amino acid sequences of
¥>
been proposed to account for the production of the variable regions. 
Lederberg (1959) suggested that somatic hypermutation of a few genes during 
cell division accounted for the specificity. Brenner and Milstein (1966) 
reviewed this theory and proposed that there was one uvH gene per variable 
region and that hypermutation of the v gene occurs independently in each 
individual. Dreyer and Bennet (1963) proposed that there 'were multiple 
genes encoding the v regions and separate genes for the 1 c" regions.
Smithies (1963) suggested a third mechanism in which somatic recombination 
occurs in a limited number of genes, probably the v genes. There is however 
no direct evidence to support any of these theories completely, although 
evidence is available to substantiate parts of each (Smith, Hood & Fitch,
1971).
iv. Antibody Assessment.
Several factors such as pH, protein concentration and molarity can 
influence the binding of antigen to antibody and their relative importance 
varies according to the particular antiserum used. Such factors should be 
evaluated on a system that approaches the assay system for which it is 
intended. Separation procedures relying on non-specific adsorption (eg. 
charcoal and cellulose) are particularly sensitive to the protein concent­
ration.
Assessment of an antiserum should include measurements of titre, 
effective avidity and an investigation of specificity.
Assessment of antibody titre.
The presence of antibodies in immunised animals can be demonstrated
41
antigen of known purity is available. Constant amounts of labelled antigen are 
incubated with increasing dilutions of the particular antiserum, and the 
distribution of radioactivity between the bound (B) and free (F) fractions 
determined after phase separation. The distribution may be expressed in 
different ways, but is normally expressed as the percentage’bound of total 
antigen present, or the boundifree or freerbound ratio and is plotted against 
the antiserum dilution. Such a titration curve indicates the working dilution 
of the antiserum for use in further studies to determine its avidity and 
specificity. The dilution chosen is such that between 40 and 60 % of the 
labelled antigen is bound in the absence of unlabelled antigen. The titre is 
expressed as either the initial dilution of the antiserum, i.e. the dilution 
at which the antiserum is added to the system, or the final dilution, i.e. the 
dilution of the antiserum in the final reaction mixture. In an equilibrium 
assay the use of a large excess of labelled antigen, above that binding 5Qfo 
of the label in the absence of unlabelled antigen, results in a loss of 
sensitivity since all the binding sites must be occupied before the unlabelled 
material can compete with and displace the labelled antigen.
Assessment of Antibody Avidity.
Antiserum dilution curves can be used as an indication of the avidity 
of an antiserum. The steepness of the descending part of the dilution curve 
reflect the avidity of the antiserum (Berson & Yalow, 19^4)* Alternatively, 
the avidity may be calculated by the construction of a modified Scatch&rd 
plot (Scatchard, 1949)- The concentration of the antibody found from the 
dilution curve to bind 50 % of the added label, is incubated with increasing
U2.
BKesselring, 1974). After phase separation the ratio is plotted against 
the bound antigen concentration to give a modified Scatchard plot. The slope 
of the assymptote to the curve gives the effective avidity, K, and the 
intercept of the asymptote with the abscissa gives the effective antibody 
binding site concentration (Albano & Ekins, 1970). These values refer to 
the labelled material alone and may be different in the presence of 
unlabelled antigen. An assessment of the effective avidity for the un­
labelled antigen can be obtained by using a small constant amount of the 
labelled antigen and varying the amount of unlabelled material.
Assessment of antibody specificity.
A radioimmunoassay is based on the competition between labelled and 
unlabelled antigen for a limited number of antibody binding sites; anything 
that competes for such sites or in any other way affects the binding of 
labelled antigen, will influence the results obtained.
One method of assessing the specificity of an antiserum is to set up 
a series of standard curves using a variety of unlabelled compcunds as the 
standards, and comparing the standard curve obtained with that derived 
using the antigen to which the antiserum was raised. The percentage cross­
reactivity is normally calculated from the ratio of the amount of antigen 
needed to suppress the binding of label by $0 % to the amount of cross­
reactant producing the same effect.
Landon, Girard and Greenv/ood (19&9) stated that, in general, compounds 
containing a chemical group identical to that of the antigenic determinants 
in a specific antigen will cause parallel inhibition binding whereas
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the whole molecule appears to act as the antigenic determinant. In such 
cases, those, analogues of the drug differing from the antigen only at the 
point of conjugation to the carrier will in general, influence the binding 
of the antigen (Hunter, 1974). The specificity of an antiserum against a 
drug molecule can be influenced by choosing the site of attachment to the 
carrier molecule, depending on the structure of the related compounds with 
which one wishes the antiserum to cross-react (Morris, Robinson, Piall, 
Aherne & Marks, 1974; Robinson, Morris, Piall, Aherne,& Marks, in press 
(see appendix)). An antiserum that will cross-react with a group of related 
compounds is often as useful as a specific antiserum for screening 
purposes. Teale, Forman, King and Marks (in press) have raised an anti­
serum against a tetrahydrocannabinol-BSA conjugate in sheep that can be 
used to study the appearance and disappearance of tetrahydrocannabinol and 
cannabinoids in blood. 
ji. RADIOACTIVE LABELLING.
One of the main reagents in a radioimmunoassay is a radioactively- 
labelled form of the antigen. In choosing the radioisotope for use in 
labelling the antigen it is important to take into account the ease of 
introducing it into the antigen molecule. The most commonly used isotopes 
are ^H, ^C, and ^**1; other isotopes including ^ 1 ,  ^ Co, and ^Se
have also been used. Only those isotopes used during the course of this 
project will be discussed here. Some of their physical properties are 
listed in table 1.1.
nuclide life ofdecay
common
values
nuclide
(stable)max mean
-I25J
12* 26y
5370y
60*00d
/ s '
A
e~
0*018
0*159
0*006
0*050
0*035
102-10^
2
1 -10 
102-10^
3He
125le
Table 1*1 : Physical properties of the radionuclides used.
i. Tritium*
Tritium (^ H) is the radioactive isotope of hydrogen decaying by beta 
emission to helium. Drugs labelled with tritium can usually be obtained from 
the manufacturers of the drug'or from radiopharmaceutical suppliers. To be 
of value it is necessary that the tritiated preparations are of high molar 
specific activity (Ci/mmole) in order that very small amounts (pmole) may 
be used in the radioimmunoassay. Liquid scintillation counting techniques 
are essential for the efficient detection of the low energy beta radiation 
emitted by this isotope and will be described later.
Tritium can be introduced into a molecule by catalytic exchange , 
reactions, a technique used by Kepler (personal communication) for the 
tritiation of phenytoin. In his method, the dibromo salt of phenytoin v/as 
stirred in an atmosphere of tritium gas in the presence of a 10 % platinum 
on charcoal catalyst, resulting in 5,5-his(phenyl-lf-^H)hydantoin (see appendix).
ii. Carbon-14*
This isotope is frequently used to label drug molecules although the 
specific activities attained are low (table 1.1)* The beta particle energy 
is higher than that of tritium,however liquid scintillation counting 
must still be used for its detection.
Radiocarbon is normally introduced into compounds by synthesis of
iii. Iodine-125.
Radioiodine is a widely used radioisotope largely because of the 
ease with which it can be introduced into the molecule to be labelled, A 
major advantage in using this isotope is that gamma counting techniques can 
be used for the quantification of the radioactivity.
Six methods have been described for the introduction of radioiodine into 
molecules with resulting high specific activities. These are :-
a) the iodine monochloride method (Samols & Williams, 19&1)
b) the chloramine-T method (Hunter & Greenwood, 1’962; Greenwood,
Hunter & Glover, 1963)
c) the electrolytic method (Rosa, Scassellati, Pennsis, Riccioni,
Gianoni & Giordani, 19^4)
d) enzymic iodination (Marchalonis, 19^9)
e) conjugation labelling (Bolton & Hunter, 1972)
f) the hypochlorite method (Redshaw & Lynch, 1974)*
Of these the chloramine-T method is the most widely used.
For small molecules such as drugs, the introduction of such a large 
atom as iodine into the molecule may cause a breakdown in the structure of 
the molecule, or at least interfere with the antigen-antibody binding 
reaction by changing the shape of the molecule. The oxidation conditions 
used in the chloramine-T method rnay also have an adverse effect on the 
antigen molecule. In addition to these problems, drug molecules can, in 
general, only be iodinated directly if they contain certain reactive 
groupings,in particular a phenolic hydroxyl group adjacent to a -CH=
46
means of a “radioiodination tag”, This kind of tag is usually a small 
molecule that can be iodinated and that can be introduced in such a way as 
to cause as little structural alteration of the antigen as possible^o that 
the affinity of the tracer will be close to that of the antigen itself.
The smallest compound that can be used for this purpose is an iodophenol 
group such as that found in tyrosine methyl ester. Tyramine and histamine 
have also been used as radioiodination tags. These compounds can all be 
linked through their -Regroups to the antigen. It has been suggested 
(Hunter, 1974) that antisera are relatively indifferent'to changes in 
substituents attached to the antigen molecule at the point of attachment 
used in the preparation of the immunogen. However, with drug molecules 
this is not always the case as will be demonstrated later (see also 
Robinson, Aherne, Teale, Morris and Marks, appendix). This method of 
labelling has been used successfully to introduce radioiodine into drugs 
such as digoxin (Oliver, Parker, Brasfield and Parker, 1968; Lader, Court, 
Johnson,& Hurn, 1972), cotinene (Langone et al., 1973) and morphine (Van 
Vunakis, Wasserman & Levine, 1972). Gilby, Jeffcoate and Edwards (1973) 
have compared the use of tyrosine methyl ester and histamine as radio­
iodination tags. These workers reported that tyrosine methyl ester 
derivatives were difficult to prepare and were unstable after radioiodina­
tion; histamine tracers however, were relatively easy to prepare and were 
stable.
In an attempt to overcome the effects of the iodination oxidants and 
reductants on the antigen, Bolton and Hunter (1972, 1973) have developed
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agent, 3-(p-hydro2yphenyl) propionic acid N-hydroxysuccinimide ester is 
first iodinated by the chloramine-T method. The ester is extracted into 
benzene and evaporated to dryness. The addition of aqueous solution of 
antigen to this residue results in the immediate condensation of any free 
amino groups to the iodinated acyl groups by peptide bond formation. The 
reaction sequence for this method is illustrated in fig.1,12.
OH
Ti i
CIJ2 /■
125 * 'Na'°I + Ho—  C— C — 0— N ,
2 H \0 V
I 
0
Acylating Agent
+
I
C=0
I
NH
m —  (ch2)-^— ch
HH
Fig. 1.12 : Conjugation labelling reaction scheme from Hunter (1973)*
A similar method was used to prepare labelled oestradiol (Nars & 
Hunter, 1973), by first iodinating histamine by the chloramine-T reaction, 
and coupling this to the steroid by the mixed anhydride method of Erlanger, 
Borek, Beiser and Lieberman (1937).
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steroids, although only the former has been used for the radioiodine
151labelling of drugs. J I emits gamma radiations of three different energies
(0*28, O 36 & 0*64 MeV) and beta particles having a mean energy of 0*19 MeV 
125I emits only gamma radiation. The specific activities attainable with
radioiodinated compounds depends on the individual compound and on the
125isotopic abundance of the radioiodine. I can be obtained virtually
151carrier free while I cannot; however, the iodination efficiency achieved
125by G-enuth, Frohman and Lebovitz (1965), using I was not. as great as that 
151achieved for I. Under storage conditions such that non-specific damage
125
is minimised, the total damage to the antigen is greater -with I than 
151with I labelled compounds (Yalow & Berson, 1968).
125 151I is used in preference to I, initially because of the desire
to avoid repeated and frequent handling 'of the radioactivity. The sixty 
125day half-life of I means that the iodination reaction may be carried 
out less frequently, and the absence of beta radiation decreases the radi­
ation hazard during the iodination procedure, even though 7j times as many
N
125atoms of I must be incorporated to give a specific activity comparable
151 '
to that of I.
During the decay of a total of 143 "useable” (27’4-35#4 keV)
loY? energy gamma rays are emitted on average per 100 disintegrations
(Myers & Yanderleeden, i960) This represents 50 % more useable photons
131than are obtained per disintegration of I. From studies of thyroidal 
radiation damage in mice (Schindler & Liebelt, 1964) it has been suggested 
that the danger to laboratory personnel by accidental ingestion is smaller
during the course of this work.
Although radioiodination results in the high specific activities 
needed for sensitive radioimmunoassays, it is not always* a suitable isotope 
for labelling drug molecules. Some of the problems encountered in the use 
of radioiodination tags in lab elUing drug molecules have been examined 
(Robinson, Aherne, Teale, Morris and Marks, in press), and in general 
tritium was found to be a more suitable radioisotope to use, causing less 
steric hindrance in the antigen-antibody reaction, and giving the high 
specific acitivities required. Of the published drug radioimmunoassays only 
four have used radioiodinated antigens (see page 47)* 
jj, COUNTING TECHNIQUES.
The detection of the amount of radioactivity present in the bound 
and/or free fraction is a vital step in the assay procedure. Both and
J] I A pC
C yield low energy beta particles while I emits gamma radiation.
Liquid scintillation counting is the most suitable for the quantification
3 14 125_of H and C, and can be used for ±, although gamma counting using
• %
a sodium iodide crystal is a simpler method for this isotope.
i. Liquid scintillation counting.
The correct preparation of samples for liquid scintillation counting 
is as important in achieving satisfactory results as is proper instrument 
operation. The technique normally used in radioimmunoassay is to dissolve 
the test substance in a solvent, usually toluene, containing protein 
solubilisers such as triton, and scintillators (Dufau, Dulraanis, Catt &
Hudson, 1970; Corker & Naftolin, 1971). The role of the scintillant
■>
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tions, and to convert it into light photons which match the spectral 
sensitivity of the photomultipliers (Newton Hayes, 19^3)• The best light 
emitters have emission spectra of too short a wavelength for most photo­
multipliers and it is usual to employ a two-solute combination. A primary 
solute, such as 2,5-dipheqyl-oxazole (PPO) is used to ensure a large 
number of eventually emitted photons, while the secondary solute, eg. p-bis- 
(2,5,-diphenyloxazole)-benzene (POPQP) is the actual emitter and controls 
the spectrum of the emitted photons. It is also important that the solvent 
has a small absorption coefficient for the light emitted by the solute to 
facilitate maximum scintillation efficiency.
Since tritium is the most difficult of the radioisotopes to detect, 
any system that will permit efficient quantification of this isotope will 
detect the others with a greater efficiency. The problems of tritium 
counting are mainly associated with the low energy of the beta particles.
The most sensitive arrangement for tritium detection in a liquid scintilla­
tion spectrometer involves viewing the counting solution with two co-axial
■v
photomultiplier tubes. The detectors are operated in coincidence, a count 
being recorded only when both the photomultipliers produce simultaneous 
pulses.
The maximum energy of the tritium beta particles is 18 keV, but the 
average only 6 keV. The dissipation of the latter amount of energy in a 
high efficiency liquid scintillator will produce approximately 30 photons. 
However, since the cathodes of most photomultipliers have efficiencies of 
only 10 the average tritium disintegration produces three electrons in
which require at least one electron to be produced simultaneously in each
of the two photomultipliers (Tamers, 1964)•
In the best scintillator solutions about of the tritium beta
particles are sufficiently energetic to produce the necessary two electrons
(Swank, 1953). The probability of electrons being produced in each of the
photomultipliers simultaneously is the square of the fraction of disintegr-
2 2 kations producing two photoelectrons, ie. ( /3) = /Q = f°.
Quenching, caused by the dissipation of the 7V-electron excitation 
energy of the excited solvent or solute molecules by other soluble, material 
present in the system, does not present a great problem in radioimmunoassay 
since it occurs to the same extent in both the standards and the unknowns. 
Colour quenching, caused by coloured or opaque materials absorbing some of 
the scintillation light energy before it reaches the photomultipliers, may 
occur with haemolysed or jaundiced plasma samples. This can be corrected
by applying the channels ratio technique for quench correction (Baiilie,
1960; Herberg, 1965).
ii. Gamma counting.
125
I is a gamma emitter and the sample preparation for counting this
isotope is much simpler. In most cases no preparation is necessary, the
sample is simply inserted into the gamma counter. The detector consists of
a sodium iodide ciystal activated with thallium and viewed by one or more
photomultiplier tubes. The thallium' is included to increase the efficiency
of the energy transfer mechanism in the crystal, acting in the same way as
the secondary solute in the liquid scintillation system. Most gamma
detectors used for radioimmunoassay employ a well sodium iodide crystal
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only one photomultiplier. If the volumes of material in the sample 
containers are kept constant, the counting efficiency for all the samples 
should remain the same. *
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Chemical structure of 
phenytoin.
Summary.
Phenytoin was conjugated to bovine serum albumin through th 3~N 
position of the hydantoin ring using a carbodiimide condensation reaction. 
The conjugates ?/ere injected into rabbits, sheep and goats, and using 
antisera raised in a sheep a sensitive radioimmunoassay has been developed. 
A comparison between the radioimmunoassay and a gas-liquid chromatographic 
method showed a good correlation betYfeen the two assays. The assay has 
been used to follow the disappearance of phenytoin from the blood of normal 
volunteers following the administration of oral phenytoin sodium. Two 
peak concentrations of phenytoin were demonstrated and the half-life of 
the drug, calculated from the second peak, was found to be 9*8 h.
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2a. PRODUCTION OF IMTOTOGENS.
Phenytoin was coupled to bovine serum albumin (BSA) using both 
carbodiimide and glutaraldehyde condensation reactions, and via the 
Mannich reaction using formaldehyde. The chemistry of the condensation 
reactions has already been discussed.
i. Carbodiimide condensation.
A typical carbodiimide condensation involved dissolving phenytoin 
sodium (149*3 rag) (Parke-Davis & Co. Ltd.) in distilled water. (3*0 ml) 
made alkaline by the addition of 4-6 drops 6n NaOH. BSA (201*7 rag) (Sigma) 
v/as added with vigorous mixing using a magnetic stirrer, followed by 
carbodiimide (250 mg) (EDC or CMC) (Sigma) and the solution stirred over­
night at room temperature. The conjugate solution was purified by dialysis 
against two changes of distilled water (1L each), freeze dried and stored 
until use.
ii. Glutaraldehyde condensation.
Phenytoin sodium (8*0 mg) was dissolved in alkaline dj.stilled water 
(3.0 ml) and BSA (20*0 mg) added as for the carbodiimide reaction. 2 fo 
glutaraldehyde solution (1*0 ml) (Sigma) was added dropy/ise with stirring 
and the mixture all owed to stand at room temperature for approximately 
3 h. During this time the solution changed in appearance from colourless 
to yellow. The solution v/as purified by dialysis against distilled water 
and freeze-dried.
iii. Mannich reaction.
For condensation using this reaction 3M sodium acetate (1*0 ml) and
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distilled water (3*0 ml). This was then added to a solution of phenytoin 
(24-6 mg) in alkaline distilled water (2*0 ml) and stirred for half an 
hour. After this time the pH was adjusted to 6*0 with glacial acetic acid 
(BDH) and the stirring continued for 1^ h. The solution v/as then dialysed 
against distilled water and freeze-dried.
Samples of all the dialysates were retained for U.V. analysis to 
■ determine the amount of drug that had not coupled to the BSA carrier.
Tahle 2.1 summarises the quantities of reactants used in the different 
pherytoin-BSA con jugation reactions and indicates the degrees of derivat- 
isation achieved. U.Y. analysis showed that the glutaraldehyde condensation 
reactions were unsuccessful, no phenytoin being bound to the carrier. Fig. 
2.1 shows the chemical structures of the conjugates that are thought to have 
been produced.
Conjugation .Wt. of Amount of Wt. of Amount Hapten:
method BSA couplingagent drug bound
carrier
ratio
mg mg or ml mg mg
CMC 1 20*6 101.0 20*8 9-2 152:1
condensation 2 202.1 251.1 150*6 43*0 55:1
EDO , 
condensation^ 201*7 249- 9 ■ 149-3 25.2 32:1
2 %' 4 20*0 1*0 8*0 0*0 ..
glutaraldehydq. 21.1 1.0 6* 3 0*0 —
Mannich 6 150-0 24-6 - -
Mannich prI7 7 150*0 25-8 18*2 29:1
with pHl2 8 150*0 25-8 17-4 28:1
HPFH dioxane 9 150-0 25-8 22. 9 37:1
Table 2.1. : Quantities of reagents used in Phenytoin-BSA conjugates.
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Fig 2.1 : Chemical structure of the phenytoin-BSA conjugates.
2b, DETERMINATION OF DEGREE OF DERIYATISATION.
The U.V. spectra of phenytoin, HPFH, BSA and carbodiimide, measured 
on a SP800 spectrophotometer, are shown in fig. 2.2; fig.2.3 shows the 
‘ U.V. spectrum produced by the phenytoin-BSA conjugates. Calibration curves 
U.V. absorbance against concentration of phenytoin (at235 nm) and HPFH (at 
243 nm) are illustrated in fig.2.4.
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0* 2
0*0
200 225 250 325300
Wavelength nm.
Fig 2.2 :U.V. absorption spectra of conjugation reactants.
The phenytoin U.V. spectrum shows a slight inflection at 235 nm that
was found to be concentration dependent; HPPH shows a distinct concentration 
dependent peak at 2A3 nm. .Neither the BSA nor the conjugating agents at the 
concentrations used , shov; strong U.V. absorbance at these wavelengths and 
would not therefore interfere with the measurements of phenytoin and HPPH..
When the U.V. spectra of the dialysates indicated the presence of 
unconjugated drug, the U.V.absorbance was measured and compared with the 
calibration curve and the amount of drug present in the dialysate determined. 
The amount of unconjugated drug was calculated by difference, and the hapten:
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Fig. 2.3 : U.V. absorption spectrum of pherytoin-BSA conjugates.
' *v
carrier ratio calculated from
y M W
x —*—-*-0 = Z moles hapten per mole carrier. . ii y
where x = wt. of hapten M.Y/.^  = mol.wt. of hapten
y = wt. of carrier M.W. = mol.wt. of carrier.c
The hapten:carrier ratios of the phenytoin-BSA conjugates are shown in 
Table 2.1.
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Conjugates 4 & 5 in table 2.1 were not used as the phenytoin had not 
bound to the BSA; conjugate 1 was also not used as it was thought that the 
degree of derivatisation was too high. The remaining conjugates were 
injected into rabbits, two rabbits receiving each conjugate. Those receiving 
the carbodiimide conjugates were each given a total of 520 ;ug conjugate over 
a period of six months. The conjugates were dissolved in sterile water (1*0 
ml) and emulsified with two parts Freund,1 s "complete" adjuvant (Difco), The 
initial dose was given by the low dose, multi-site, intra-dermal technique of 
Vaitukaitis et al.(1971) over 50 sites (0*05 ml/site) on the back and legs. 
Five booster injections were given intramuscularly at monthly intervals.
One year after the last boost, two of the rabbits, one on each preparation, 
were given a further booster containing 1 mg of conjugate in 0»5 nil sterile 
water, emulsified with two parts of an adjuvant consisting of Marcol 52 
(Esso Petroleum Co. Ltd.) with 10 % Arlacel A (Hill Top Research Co. Inc., 
Ohio, U.S.A.) (Marcol 52 adjuvant) (Morris, personal communication).
The animals receiving conjugate 6 were each given a total of 440 pg 
over four treatments. The initial dose was by id. injection with boosters 
by im. injection*, The immunogen was administered in aqueous solution 
emulsified with Marcol 52 adjuvant as before. The initial treatment also 
included 3 rog BCG vaccine/animal.
The phenytoin-EDC-BSA conjugate was administered to a goat by intra­
muscular injection. The goat received six im. injections,distributed over 
six sitesjat weekly intervals, each treatment consisting of 2 mg conjugate 
in 1 ml water emulsified with 2 ml Marcol 52 adjuvant. After a rest period
^4
was given by the same route.
The carbodiimide conjugates (nos.2& 3) were also administered intra­
muscularly to two sheep (Suffolk-cob hybrids). Both received similar 
treatment; the doses of conjugate and the timing of immunisations are 
illustrated in fig..2.6. The immunogens were dissolved in sterile water, for 
the first four treatments this was emulsified with Freund.*s "complete” 
adjuvant, and for the remainder with Marcol 52 adjuvant.
Venous blood samples were collected from the marginal ear vein of 
the rabbits and from the external jugular vein of the sheep, seven to ten 
days after each booster injection. Blood was collected from the jugular 
vein of the goat after the fifth, . immediately before and seven days after 
the sixth booster. The blood was allowed to clot overnight at. room temperature 
and the serum decanted after centrifugation. Merthiolate solution (0*6mM)
.(Lilly) was added as a preservative and antibacterial agent, and the serum 
stored at 4°C until use.
The sera were each given a reference code enumerating the animal and 
bleed, eg. G/s/3-Vc indicates that the animal was housed in Guildford (&) 
and was sheep (S) number three (3). The Roman numeral indicates the number 
of the booster immunisation, in this case the fifth, and the letter the 
bleed after the booster, here it is bleed "c”- the third serum sample 
collected following boost V and before boost VI. R indicates that the 
animal is a rabbit and G- a goat. The titre, ie. the dilution of the anti­
serum that will bind approximately 50 % of the added label in the absence 
of unlabelled antigen, is also indicated after the bleed number and is expressed 
as the final dilution. The values quoted in the dilution curves are the
2d. .assay procedure.
The protocol for both antiserum dilution curves and standard curves 
is shown in Table 2,2.
TOTAL NON-SPECIFIC A/S DILN. STANDARD CURVE
Ml
BINDING
Ml
CURVE
Ml
1,13
pi
ZERO
Ml
STD./SAMPLE
Ml
Diluent 300 300 200 100 100 100
Std/sample/
buffer - - - - 100 100
Label 100 100 100 100 100 100
Antiserum - - 100 200 100 100
DCC. - 200 200 200 200 200
Buffer 200 - - - -
Aliquot for 
liquid 
scintilla­
tion
counting
200 200 200 200 200 200
Table 2.2 : Assay protocol.
The diluent used initially was a 1:6 dilution, with 0*05 M phosphate 
buffer, pH 8*0, of Factor -VIII- and Fibrinogen-Free plasma (FF), obtained from 
the hospital blood bank, but was succeeded by 0*1 M phosphate buffered 
saline containing 0*1 % gelatin (PBSG-) (Cook et aj., 1973)? prepared as 
indicated in table 2,3.
Two different radioactive labels have been used in the development of 
the phenytoin radioimmunoassay. The first was a low specific activity ^ C  
label (A* 65 mCi/mmole) supplied by HEN with the radiocarbon at position 4 
in the molecule. Initially 0*20 nmole (0*926 nCi; 50 ng) were added per
(i) (2)
NaH2P0^2H20 7-8 g Na HP0. d 4 7-1 g
NaCl 4*5 g NaCl 4.5 g
NaN,
j
0*3 g NaN,
j
0*5 g
Gelatin 0*3 g Gelatin 0*5 g
Distilled
water
300*0 ml Distilled 500*0 nl 
water
Solutions (1) & (2) are mixed to give a solution 
having a pH 6*7 and a molarity of 0*1 M. .
Table 2.3 : Phenytoin assay buffer (PBS&)
assay tube, but this was later reduced by half.
The second label, a gift from Dr.J.Kepler (Research Triangle Institute,
North Carolina, U.S.A.), was tritiated phenytoin (^H-PPH, 56 Ci/mmole).
• 0*5 pmole of this label was added per assay tube.
\
The system used to separate the antibody-bound from free fractions 
was adsorption onto dextran-coated charcoal (DCC). To prepare the DCC 
suspension a 1*25 % w/v solution of Norit A charcoal (Sigma) was added to 
a 0*123 % w/v solution of dextran T-70 (Pharmacia) and the mixture stirred 
overnight at 4°C. The suspension was centrifuged at 20Q0 rpm and 4°C for 
3 min, and the supernatant discarded to remove the finings (ie. the particles
too fine to be precipitated at this speed). The same total volume of fresh
 ^ o
buffer was added to resuspend the DCC, which was then stored at If. C until
use. The aliquots of D.CC for the assay were taken while the suspension
was being stirred vigorously.
The liquid scintillant used was sulphur-free toluene (BDH) : Triton
X100 (BDH) (2:1) with 0*4 % w/v PPO (Packard Instruments) and
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For the detection of antibodies, dilution curves of the sera were 
constructed. Each serum was initially diluted 1:5 and then double-diluted 
with diluent over the range to be studied. 100 pi diluted antiserum was 
added to the appropriate tube and the assay carried out as described below.
For the standard curves^ a stock solution of the standard was prepared 
in buffer and diluted to the appropriate concentration with buffer. When 
^C-DFH was used^the stock solution (16 pg/ml) was diluted to 0«8 pg/ml 
and then double diluted to 15*6 ng/ml. Y&en ^ H-DFH was the label}10 pi of 
Hie stock solution (100 pg/ml) was made up to 10 ml with buffer (100 ng/ml) 
and then double diluted to give the range of standards used in the assay.
The assays were carried out in duplicate under equilibrium conditions 
by pipetting the reagents in the order indicated in the protocol, into 
numbered plastic tubes (LP3, Luckham) using Oxford raicrosamplers. After 
addition of the antiserum the contents of the tubes were mixed on a vortex 
mixer (Fisons) and allowed to incubate at room temperature for 25 h. The 
tubes were, then placed in iced-water for 15 min before the addition of cold 
(4°) DCC suspension. After mixing .the contents, the tubes were left 
for a further 10 min in ice followed by centrifugation at 2000 rpm and 4°C 
for 5 min on a Mistral 4C centrifuge (MSS). 200 ul aliquots of the super­
natants were pipetted into liquid scintillation vials (low potassium glass, 
Packard Instruments Ltd.) and 0*5 ml distilled water and 5*0 ml scintillant 
added. After shaking to obtain a clear solution the vials were loaded into 
a Packard Tricarb Liquid Scintillation counter and counted for 4 min per 
sample.
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The mean counts/minute for each set of duplicates, after subtraction 
of the mean non-specific bound (NSB) counts, was expressed as a percentage of the 
mean total count (fc Total). In the antiserum dilution curves^the titre of 
the antiserum was calculated from a plot of the % Total values against the 
antiserum dilution. For comparisons-between dilution curves, the values 
y/ere expressed as a percentage of the "Neat” antiserum value, and so all 
the curves started at 10C£b bound. For the standard curves^the % Total value 
was recalculated and plotted as the percentage of "maximum binding" value 
(MB) against the concentration of standard. The MB gives'an estimate of the 
amount of immunoreactive label present and not merely the total activity 
added.
2f. . ANTISEBLTM DILUTION .CURVES.
Using both ^C-DFH (0*1 nmole j/tube) and ^H-DFH (0*5 pmole/tube^ all 
the sera from the rabbits we re screened for antibodies to phenytoin. None 
of the sera showed any binding of the labels and it was assumed that no 
antibodies to phenytoin had been produced in these animals.
The screening of the sheep antiserum Y/as more successful in that serum
Jj I
from one of the sheep (g/3/3) showed binding of the label. Using C-DPH 
(0*1 nmole/tube) and 0*05 M phosphate buffer, pH 8*0, antibodies were 
first detected in G/S/3-IVb and a dilution curve set up. Dilution curves 
for this antiserum were also constructed with H^-DPii (1*0 pmole/tube) in 
the same buffer system and later with 0*5 pmole/tube in a PB3G- system.
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The three Oi-Lution curves-are snown m  n g .  <£.;?.
Defining titre as that dilution of antiserum that binde 50 % of the 
total amount of radioactive label present, the titre of the sheep antiserum
increased from 1:5 to. 1:640 final dilution depending on the concentration of
the label, the highest titre being found with the tritium label (0«3 pmole/ 
tube). Using this quantity of label and the PBS& diluent system, antiserum 
dilution surves were set up for all the serum samples obtained from sheep 
G/S/3. Fig. 2.6 shows the variation of antibody titre with time and the 
effects of boosting in this, animal.
The ability of the labelled drug to be displaced from combination with 
the antibody by unlabelled phenytoin, was examined by comparing two antiserum 
dilution curves of G-/S/3 Va. 0*5 pmole ^H-DFH was added to the tubes of each 
antiserum dilution curve and 39*5 pmole unlabelled phenytoin were added to 
the tubes of one of the curves. Fig. 2.7 show3 the two curves obtained, from 
which it can be seen that at 50 % binding, the addition of unlabelled drug
causes a fall in percentage bound of over 40 indicating that the anti­
body recognises both the unlabelled and labelled forms of the drug to 
a similar extent.
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a  = 0*10 nmole C-DPH
0*05M phos. buff. pH8*0 
© = 1*0 pmole ^H-DFH
0*05M phos. buff. pH8«0 
□ = 0»5 pmole ^H-DFH 
PBSG-.
100
<D
50.
50.
20*
10-
1:160 1:3201:40 1 :80:5 1:10 1:201
Antiserum Dilution (initial).
Pig. 2.5 : Antiserum dilution curves v/ith G/s/3-IVb.
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Antiserum G/S/3-Va
B= 0«5pmole 3H-DPH/Tube 
□ = 0*5pmole ^H-DPH + 39*5pmole DPH/Tube
100
1 :801:20 1:40 
Antiserum Dilution (initial),
1 :10
Pig.2,7 : Gr/3/3-Va - Antiserura dilution curve showing displacement 
of label by the addition of unlabelled DPH.
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Some of the factors affecting the radioimmunoassay for phenytoin 
were examined by constructing dilution and standard curves under different 
" conditions. Unless otherwise stated the antiserum used throughout these 
experiments was G/s/3~Va.
i. Effect of Label Concentration.
The effect of different concentrations of label on_the radioimmuno­
assay was examined by constructing antiserum dilution curves in the
3presence of different amounts of H-DFH label. The label dilutions were 
prepared in PBSGfrom a concentrated stock solution (2*5 mCi/ml; 4*4^ nmole/ 
ml) as shown in table 2.4.
nl STOCK ml PBSG- LABEL C0NC. 
pmole/ml.
30 3*31 130 .
20 3*32 100
10 3*33 30
10 16*70 10 = A
vol A
1*0 ml 4*00 5
300 ul 2*70 1
100 ul 4*90 0*3
30 ul 2*97 0*1
Table 2.4 : Preparation of phenytoin label at different concentrations.
The resulting dilution curves (figs. 2.8a & 2.8b) show that at low 
concentrations a smaller proportion of label is bound to the antiserura, 
while the NSB values, expressed as % Total,increase as the amount of label 
decreases (fig. 2.9). At higher concentrations of label the effect is less
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Antiserum G-/S/3-1/&
'H-DPH 130pmole/ml © 
100pmole/ml □ 
50praole/ml O 
10pmole/ml s
100 ^
60*
20.
10 *
1:160 1:3201:801 :10 1:20Neat
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3Fig.2.8a : Effect of H-DPH concentration on antiserum dilution 
curves.
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3Fig. 2.8b : Effect of H-DPH concentration on antiserum dilution 
curves.
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Fig. 2.9 : Effect of H-DFH on non-specific binding values.
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neat antiserum varying by only 10 %, The titre of the antiserum (table 2.5) 
varies with the amount of label added and is greatest at concentrations of 
50*0 and 5*0 pmole/ml (ie. 5*0 & 0*5 pmole/tube).
LABEL C0NC. 
PMOLE/ML
ANTIBODY TITRE 
(FINAL DILUTION)
150 1:.. 64* 8
100 1s 89*6
50 1:121*2
10 1: 67 *6
5 1:107*7
1 1: 80*0
0*5 1: 80*0
0*1 1: 45*0
Table 2.5 : Variation of antibody titre with concentration of label.
From the results it is apparent that the highest titre antiserum 
was obtained using 5*0 pmole/ tube, although this was only marginally 
higher than that obtained with 0*5 pmole/tube. In contrast when 5*0 pmole 
was used the N3B value was slightly .higher than that -shown, with 0*5 pmole.
Standard curves were constructed using 0*5 pmole and 5*0 pmole 
Al-DEH/tube and the results plotted as the percentage binding of zero 
for easier comparison (fig* 2.10). The two curves are virtually super- 
imposable indicating that a ten-fold increase in the amount of label has 
little effect on the sensitivity of the assay.
As the label was a gift and is not yet commercially available, 0*5prool®
□ 50* Opmole/ml M.B.= 32*53/^  ^ 
NSB = 2*99 $ T
o 5*0pmole/ml M.B.= 39*99^ T 
NSB =80 • 4*3^ T
70.
o—
Concentration ng/ml
3 ■
Fig. 2.10 : Effect of ^H-DFH concentration on phenytoin standard 
curve.
per tube was chosen as the concentration for use in other experiments, 
ii Effect of pH.
The effect of pH, over the range 6*5 to 8*3> was examined at 0*2 pH
intervals by setting up NSB, Zero and MB tubes at each pH value; Total
tubes were set up at pH 7*3- Buffers were prepared according to table 2.3 
and the pH adjusted by varying the ratios of the two solutions.
The results were expressed as the percentage binding of total and 
plotted against the pH value (fig.2.11).
The NSB value was found to be constant over the pH range tested while
the maximum binding and zero values fluctuated, the highest values being
found between pH 6*5 and pH6*9. A pH of 6*7 was therefore chosen as the
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optimum for the phenytoin assay
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Fig, 2.11 : The effect of pH on the maximum, zero and non-si:>ecific
x
binding values for
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The effect of protein concentration on the standard curves obtained
*1 h.
during a phenytoin radioimmunoassay was first examined with C-DFH and 
0*05Mphosphate buffer, pH 8«0, using three different systems. In the first 
system the standards were prepared in buffer with neat FFP added to the 
tubes to compensate for the amount of protein in any unknown samples. In 
the second and third systems the standards were prepared in a 1:5 or 1:100 
solution of normal serum respectively. The assay protocols are shown in 
table 2.6.
System (i) - standards prepared in buffer.
TOTAL
jul
NSB
Ml
MB
Ml
ZERO
Ml
STDS.
P1
Buffer 200 200 100 100 -
FFP 100 100 - 100 100
Std. - - - . - 100
Label 100 100 100 100 100
Antiserum - - . 200 100 100
Buffer 200 - - - -
DCC - 200 200 200 200
System (2) - standards prepared in —
System (3) standards prepared in —— j
TOTAL
Ml
NSB
Ml
MB
Ml
ZERO
Ml
STDS.
Ml
Serurn Serum 
3 °r 100 300 300 100 200 100
Std.' - - - - 100
Label 100 100 100 100 100
Antiserum 100 100 ,100 100 100
Buffer 200 - - - -
DCC 200 200 200 200
Table 2.6 : Assay protocols for the effect of protein concentration.
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The three standard curves produced are shov/n in fig, 2,12. The most 
sensitive assay results from the dilution of the standards in buffer
Antiserum G/s/3-IYb-1:5» 6 Label ^C-DFH 0*10 nmole/
tube.100
o Buffer 
AEFP/5
□ FFP/100
NSB = 10
bO •
30 ■
10 *
0 300 1000 1300
Concentration of DFH ng/ml
2000 2300 3000 3300 4000
Fig. 2.12 : Effect of diluent on phenytoin standard curves using ^C-DPH.
and the addition of serum to the diluent.
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four different diluent systems. These were as follows,
(1)all dilutions of the standards, label and antiserum were 
made with 0  05 M phosphate buffer, pH 8*0, and a 1:6 dilution of FFP was
added to all the tubes as diluent.
(2) All dilutions were made with 0*05 H phosphate buffer, pH8*0 
and buffer was added to the tubes as diluent.
(5) The standards were diluted with FFP, and 1:6 FFP in 0*05 M 
.phosphate buffer, pH 8*0, was used to dilute the label and antiserum and 
as the diluent.
(4) All the dilutions were made in PBSG-. .
Fig 2.13 shows the four standard curves produced, plotted as percent­
age of zero for easier comparison, and table 2.7 shows the variation of
NSB and MB values in the four systems expressed as the percentage of total.
SYSTEM (1) (2) (3) (4)
NSB 4*1 2*7 33*1 3*6
MB 54-8. 73-1 53*3 80*8
Table 2.7 : Effect of diluent system on NSB and MB values.
From these results it appears that system (4) is the most suitable 
producing low NSB and high MB values. Fig. 2.13 shows that system (1) 
results in the steepest curve, ie. shows the greatest fall in percentage 
binding with small increments in standard concentration. Curve (4) almost
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100
Diluent System:
80 'I
30 •
•H
10 «
Concentration ofDHi ng/ml
Fig. 2.13 i Effect of diluent on the phenytoin standard curve using 
3H-DEH.
parallels curve (1) and the higher MB values obtained with system (4) 
mean that the range of binding obtained with the antiserum is greater. 
This diluent system was that used by Cook et al* (1973) in ■’Qiei'r phenytoin 
assay and was used for all the phenytoin assays described here. Curve (4) 
(fig. 2.13) is typical of all the other standard curves produced under 
these assay conditions.
iv. Summary.
The optimum assay conditions, based on the results of the preceding 
experiments involve the use of 0»5 pmole ^H-DPH /assay tube with the 
standards, samples and antiserura being diluted with 0»1 M phosphate 
buffered saline, pH 6*7, containing 1 % gelatin.
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is little difference between systems (2) and (4), confirming that pH has 
little effect on the assay. However, the incorporation of an inert protein 
into the system results in a standard curve in which the points are much 
less scattered.
2h. . CHARACTERISTICS Off PHENYTOIN RADIOIMMUNOASSAY.
i. Determination of Avidity,
i
An assessment of the avidity (k ) and binding site concentration (n) 
of the phenytoin antibody was obtained by constructing modified Scatchard 
plots of the results of a standard curve* Table 2*8 shows the calculations 
involved; the"total nmole added/l" column also takes into account the 
concentration of the added ^H-DFH; fig* 2*14 shows the resulting curve.
TOTAL nmole 
ADDHD/l
ABOUND OF 
TOTAL
BOUND
nmole/l
FUEL
nmole/l
B
F-
1.25 53-07 o* 6634 0*5866 1*1310
2*04 49-06 1*0008 1*0392 0.9632
2*82 47-61 1-3426 1-4774 0*9088
4-39 39-84 1-7490 2.6410 0.6^23
7-50 32-79 2.4592 5-0408 0*4879
13-75 23.47 . 3-2271 10-5229 O.3067
26.25 16.93 4.4441 21-8059 0.2038
51-25 11-93 6.1141 45-1359 0*1355
101-25 8.91 9-0214 92* 2286 0*0979
Table 2.8 : Calculations for a modified Scatchard plot using 
&/S/3-Va-1:40. '
The shape of the modified Scatchard plot indicates that there are 
at least two populations of antibody binding sites in the antiserurn, these
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1*2 Antiserum G/3/3-Va-1 :lfX) 
Label - 3*0 pmole/ml
1-1
1*0
0*9-
0*8 .
0*7
0* 6 ■
0*5
0*4
0*3 '
0*2 .
0*1 .
63\
0 v 1*0
■ T ’
2*0
\
\
t-4-
3*0
Bound M/L x 10"^
4*0 3*0 6*0 7*0
mmpmmm
8*0 9*0
Fig 2.14^ :Modified Scatchard plot of G/s/3-Va~^  :^ 0*
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given by the slope of the asymptote to the curve, while its intercept 
with the abscissa gives the effective binding site concentration, n. Thus 
from fig. 2,11+a for G-/s/3-Va-1:40 the high avidity sites have
o a —q 4
K = 4* x 10 L.M. at an effective concentration of n = 3*18- x 10 M.L. .
7 —1The low avidity sites in the antiserum have K = 1*06 x 10 L.M. and it 
is possible that these are non-specific binding sites on the serum proteins.
As the titre of the antiserum increased so did the K and n values
’ — ■ 1 0 - 1  
(fig. 2.14b). Thus with G/s/3-Xa-1:2400/ K had increased to 1*23 x 10 L.M.
- 1 1 - 1while n = 3*40 x 10 M.L. . The low avidity binding sites have a decreased
6 -1
avidity, K = 4*80 x 10 L.M. , and are less significant when compared with
the high avidity sites.
These figures indicate that the high avidity binding sites have
increased in avidity but their effective concentration has decreased.
However, if this value is multiplied ty 60 to correct for the differences
- 9  -1in dilution>n becomes 2*04 x 10 M.L. , and since the antiserum dilution 
curves are not linear (see fig 2.8) this figure is comparable with that
•V
for &/s/3-Va-1:40. Thus the effect of the immunisation schedule employed, 
has been to increase the dilution at which the antiserum may be used to 
bind 50 fa of the label and to increase the avidity, but it has not altered 
the effective binding site concentration.
A modified Scatchard plot was also constructed to determine the avidity of 
the antiserum for the label alone. To do this a label dilution curve was 
set up in which a constant amount of the antiserum, &/s/3-Va-1:40, was 
incubated with doubling dilutions of ^H-DEH. A stock solution of %-DPH
88
tubes were set up in addition to those containing antiserum at each label 
concentration and the assay carried out as for an antiserum dilution curve. 
After correction for NSB, the binding of the label was expressed as the 
percentage of total label added and plotted against the label concentration. 
The values were also plotted in the form of a modified Scatchard plot.
Fig. 2.15 shows both the label dilution curve and the corresponding 
Scatchard plot.
Under these conditions &/3/3-Va has an avidity of 2«17 x 10 L.M.
—9 —1at an effective binding site concentration of 2*96 x 10 M.L. . This
—  x
indicates that the avidity of &/S/3-Va is greater for H-DPH than it is
for unlabelled phenytoin. However, the value when both labelled and un­
labelled phenytoin are present is only slightly lower and the difference 
in avidity should not affect the assay to any great extent.- In an ideal 
equilibrium system the avidity of .the antibody for the labelled and 
unlabelled antigen would be the same; if this is not the case and the 
avidity for one is much greater than for the other, then a^disequilibrium 
situation could result in a more sensitive assay. In this system the anti­
serum would be pre-incubated with the material of lower affinity before 
the addition of the one of higher affinity; a shorter incubation time would 
also be employed.
The high avidity of the phenytoin antiserum, in addition to the high 
dilution at which the samples must be assayed^ should be sufficient to over­
come the effects of non-specific binding to the serum proteins, if this is
6 7 -1
of the order of 10 to 10 L.M. as/with many other drugs.
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The sensitivity of the phenytoin radioimmunoassay was calculated 
from a standard curve constructed using G/S/3-Xa-1:2400. The sensitivity 
of the assay was defined as the gradient of the dose-response curve at zero 
concentration of unlabelled antigen divided by the standard deviation at 
zero (Albano <& Ekins, 1970). In this assay, the value was found to be 
320 - k-0 pg phenytoin / ml serum.
iii. Assay Variation.
An estimate of the intra-assay variation of a standard curve was 
obtained by setting up ten replicates at each point on a standard curve.
The standard error of the mean of each point was calculated and plotted on 
the mean standard curve (fig. 1.16). The &.E. of mean ranged from - 3*03 % 
at 25*0 ng/ml t o 1.53 ^  at 50*0 ng/ml.
The inter-assay variation was assessed on ten separate standard curves, 
each constructed in duplicate, over a period of one week. The same stock 
solution of phenytoin standard was used in each assay and stored at 4°C 
between assays. The mean standard curve - S.S. of mean, ranging from 
i 0*23 at 100*0 ng/ml to - 2*70 % at zero concentration of standard, is 
shown in fig. 2.17.
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Known amounts of phenytoin were added to two serum samples whose pher^ytoin 
content had previously been determined by radioimmunoassay. One of the 
samples was a normal serum pool, while the other was a pool of two clinical 
samples (endogenous pool) containing 3*686 jig/ml phenytoin,
A stock phenytoin solution (2.5 mg/ml) was prepared in PBSG and 
diluted to give a series of solutions containing 250 pg, 200 pg, 150 pgj 
100 pg and 50 jig /ml respectively. 10 jil of each of these solutions were 
added to 1 ml aliquots of the pooled sera.to give two series of samples, 
one containing only exogenous material and the other with both exogenous 
and endogenous phenytoin. For the assay, the samples were diluted 1 :250,
1:500, 1:750, 1:1000 and 1:2000 with PBSG.
The standards were prepared from th same stock phenytoin solution 
diluted to give 100 ng/ml and then double diluted with PBSG. The antiserum 
( G/S/3-Va-1 :if0) and label ( ^H-DFH, 0*5 pmole/tube ) were diluted with 
PBSG.
Table 2.9 shows the amounts of phenytoin recovered from both samples.
The recoveries are within the range normally found in radioimmuuoassays.
It is interesting to note that the recoveries of the endogenous pool are 
higher that those found in the normal pool, but show a greater variation.
The experiment indicates that the assay can be used to measure endogenous 
phenytoin and that the most suitable dilutions of the sample to use are 
1:750 and 1:1000.
94
SAMPLE DILN.
ng DPH 
ADDED
1:250
7°
oo' ^ 
^
 
v- 1:750
</°
ooO■v 1 :2000 
%
MEAN
RECOVERY 
OVER DILN 
RANGE A
5 88*0 101*0 75*0 68*0 64* 0 79*2
10 9 6-3 90*0 99*0 85*0 88*0 91*7
15 95-0 71*7 101*5 66* 7 73*3 81*6
20 97*5 103*8 93*8 95*0 85*0 95*0
25 72-5 85*0 90*0 74*0 61*6 76* 6
MEAN RECOVERY OVER 
CONCN. RANGE
89*9 90*3 91 *9 78*3 74*4
MEAN RECOVERY : 84* 9 fo
(2) Endogenous pool.
SAMPLE DIM. 1:250 1:500 1:750 1:1000 1:20Q0 MEANRECOVERY
ng DPH 
ADDED % % % /° %
OVER DILN 
RANGE %
5 156*3 88*3 81*3 9 6.3 - 105*5
10 127*1 153*1 89*1 127*1 95*1 118*3
15 93*8 84*8 79*0 91*4 67*4 83*3
20 111*6 129*1 90*3 60*1 59 *6 90*1
25 48* 6 98* 6 84*9 98* 6 69*4 80*0
MEAN RECOVERY OVER 
CONCN. RANGE
107*5 110*8 84*9 94*7 72*9
MEAN RECOVERY : 94* 8 %
Table 2,9 : Percentage recoveries of phenytoin from normal and 
and endogenous serum pools.
A clinical sample containing phenytoin was assayed at doubling 
dilutions from 1:20 to 1:1280; the sample dilution curve is shown in 
fig 2,18 superimposed on the standard curve obtained in the same assay.
The sample dilution curve closely follows the standard curve indicating that
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and that, since the standards were prepared in buffer, the serum protein* 
do not affect or interfere with the assay.
v. Cross-Reactivity.
The cross-reactivity of the phenytoin antiserum G/S/3-Va with the 
major metabolite of phenytoin, HPPH, was assessed by means of /a cross-react­
ivity curve . Two standard curves were set up, one using phenytoin as the 
standard and the other using HPPH. The antiserum was diluted with PBSG- 
to give a final dilution of 1:ipO, and the assay carried out as already 
described. Pig. 2.19 shows the two curves produced. The'percentage cross 
reactivity of the metabolite was calculated from the curves by applying 
the formula :-
Amount of phenytoin inhibiting binding at
zero by 50 % ________   X 100 = % Cross-
Amount of cross-reactant inhibiting binding reactivity
at zero by 30 %
For the antiserum &/s/3-Va this value was found to be 9 As has 
already been shown (fig. 2.6), the antibody titre increased with time and 
booster injections. Using G/s/3-Xa at a final dilution of 1 :1.600 in a 
similar experiment, the cross-reactivity was found to have.decreased to
_5 ^
<4*0 x 10 f0. Fig. 2.20 shows the cross-reactivity curves produced with
this antiserura both in linear (fig.2.20a) and log. (fig.2.20b) plot3.
The interference from twelve structurally related anticonvulsant drugs 
(Table 2.10) with the phenytoin radioimmunoassay was also examined by 
determining their cross-reactivity, Sulthiame, which is often used in
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Fig. 2.19 : Cross-reactivity curve of HPPH with G/s/3-Va.
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Fig. 2.20 : Cross-reactivity curve of HPPH with G/s/3-Xa. ^
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Ri E2 R3
X
PHENYTOIN (Parke-Davis)
c6H5 c6h5
H NH
HPPH (Parke-Davis) c6h4°h
c6H5
H NH
ETH0T0IN (Abbott)
c6H5
H C2H5 NH
MEPHENYTOIN (Sandos)
c6h5 Ci & CH,
WH
TRBIETHADIONE (Abbott)
CH3 CH3
CH, 0
PARAMETHADIONE (Abbott)
“ 3 CH3
0
FHENSUXIHIDE (Parke-Davis)
c6h3 H CH3
CH2
METHSUXIMIDE (Parke-Davis)
c6h5 CH3 CH3
ch2
ETH0SUXLMID3 (Parke-Davis) C2fI5 CH H ch2
PHENOBARBITAL
c6H5 C*
H CO-WH
METHYLPHENOBARBITAL 
(Winthrop)
c6h5 C2fI5 CH^ CO-NH
PRIMIDONE (i.e. I.)
c6H5 CA
H CO-WH
AMINO-G-HJTETHIMIDE (Ciba) c6h5i® 2
C# 5
H CH2*“CH2
HIEWETQRIDE (Bengue)
c6H5 C2tI5>H
H n h2 ' '
Table 2.10 jAnticonvulsants structurally related to phenytoin.
combined therapy with phenytoin, was also screened for cross-reactivity Tsith 
,the antibody.
Using G/S/j5-Va as the antiserum^none of the compounds listed in table 
2.10 (except phenytoin and HPPH) showed any reactivity with the antiserura
over T-ne xange U-IUU Ilg/lilX. XJIXO XXiU.JLUa.ocs> uiio.u one oawseiuiu xs> epeeXI XU
for phenytoin and unless other drugs possess an almost identical structurej 
it is unlikely that they will cross-react.
Parallel cross-reactivity studies were carried out with a phenytoin 
antiserum provided by Dr.C.E.Cook (Research Triangle Institute). This 
antiserum was raised in rabbits (New Zealand White) against a 5,5-diphenyl- 
hydantoin-3-(w-valeric acid)-BSA conjugate (Cook et al., 1973)* Preliminary 
studies indicated that this antiserum (code no. DR16-9) could be used at a 
final dilution of 1 .*7200. The cross-reactivity curves showed that the anti­
serum was specific for phenytoin^showing 0*08 % cross-reactivity with HPPH 
and none at all with the other compounds examined.
vi. Comparison with the Gas-Liquid Chromatography Method.
Thirty serum samples from patients receiving phenytoin therapy were 
obtained from Y/est Park Hospital, Epsom, where serum phenytoin extimations 
are carried out by gas-liquid chromatography (Papadopoulos et al, i 973) •
The samples ¥/ere assayed,using &/S/3-Va-1 ri^at three dilutions *1:500,
1:750 and 1:1000, and the concentration of phenytoin calculated. The values 
obtained by radioimmunoassay were plotted against the results of the GLC 
assay (fig.2.21). A highly significant correlation (r = 0*7825) between 
the two assays was seen and the Student’s paired "tn test showed no 
significant difference.
vii. Summary.
The applicability of the phenytoin assay to the analysis of clinical 
samples is demonstrated by the good recoveries that are observed with both 
endogenous and exogenous phenytoin. In addition there is vexy little
101
Y = 0« 8801X + 1 ♦ 4937 
r = 0-7825 
n = 30
22 •
20 *
^  16 *
•r!
O
0 2 4 6 8 10 12 14 16 18 20 22 24 26 23
Concentration By G-LC /ig/ml
Pig. 2.21 : Correlation between concentrations of phenytoin in unknown 
serum samples determined by radioimmunoassay and GLC.
variation either within or between assays. The antiserum is specific for 
phenytoin and is extremely unlikely to cross react with any other drugs 
that a patient may be taking. The high sensitivity of the assay enables 
determinations to be made on small samples of blood used at high dilutions. 
The high avidity of the antiserum for phenytoin and the high dilutions at 
which the samples are assayed obviate the effects of serum proteins on the 
assay and overcome the high non-specific binding of the drug to these serum
102
technique (GLC) for measuring phenytoin in' blood.
2i. DISAPPEARANCE OF PHENYTOIN FROM THE BLOOD OF VOLUNTEERS AS MEASURED BY 
JtAPIOB3fflJNOASSAY.
The disappearance of phenytoin from the blood of five normal 
volunteers was studied^using the radioimmunoassay just described to 
measure the blood levels of the drug.
i. Experimental Method.
Each of five subjects ingested 2 x 50 mg tablets of phenytoin sodium 
(Epanutin equivalent) following an overnight fast; food was not pemitted 
until 3 h after ingestion. Venous blood samples (1*0 ml) were collected 
before ingestion and over the next 102 h at the intervals shown in table 
2.11. The blood was allowed to clot at room temperature, the serum decanted 
after centrifugation and stored at 4°C until assayed. The radioimmunoassay 
was carried out in duplicate on the samples at 1:50, 1:100, 1:200, 1 :i*O0, 
1:800, 1:1600 and 1:2000 dilutions using G/s/3-Xa>-1:1600. All the dilutions 
were made using PBSG and all the samples from one subject were assayed in 
the same assay,
ii. Results.
Table 2.11 shows the concentrations of phenytoin and the standard 
errors pf each serum sample. Figs. 2.22 (a)^ (b) & (c) show the disappearance 
curves for each subject. All volunteers exhibited two plasma phenytoin peaks 
at 2«5-3«5 h and at 10-12 h after ingestion. Maximum serum concentrations 
ranged from 1*56 pg/ml to 2*76 pg/ml. Examination of the standard errors 
of the means at each point shows these peaks to be real and not due to
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Fig. 2.22 (c) : Disappearance of oral phenytoin from the blood 
measured by radioimmunoassay.
experimental error in three of the subjects. Logarithmic plots of the 
results obtained after the second peak had been reached in all subjects, 
v/ere used to calculate the half-life jaf. the drug (table 2.12). The mean 
half-life of phenytoin under these conditions was found to be 
9*81 - 0»66 (S.E, of mean) h.
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B.M. 9*30
J.R. • 8*30
D.T. 12.00
S.W. 10*30
W.A. 8-73
Mean T-J = 9*81 ~ 0*66 (S.E.of mean) h.
(T^ - calculated from first peak is approximately 13*2 h)
Table 2.12 : Serum half-lives of phenytoin following a single oral 
dose of 100 mg phenytoin sodium.
A. similar experiment was carried out with one volunteer (J.R) who 
ingested 100 mg HPFH contained in a gelatin capsule. Blood samples (200 pi) 
were collected by finger-prick before ingestion and 2, 3, 4, 5, 7, 10, 12,
15, 18, 25 and 33 h later. The samples were assayed using the same anti­
serum and assay conditions as were used to follow the phenytoin disappearance.
None of the samples assayed contained any phenytoinjdemonstrating that 
the second peak seen in the disappearance studies could not have been due 
to the dehydroxylation of any HPFH formed and the subsequent reabsorption of 
the free drug. The study also confirms that endogenous HPPH. Ndces not 
interfere in the assay.
iii. Discussion.
Many reports have indicated that peak plasma phenytoin concentrations 
occur 4-8 h after the ingestion of a single oral dose of phenytoin (G-lazlco, 
Chang, Baukema, Dill,Goulet & Buchanan, 19&9; Woodbury & Swinyard, 1972;
Kutt & Louis, 1972) and it was therefore surprising to find a second peak 
appearing after 10-12 h. Similar results, however, were reported by Lund, 
Alvan, Berlin & Alexanderson (1974) using a GLC method, although they them-
108
reason for this and for the failure of other investigators to observe the 
second peak may be a combination of the relative insensitivity of their 
'techniques (Lund and co-workers rejected all values below 3 y^ s/ral) an& the 
much higher doses administered.
The disappearance of phenytoin from the blood as observed using the 
radioimmunoassay and the plasma half-life agree with findings already 
published (Loeser,196.1, Tg = 18 h with 400 mg oral dose; Glazko et al., 19&9, 
Tg = 18-24 h with 250 mg oral dose and Tg = 14 h following an. intra-venous 
injection of 250 mg phenytoin; Dill et; al., 1971, Tg = 8 h with a 250 mg 
intra-venous dose). There is some evidence that at doses above 100 mg the 
half-life of phenytoin is dose dependent (Arnold & Gerber, 1970), but 
information regarding smaller doses is not currently available.
Phenytoinis rapidly taken up by hepatic tissues after oral 
administration (Woodbury & Swinyard, 1972), and the slow conversion to 
HPPH and/or conjugation with glucuronic acid may affect its metabolic 
disposition.
Dayton, Cucinell, Weiss & Perel (19&7) suggested that, in dogs, high 
doses of phenytoin may inhibit the microsomal enzyme systems involved in 
the metabolism of the drug and so cause a longer plasma half-life.
Although it is known that other drugs, such as sulthiame (Houghton &
Richens, 1974), inhibit the metabolism of phenytoin^there is no direct 
evidence to suggest that excess phenytoin inhibits its own hydroxylation 
mechanism. It was also suggested (Dayton et al., 19&7) that excess phenytoin 
might inhibit the glucufonidation step, thus interfering with the conjugation
109
If the situation does occur in man^t is conceivable that after an 
initial peak concentration of phenytoin has been reached, the feedback 
mechanism is activated and free phenytoin is released into the bile, 
returned to the intestine and reabsorbed. This, however,is more likely to
occur at much higher doses than were used in these experiments since the
/  >'! '
doses in this study were well below the therapeutic dose.
2 j. GENERAL DISCUSSION AM) CONCLUSIONS.
The conjugation techniques used in the production of the immunogens
for this work assume that the 3-N of the hydantoin ring :of phenytoin sodium
reacts in the same way as an group Jt has already been shown (section 1a)
thatjUnder alkaline conditions, the sodium salt of phenytoin dissociates
and electron rearrangement results in this nitrogen atom becoming activated.
Coupling can then occur, via a covalent bond, if an activated carbonyl
group is also present in the solution. This reaction is effected by the
action of a carbodiimide. The fact that glutaraldehyde could not be. used
to couple phenytoin to BSA indicates that the activated nitrogen is not
able to react as a secondary amino group. This contrasts with the situation
found with normorphine (see chapter 4) in which a cyclic secondary amino
group will apparently react with glutaraldehyde. In normorphine^the -N atom
is part of a six-membered piperidine ring while in phenytoin the activated
nitrogen is one of two in a five-merabered hydantoin ring. In the latter
case^the unreactivity with glutaraldehyde must be due to the electron
withdrawing properties of the rest of the molecule.
The lack of antibodies to phenytoin in many of the animals immunised
suggests that the conjugates may be non-immunogenic or only weakly so.
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one animal indicates that this is not so. The absence of antibodies can 
possibly be attributed to the immunisation schedule. All of the rabbits 
and the goat received only microgram amounts of the immunogen as a low dose 
is reputed to result in high avidity antisera (Playfair et al., 1974).
The sheep received much larger doses of immunogen, milligram amounts, and 
antibodies were produced. This suggests that with drug-carrier conjugates, 
particularly when the drug molecule is small, - large doses of immunogen are 
required. The avidity of the antiserum does not appear to have been 
adversly affected by the. large immunogen dose as it is as high as the 
avidities published for other drug-carrier immunogens.
lising the antisera thartr were'produced in the one sheep, it was 
possible to develop a radioimmunoassay for phenytoin. Some of the factors 
affecting the assay have been examined and it appears that pH changes have 
little effect as do changes in the amount of label within the range 50 to 5 
pmole ^DHi / ml.
It was thought that the high degree to which phenytoin is bound to
*v
serum proteins in the blood might create a problem in the assay. However,
the high sensitivity (320 - 40 pg/ml) enables the serum sample to be
assayed at a high dilution ( 500 times). It is known that at such a high
dilution most of the non-specifical!ly bound phenytoin is released and is
free in solution (Lunde, Pane, Yaffe, Lund & Sjoqvist, 1970; Lunde, 1971).
10 —1In addition the high avidity (10 L.M. ) of the antiserura for phenytoin
is sufficient to overcome the non-specific binding, which is thought to .
6 7 - 1
be of the order of 10 —10 L.M. . The recoveries of both endogenous and Exogenous
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radioimmunoassays (80-100 ?b). The radioimmunoassay is very specific for
of G/s/3-Xa
phenytoin, the cross-reactivity/with the metabolite being less than 4 x 10 
and it is unlikely that any other drugs, in addition to those examined,will 
interfere with the assay. There are two reasons for this, the first being
i f
that the antiserum appears to be specific for the chemical structure of 
phenytoin and can discriminate against drugs whose structure differs only 
at one site. The second is that very few drugs are administered at the same 
high doses as phenytoin; thus^ when the sample is diluted for the assay^ the 
concentrations of these drugs will be well below that of phenytoin and 
can be expected to be too low to have any effects.
The suitability of the assay for the measurement of phenytoin in 
clinical samples has also been verified by comparison with a standard GLC 
technique; there is good agreement between the two methods. The major 
advantage of the radioimmunoassay is its high sensitivity enabling 
determinations to be made on micro-samples of blood, such as those obtained 
from a finger-prick. This is an important factor particularly when the 
patient is an infant.
The high sensitivity of the assay has also proved valuable in 
following the disappearance of phenytoin from the blood of normal 
volunteers. Using the radioimmunoassay>it has been possible to detect, 
plasma phenytoin peaks that have been overlooked when less sensitive 
methods were used.
<
The radioimmunoassay for phenytoin, in additi.on to being used in the 
clinical situation to monitor therapy, could prove to be an invaluable
112
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made.
Of tho two published radioimmunoassays for pheiytoin, only that of 
Cook et al. (1973) bas characteristics comparable to those described here. 
The antiserum used in their assay was raised in rabbits against a conjugate 
of phenytoin to BSA^employing a 4 C spacer group between the drug and the 
carrier. The spacer group was attached at the 3-N position of the hydantoin 
ring and confirmed the same specificity on the antiserum as described here 
for a conjugate to the same site but lacking the spacer group. The addition 
of the spacer group increased the immunogenicity of the conjugate, the 
antiserum could be used at a dilution of 1:7200,compared with a titre of 
1:1600 when the drug was linked directly to the carrier. The specificity 
and avidity of the rabbit antisera are approximately the same as those 
for trie sheep antiserum; in fact the sheep antiserum shows slightly less 
cross-reactivity with HPPH and slightly higher avidity. This indicates that 
the insertion of a spacer group has no effect on the avidity and specificity 
of an antiserum, but will increase the immunogenicity of a %conjugate.
The phenytoin radioimmunoassay of Tigelaar ejt al. (1973) used ® low 
titre antiserum raised in guinea-pigs against 5-(p-carboxymethoxyphenyl)-
1 2l
5-phenylhydantoin-chicken-gamma-globulin.Their assay incorporated C-DPH 
as the label and had a sensitivity of only 300 ng/ml ( cf. a detection 
limit of 3 pg for the assay of Cook fct al. (1973) and 300 pg/ml for the 
assay described in this thesis); the results obtained, however, showed good 
correlation with the values obtained by GLC. The low dilution at which the 
antiserum had to be used (final dilution =1:8) and the inability of the
113
Tigelaar and co-workers prepared two immunogens of phenytoin, both coupled 
to the carrier by the same method; one being soluble and having 7 residues 
per mole and the other, with 47 residues per mole, being insoluble. It was 
the soluble conjugate that proved to be immunogenic. This may have been due 
to either the overderivatisation of the insoluble complex or to its 
hydrolysis, since this complex was solubilised with NaOH before administra­
tion (Tigelaar, personal communication).
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Following discussions with Professor R. Ekins of the Middlesex 
Hospital Medical School, London, it was decided to apply the computer 
optimisation programme of Mr. S. W. Elliot (Middlesex Hospital Medical 
School) to the phenytoin radioimmunoassay to discover v/hether or not the 
assay could be improved. For the optimisation several assay parameters were 
required':- target ligand concentration, time of constraint, response 
metameter, assay constants and the experimental error curve,
i. Determination of assay parameters.• ■
Target ligand concentration :- this was set at zero to give an assay 
of the highest possible sensitivity.
Time of constraint :- this is the maximum time allowed for the 
performance of an assay> including the counting time; no value was specified. 
Response metameter:- the metameter used was percentage bound of total 
Assay constants :-
a. Specific activity of the label this was supplied by 
Dr. J. Kepler^v/ho prepared the label, and was $6 Ci/mrnole.
b. Incubation volume determined by the assay protocol; this
was 400 /il.
c. Reaction constants these were determined for the anti­
serum G/S/3 -7a-1:40.
The equilibrium constant was determined by constructing 
a standard curve, each point being replicated ten times, and plotting the 
results in the form of a modified Scatchard plot (see 2h i). The 
equilibrium constant, rtK value" determined was 4*49 x lO^L.M^at a binding
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serum.
The dissociation constant (k^ was determined for the same
* 3 .antiserum using 1*0 pmole H-DFH per tube. Initially the antibody binding
sites we re saturated with label by adding twice the amount of ^H-DHi that 
would normally be used in an assay. After phase separation^the bound fract­
ion in the supernatant was transfered to a second series of tubes and 
either buffer or unlabelled phenytoin added to the tubes. In this way when 
the label was displaced from the binding sites to restore the equilibrium 
conditions, its place would be occupied by unlabelled material where this 
was present in excess. Thus by separating the free and bound phases again 
at various time intervals^ a measurement of the dissociation rate could be 
made.
Sixty-four tubes containing 200 pi PBSG-, 100j i l  ^H-DFH and 100 pi 
antiserum were incubated for 2%h at room temperature before being placed 
in iced-water. 15 min later^200 pi DCC suspension were added and the tubes 
centrifuged. 500 pi aliquots of the supernatants were transferred to a 
second series of tubes in iced-water. 100 pi phenytoin solution (200 ng/ml) 
were added to half the tubes to compete with the label for the antibody 
binding sites in the equilibration, reaction, and 100 pi P3SG to the 
remaining tubes. At various time intervals after this addition DCC was 
again added to the tubes, in groups of four, which were then centrifuged 
5 min later, and 500 pi aliquots of the supernatants transferred to liquid 
scintillation vials. 5*0 ml liquid scintillant were added and the activity 
counted on a beta-counter. The results were expressed as percentage bound
116
with and without the addition of unlabelled phenytoin.
Assuming that the reaction taking place :-
kP
CAgAb]   s[AgJ + fi-W .
k 1
is a first order reaction then the dissociation of the antigen-antibody 
complex with respect to time is given by
=  k  CAglfAbl. 
dt *
By applying physical chemistiy principles, then
* = log a _ log (a-x)^
k2 k2
where " (a-x)M is the concentration of AgAb complex remaining after time
wttt, and "a" is the initial concentration of complex. Thus a graph of
t against log (a-x) should be linear with a gradient of from which
2
kg can be calculated. Fig. 2,23b shows such a plot having a gradient of
-  100 
0*39 x 1CT15 %
Thus -2* 303 _ -100
k2 0*39 x 10“i5
Therefore kg = 8*89 x 10“^  sec*^.
For the Scatchard plot data,
k
K = rr where K = 4*494 x
2 ‘ .
-10  ~  k1 Thus 4*494- x 10 = ______  .. ,
8*89 x lO”^
Therefore the association constant k^ = 4*036 x 10~^L.M7^sec~^.
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assay error, taking into account the counting error, operator error and 
equipment error. The error curve was based on the results of the standard 
curve that was set up in ten replicates. The variance at each point on the 
standard curve was determined and from these values the counting error 
variance was subtracted to give the experimental error variance. The 
counting error is given by j j-
Sample cts. in time t / Background cts. in t
Counting Error = I ~ ‘ - / “
^ s ™ ^ b
where the subscripts Hsn and r,bM indicate sample and background respectively. 
Since the background counts were low and constant for all the samples>this 
was ignored; thus the counting error was based on the cts./min for the 
sample. The coefficient of variation for each point was calculated from
Coeff, of Variation = /Experimental Error Variance
/V x
and plotted against the mean count rate (x) (fig. 2.24).
This information was fed into the London University computer by
Mr.S.Elliot to produce the optimum assay conditions.
ii Results.
The assay was optimised for both equilibrium and disequilibrium 
conditions and it was found that for an equilibrium assay, the antigen- 
antibody binding reaction was completed after 2^ h, the incubation time 
chosen arbitarily at the beginning of the work. For an equilibrium assay 
employing a sample counting time of 10 min per sample the concentrations of 
antiserum and label shown in table 2.12, at various incubation times were
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INCUBATION PRECISION PREDICTED LABEL C0NC. Ab. C0NC.
' TIMS MIN. / BOUND M.L."1 M.L."1
7-5 1*02 x 10~9 8* 91 1*02 x 10~9 7*67 x 10"10
15*0
-10
5*57 x 10 8*90 6*31 x 10 ^ 4*36 x 10~10
45-0 2*65 x 10"10 8* 90
—1 n
3*62 x 10
-10
2*72 x 10
60*0 2*36 x 10~i0 8*90 3*43 x 10“10
-10 
2.57 x 10 '
90*0 -102.15 x 10 8*90
-103*32 x 10 -101.49 x 10
. -10 . -10 -10150*0 2*09 x 10 8*90 3*30 x 10 2.47 x 10
Table 2.12 : Optimisation of phenytoin assay - optimum concentrations 
of label and antibody for 10 min counting time.
An experiment was set up using the concentrations.of reagents 
indicated above. For each incubation time a series of Total, N3B, MB, Zero 
and 10 ng standard tubes were set up in duplicate. Separation was achieved 
by DCC and 500 pi aliquots of the supernatants were counted for 10 min.
The results were calculated as the percentage of total and are shown in . 
table 2.13.
INCUBATION 
TIME MIN.
TOTAL
c/m
NSB
/To
MB
/To
ZERO
/To
10 ng Std. 
/To
7-5 641*2 25*0 27*6 25*2 38*2
15.O 373-9 32*1 79-8 34-2 29-0
45-0 323-8 31-3 43-5 41*1 3^*1
60*0 307-1 28*8 37-6 33-3 33-4
90*0 316*1 33-8 33-6 33-2 39-3
150*0 417-1 100*0 33-2 43-9 2 5*6
Table 2.13 : Results of experiments using optimised conditions.
The MSB values for all the incubation times were found to be high 
and often higher than the value for the 10 ng standard (none of the figures 
reported are corrected for USB). The most useful results are found with
121
high MB value hut only a 5 % fall in percentage binding when 10 ng standard 
were added. This suggests that the resulting assay would be relatively 
insensitive as a large amount of antigen would be needed to reduce the 
binding by as much as 10/5. The predicted percentage bound value is much 
lower than any of the experimental values. An assay in which the percentage 
binding in the zero tubes was only 9 % could also be expected to be 
relatively insensitive and therefore not applicable to a clinical situation 
where the correct serum levels may be crucial.
iii.Comparison of Equilibrium and Disequilibrium Conditions.
Two phenytoin standard curves were set up in duplicate using th8 
antiserum &/S/3-Xa-1:1600 with 0*5 pmole ^H-DPH/tube. One standard curve 
was set up under normal equilibrium conditions with an incubation period 
of h as already described. The other curve was. under disequilibrium 
conditions, with the antiserum and standard being incubated for 1-J h before 
the addition of the label. The total incubation time was h.
Fig, 2.25 shows the two standard curves produced and indicates that 
a disequilibrium assay results in a slightly greater fall in percentage 
binding over the range of standards used. In this experiment the same 
concentration of label was used in both assays, but a recent communication 
(Ekins, Elliot & Newman, in press) has suggested that in disequilibrium 
assays a large excess (up to 100 times) of label over the concentration 
of hapten should be added for the most sensitive assay. However, because 
of the shortage of ^H-DPH and in view of the fact that there is little to 
be gained by increasing the sensitivity of the phenytoin radioimmunoassay,
122
iv. Conclusions.
The results from the experiments using the optimised quantities of 
reagents„indicate that the phenytoin radioimmunoassay cannot be improved 
very much. A dis-equilibrium assay would appear to be slightly more sensitive 
than an equilibrium assay, using the same amounts of labelled phenytoin. It 
is possible that the use of a large excess of labelled phenytoin in a dis­
equilibrium assay would result in even greater sensitivity than is already 
achieved with an equilibrium system. However, the label is not readily 
available and this approach was not therefore viable. Thus,it was concluded 
that the existing phenytoin radioimmunoassay could not be improved upon, 
and the values obtained for the concentrations of reagents in the optimised 
system were not utilised in the experiments using the radioimmunoassay.
12 3
oj
LT\
«r-' Vo" ' 
fAVO CM VO
• . • • •I"- m  KMA
r-
W
K">
CO * CO
o
CO
m
ooN^> oomo ovooCO
I—I
i
d
o*H+>
a
"Sooc;
o
o
W-4
&
-skjo s«tp«ts ^
124
ig
. 
2.
25
 
: 
Co
mp
ar
is
on
 
of 
eq
ui
li
br
iu
m 
an
d 
di
se
qu
il
ib
ri
um
 
co
nd
it
io
ns
 
fo
r 
ph
en
yt
oi
n 
ra
di
oi
mm
un
oa
ss
.
CHAPTER 3
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Chemical structure of sulthiame*
Summary.
Sulthiame has been conjugated to BSA through the sulphanilamide 
grouping of the molecule using a variety of coupling reactions and the 
immunogens injected into rabbits, sheep and goats for antibody production.
The sera were screened for the presence of antibodies to sulthiame
125using a sulthiame molecule radioactively labelled with I. Sulthiame has
• been labelled by catalytic tritiation at the Radiochemical Centre and this 
label used to screen the sera for antibodies to sulthiame.
Although the iodine label bound to the sera, it could not be 
displaced with unlabelled sulthiame. The tritium label, howeVer, did not 
bind to the sera suggesting that the antisera are not reactive for sulthiame.
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3a. ANTIBODY PRODUCTION,
i. Preparation of Immunogens.
Sulthiame (Bayer Pharmaceuticals) has been coupled to BSA using 
several' different methods. The quantities of hapten, carrier and coupling 
agent used are shown in table 3*1* The procedure for the reactions using 
earbodiimides and glutaraldehyde as the coupling reagents, and for the 
Mannich reaction, was the same as that already described for the production 
of the phenytoin conjugates (section 2,i).
Conjugation
method
Wt. of 
BSA 
mg.
Amount of 
coupling 
agent 
mg or ml
Wt. of 
drug 
mg
Amount
bound
mg
Hapten:
carrier
ratio
SULTHIAME , 
CMC . '
condensation 2
10*5
200*5
101*0
1999*8
20*0
64*0 10*8 12:1 *
3 200*4 228* 6 64* 0 59*7 72:1 *
EDC ^ 20-7 102*5 6* 4 2*0 23:1
5
condensation 19-9 205*4 6.3 1*3 16:1
6 20*7 23*4 6* 8 1*4 17:1 *
Polar 7 704*8 - 43*6 14*3 5:1 *
Glutar- 20*0 1*0 6* 0 1*1 14:1
t.  ^ 0*021H 9 20*0 1*0 6* 0 0*5 6:1aldehyde
2 %  10 19*9 1*0 6*4 1*6 19:1 *
11 199*7 10*0 59.8 3*3 4:1
12 199*7 20*0 120*3 10*4 12:1
50fo 13 20*2 1*0 6* 1 0*7 8:1
Methylated BSA 14 200*9 - 12.4 0*5 1:1 *
Mannich 15 26*1 - 150*0 $
SULHiANILAMIDE
glutaraldehyde
35 . 16 200*7 1*0 20*0 8*9 18:1 *
Mannich 17 16*4 - - 150*0 5*0 13:1 *
* Denotes those conjugates injected into animals.
Table 3*1 : Quantities of reagents used for sulthiame-BSA conjugates.
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both the sulthiame and the BSA in distilled water (105 ml) and allowing
the mixture to stand overnight at room temperature. The complex was
purified by exhaustive dialysis against five changes of distilled water
(total volume = 12*5 l). Samples of each of the dialysates were retained
and the unconjugated sulthiame Dresent determined by U.V. spectrophotometry.
/ .
A similar procedure was used to 'bind sulthiame to methylated BSA 
(MBSA) using the amounts indicated in table 3.1, but resulted in fev/er 
molecules of sulthiame being incorporated per molecule of BSA.
In an attempt to leave the sulphonamide grouping of the molecule free 
to act as an antigenic determinant^ sulphanilamide was used as the hapten.
The chemical structure of sulphanilamide is
This compound was coupled to BSA by the Mannich reaction and also using 
glutaraldehyde as the coupling agent. The amounts used in these reactions 
are shown in table 3*1.
If it is assumed that the sulphonamide group behaves chemically in 
the same way as a primary amino group under these reaction conditions, then 
the structure of the immunogens would be as illustrated in fig.
ii. Determination of Degree of Derivatisation.
The U.V, spectra of sulthiame, sulphanilamide and of typical conjugates
to BSA are shown in figs. 3.2 and 3.3. The drug-BSA conjugates exhibited
129
\ _ / t \
H
SOr—  N— C— BSA2 I
Sulthiame-(EDC/CMC)-BSA
2. Glutaral dehyde:
c f \
// V ” ’ , «« xv-SO— c— (CH2)^- C— N— BSA
H
Sulthiame-Glut-BSA
lffl— iS02— \ N-C -(CH2) —  C — N—  BSA
0 H
Sulphanilamide-Glut BSA
3. Mannich Reaction:
A v  H H H
/ \  1 1 1 NHg— SO — P Vn—C—N— BSA
H H
/ V — i SO*— H — C— N-\  /  \  r  *  , . ,
-A H H
Sulphanilamide-Man-BSA Sulthiame-Man-BSA
Fig. 3.1 ; Postulated structures of sulthiame immunogens.
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BSA
Ab
so
rb
an
ce
Sulphanilamide
Sulthiame
^Carb odiimide
0*2 BSA'
0*0
250225200 300
Wavelength nm.
Fig 3.2 : U.V. absorption spectra of conjugation reactants
similar U.V. spectra to those of the phenytoin-BSA conjugates.
The degree of derivatisation was determined in the same way as 
that of the phenytoin-BSA conjugates^by measuring the U.V. absorbance of 
the dialysates at the appropriate wavelengths ( sulthiame = 245 nm; 
sulphanilamide = 253.5 nm) and comparing the values with the U.V. 
calibration curves for these compounds (fig. 3.4). The molar ratios of 
drug:BSA obtained are shown in table 3.1.
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»
1*4
0* 6
0*2
0*0
200 225 250 275 300
Wavelength nm.
^ig 3*3 i U.V. absorption spectrum of sulthiame-BSA conjugates.
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The conjugates marked * in table 3.1 were injected into rabbits, 
sheep and goats. The animals immunised v/ith each conjugate and the total 
doses of immunogen are shown in tables 3.2a and 3*2b. Each treatment by 
ini. or sc. routes consisted of six injections, tv/o in each hind limb and 
one in each fore limb. The treatments using the id. route involved 50 
separate injections at various sites over the back and hind limbs. The 
immunisation schedule for a sheep, receiving im. injections, is illustrated 
later in fig.3.14.
All the conjugates were dissolved in distilled water and, for the 
rabbits, emulsified with three parts Freund*s "complete" adjuvant for the 
initial immunisations and y/ith tv/o parts adjuvant for the boosters. The 
sheep and goats were immunised with a 1:2 aqueous:adjuvant emulsion’using 
Freund*s "complete" adjuvant for the first six treatments and Marcol 52 
as the adjuvant for the remaining injections.
The sera were collected, coded and stored in the same way as the 
phenytoin antisera (section 2.c).
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ANIMAL BREED CUEJUua.TE 1^0.
OF
nUUXXU
TREATMENTS CONJUGATE GIVEN 
mg
g/r/io NZW 1 X id. 0*030
G/R/11 NZW S-EDC-BSA 3 X sc. 0*171
&/R/19 D 4 X im. 1.250
G/r/20 D
G r/R /7 D S-CMC-BSA 1 X id. 0*050
4 X sc. 0*169
4 X im. 1*250
G-A/19 D S-GLUT-BSA 1 X id. 0*044
4 X sc. 0*169
4 X im. 1*250
&/R/18 NZW S-POLAR-BSA 1 X id. 0*021
4 X sc. 0*169
6 X im. 3*650
G/R/15 D S-POLAR-BSA 1 X id. 0*049
4 X sc. 0*169
4 X im. 1*250
&/R/26 D S-MBSA 1 X id. 0*100
4 X im. 1*221
G/R/32 D S-MBSA 5 X im. 1*321
G/R/29 D S-MANN-B3A 1 X id. 0*100
4 X im. 1*221
G/fi/36 D S-MANN-BSA 5 X im. 1*321
G/R/27 D SULFH-G—BSA 1 X id. 0*100
4 X im. 1*221
G/R/37 D SULPH-G-BSA 5 X im. 1*321
&/R/28 D SULFH-MANN- 1 X id. 0*100
BSA
4 X am. 1*221
&/R/35 D SULHI-MANN 5 X im. 1*321
BSA
D = Dutch NZW = New Zealand Y/hite
Table 3«2a :Immunisation schedules for rabbits.
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OF TREATMENTS CONJUGATE GIVEN 
nig
a /a /i S-EDC-BSA ■ 6 X sc. 3*098
4 X im. 4* 000
a/a/2 S-EDC-BSA 1 X sc. 23*000
3 X im. 3*000
a /s /3* S-EDC-BSA 9 X im. 20*000
a/s/K ti tl tt
G-/S/5 tt It it
G/S/1 S-GLUT-BSA 9 X im. 20*000
a/s/2 tt It tt
a/s/6 tt tl ti
Sheep = Suffolk x cob hybrid,
(* this sheep also produced the phenytoin antibodies)
Table 3*2b : Immunisation schedules for goats and sheep.
3b. PREPARATION. OF'RADIOACTIVELY. LABELLED SULTHIAME.
A radioactively labelled form of sulthiame was not available from 
either the manufacturer of the drug (Bayer Pharmaceuticals) or radio­
pharmaceutical suppliers and it was therefore necessary to produce a label 
for use in the radioimmunoassay. Radioiodination tags were used to
facilitate labelling with' radioiodine and the drug was also submitted to
<
the Radiochemical Centre for tritiation by catalytic exchange. 
i. Radioiodination.
Direct radioiodination of sulthiame was considered unsuitable as the
introduction of such a large atom as iodine into the molecule could alter
the overall shape of the molecule and interfere with the antigen-antibody
reaction. However, antisera are reputed to be relatively indifferent to
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for production of the immunogen (Hunter, 1974).Therefore a radioiodination
tag, tyrosine methyl ester (TMS)^  was coupled to sulthiame by a carbodiimide
125
condensation reaction and the complex iodinated with I by the 
ehloramine-T method (Greenwood, Hunter and Glover, 19&3)
Preparation of sulthiame-tyrosine methyl ester.
A typical conjugation involved dissolving THE (50 rag) (Koch Light) 
in distilled water (5 ml) and stirring in the carbodiimide EDO (30 mg). A 
solution of sulthiame (20 mg) in dimethylf ormamide (2 ml) wqs then added 
dropwise. After stirring for 18 h at room temperature^ the mixture was 
purified by gel filtration on a Sephadex G-10 column (20 x 1 cm). Fractions 
( 3ml) of the distilled 7/ater eluate were collected and screened on a 
SP800 spectrophotometer. The fractions containing the sulthiame-TME complex 
were pooled, freese-dried and stored at -10°C. The complex was eluted from 
the column first, followed by_TME and then sulthiame.
Identification of sulthiame-TME.
The material that was eluted from the column first had a U.V. spectrum 
(fig. 3*5) that did not resemble that of sulthiame, THE or that produced 
by an equimolar mixture of these two compounds. It was therefore thought 
that this was a conjugate of sulthiame and TME. The U.V. spectra of the 
remaining fractions resembled firstly that of TME, then that of a mixture 
of sulthiame and TME, gradually changing to the U.V, spectrum of. sulthiame.
Thin-layer chromatography of the conjugate in a methanol :n-butanol 
(60:40) system, using pure sulthiame and TME as markers^ showed the R^ of 
the complex to be less than that of sulthiame and greater than that of
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Fig.3.5 : U.V. absorbance spectra of sulthiame-TME complex^ sulthiame 
+ TME mixture and TME.
TME. In addition^the complex could be visualised under U.V. light (25A nm) 
and as a pink/purple spot after treatment as follows :- the plate was 
sprayed with 0*1 ^ ^ “nitroso-^-naphthol in 90 % ethanol, followed, Y/hen 
the plate was dry, by. a 10 % HNO^ spray. The plate was then dried at 70°Cj 
when the colour developed. Of the markers, only the sulthiame was visible 
.under U.V. light and only the TME stained with the dye. This evidence, 
together with the U.V. spectrum^ indicate that the material is a conjugate 
of sulthiame to TME. The reaction that is thought to have taken place is
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Radioiodination of Sulthiame-TME.
Radioiodine was introduced into the drug-tag complex by the'
128chloramine-T method. Na ^1 solution (lmCi, 10 pi)(Radiochemical Centre,
glass iodination vial using a microcap pipette 
(0*05 M phosphate buffer, pH 8*0) were added. 
"This was followed by the addition of 10 pi of conjugate solution ( 0*2 mg/ml) 
and 15 pi chloramine-T (3*5 mg/ml)(BDH). The mixture was shaken for 20 sec 
and 100 pi sodium metabisulphite (2*5 mg/ml)(BDH), 100 pi potassium iodide 
(10*0 mg/ml) (BDH) and 500 pi buffer added. The mixture was transferred to 
a Sephadex CM O' column (40 x 1 cm) and eluted with buffer; 1*0 ml fractions 
were collected.
10 pi aliquots of each of the fractions were pipetted into LP3 tubes 
and the radioactivity estimated on a Wallac gamma counter (LKB). The 
count rate was plotted against the fraction number to give the elution 
pattern of the label; fig. 3.7 shows a typical label elution pattern.
Chromatographicelectrophoresis of samples of the iodination mixture 
before purification and of the high activity fractions after purification 
were carried out on Yfriatman JsM filterpaper (lhatman » Batch 7144^07) i&
0*05M barbitone buffer, pH 8*6. The solvent front was allowed to travel 
along the paper for twenty minutes before the strips were saturated with 
buffer and the lid placed on the tank. A constant voltage (180 v) was 
applied for 1 h 20 min and the strips dried in an oven. A radiochromato­
gram scanner (Berthold) was used to locate the areas of radioactivity and
I
produce the chromatographicelectrophoretograms shown in fig.3.8.
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125Fig. 3.7 : Elution pattern.of sulthiame- I-TME from Sephadex
G—10 column*
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Fig. 3.8 : Chromatographicelectrophoretograras of sulthiame-^^I-TME iodination
’ mixture and fractions after purification on Sephadex G~10.
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mixture in place of buffer, prior to gel filtration (Hunter & Greenwood, 1962). 
It was thought that the presence of protein would reduce the adsorption of the 
drug to the glass-ware and facilitate its elution from the column. However, as 
it was found that the protein itself became labelled by adsorption of either 
free radioiodine or iodinated drug-tag complex, resulting in high non-specific 
binding values in the assays, it was not included in subsequent iodinations.
Conjugation Labelling of sulthiame.
Two other radioiodine labels for sulthiame were prepared using the 
conjugation labelling technique of Bolton and Hunter (1972). This method 
involves the radioiodination, by the chloramine-T method, of the N-hydroxy- 
succinimide ester of 3-(p-hydroxyphenyl) propionic acid (HFHS). The 
iodinated ester is extracted into benzene and evaporated to dryness. The 
addition of an aqueous solution of the antigen results in an immediate 
condensation reaction whereby the iodinated acyl groups are linked to the 
antigen through a peptide bond.
Using acylating agent kindly supplied by Professor Rddinger of Zurich, 
both sulthiame and the sulthiame-CMC-BSA conjugate were labelled with radio­
iodine by this method.
The acylating agent was dissolved in toluene:ethyl acetate (1:1) to
give a concentration of 20 pg/ml and stored at -18°C. For the iodination
reaction, the ester solution (lOpl) was tiansferred to a glass vial, using
125a microcap pipette, and the solvent evaporated. To this was added Na •'I 
(2 mCi; 20 pi) followed by 10 pi chloramine-T (0*3 mg/ml). After shaking
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each in 10 yul 0*05 M phosphate buffer, pH 7*5, and dimethyl formamide (5 /il) 
were added. The iodinated acylating agent was extracted into benzene (1*0 ml) 
far 5 min and this layer transferred to a Fiolax glass tube where the benzene 
was evaporated under an air stream.
Sulthiame or sulthiame-CMC-BSA solution (50 ug/rnl in 0*05 M phosphate
buffer, pH 7*5) was added to the dried ester and 30 min allowed for the
reaction. The reactants were then diluted with buffer (1*0 ml) and
transferred to a Sephadex G-10 column (40 x 1 cm) for purification. Fig 3*9
illustrates the reaction that may have taken place with sulthiame. Fig. 3*10
125shows the elution patterns of both sulthiame- I-HPHS and sulthiame-CMC- 
125B3A- I-HPHS labels from the Sephadex columns. The chromatographicelectro- 
phoretograms of the tY/o iodination mixtures before purification are shown 
in fig. 3.11.
ii. Tritiation.
Sulthiame was labelled by the Radiochemical Centre using a catalytic 
exchange method (Radiochemical Centre code TR 1). Before the sample of 
sulthiame was submitted for labelling^its stability under the reaction 
conditions was examined.
The sulthiame (0*5 mg) was dissolved in dimethylformamide (3 ml) and 
the catalyst (10 % Pt on charcoal) (1 g) added. The mixture was heated under 
reflux for 24 h, centrifuged to precipitate the catalyst and the supernatant 
freeze dried. U.V. analysis and melting point determinations resembled those 
of untreated sulthiame. This indicated that the drug could withstand the
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125Fig. 3.9 : Conjugation labelling of sulthiame with I-HPHS.
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Fig. 3*10 : Elution patterns of conjugation labels for sulthiame 
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Fig. 3.11 : Chromatographicelectrophoretograms of iodination mixtures 
from conjugation labelling reactions with sulthiame.
Centre.
After tritiation, the material was returned in ethanolic solution with 
an activity of 160 mCi/0*5g* and was stored at -20°C. TLC of the material in 
a methanol:n-butanol (60:40) system showed the material'to be l$fo pure, using 
untreated sulthiame as the reference compound. An aliquot of the label was 
purified.by TLC and eluted from the plate with ethanol. This material was used 
in assays to screen for the presence of sulthiame antibodies.
3o. ANTISERUM SCREENING-.
i. Using Sulthiame-CMC-BSA-1 ^ I-HPHS.
125Because of the low activity of the sulthiame- ^I-HEHS after punfic-
125ation, this label was not used in an assay. The low incorporation of I-HFHS
under these conditions indicated that the sulphonamide grouping did not act
in the same way as an amino group.
125The sulthiame-CMC-BSA- I-HFHS label, however, was used to screen sera 
from all the rabbits immunised with sulthiame conjugates. It was thought that 
if DCC was used for phase separation, the sulthiame residues might adsorb on
to the particles and the BSA would then wrap around them to form a second coat.
A preliminary experiment however, indicated that this was not the case; the 
DCC would not adsorb the label and could not be used for phase separation. 
Therefore, a double antibody system was used to separate the free and bound 
fractions.
As the sulthiame-CMC-BSA was used both as the label and the immunogen,
it was necessary to remove any antibodies that might react with the BSA portion
of the label. To do this, duplicate antiserum dilution curves were set up
using 005 M phosphate buffer, pH 8*0, containing 1 % BSA as the diluent; a
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curves, the antiserum was incubated with the diluent for 9*5 h before the
the addition of the labelj no pre-incubation period was employed in the second
curve.
The second antibody used was donkey-anti-rabbit antiserum (Burroughs 
Y/ellcome) at a 1:10 initial dilution; precipitation by the second antibody was 
aided by the addition of a 1:100 dilution of normal rabbit serum, 100 jil/tube.
The assay protocol was as shorn in table 3.3 and the procedure was the 
same as for the phenytoin diultion curves. After the addition of the label, 
the contents of the tubes were mixed and incubated at rpom temperature for 2^ h. 
Normal rabbit serum and the second antibody were then added and the tubes 
incubated at 4°C for 72 h, followed by centrifugation at 2000 rpm and 4°C for 
20 min. 200 jil aliquots of the supernatants were pipetted into a second series 
of LP3 tubes and the radioactivity estimated on a Wallac gamma counter. The 
material in the supernatants comprised the free fraction, i.e. the label not 
bound to the first antibody.
TOTAL pi NSB pi SAjMPLE jil
1 % BSA diluent 200 200 200
Antiserum - - - 100
FFP/6 100 100 -
Label 100 100 100
Normal carrier serum 100 100 100
Double antibody - 100 100
1 fo BSA diluent 100 - -
Aliquot for counting 200 200 200
Table 3*3 • Protocol for screening sera for sulthiame antibodies using 
double antibody phase separation.
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were expressed as a percentage of the mean total counts using the 
formulae :-
Blank = Total. - NSB
% Free = Mean counts in sample + Blank ^/   — -----------  x 100 '/o •
Total
The blank value takes into account the label that is non-specifically bound 
to the second antibody and precipitated along with the specifically bound 
fraction.
None of the sera examined showed any binding of the sulthiame-CMC- 
125BSA- I-HFHS label, but it is not clear from these experiments Yfhether the 
lack of binding is due to the absence of specific antibodies to sulthiame 
or to the non-immunoreactivity of the label. Another possibility is that 
the antisera recognise not only the sulthiame but also part of the BSA 
molecule. Such antibodies would have been removed from the system by the 
addition of BSA in the diluent and would not then have been available for 
binding the label.
ii. Using sulthiame 1^I-TME.
All the serum samples from the immunised sheep,rabbits and goats
125were screened with sulthiame- I-TME labels^prepared at various times. 
Antiserum dilution curves were set up using 1:6 FFP as the diluent and DCC 
(1.25 % w/v charcoal y/ith 0*125 % w/v dextran T-70) for phase separation.
The assay protocol and procedure were the same as those used for the phenytoin 
dilution curves (p. 66).
125Using the sulthiame- I-TME labels^ many of the serum samples from
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^Antiseruin :- G/R/7-I H a * 
Label :- sulthiame-^ ^ I-TME
□ Normal rabbit serum 
a  s/B/7-ma
1:320 1 :6Z|jO1:10 1:20 1 :A0
Antiserum dilution (initial)
NEAT
125Fig. 3*12 : Rabbit antiserum dilution curves using sulthiame- I-TME.
the rabbits and goats exhibited antiserum dilution curves^ suggesting that 
antibodies to sulthiame had been produced. However, dilution curves of 
normal rabbit and normal goat seimm proved to be almost identical^ 
indicating that the binding must be non-specific to the serum proteins.
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Antis e rum : - (*■/G-/1 -IVa. 
Label sulthiame—  ^ I-TME
□ Normal goat serum 
a G/G/1-IVa-
3*0.
•
HcJ
-PO
%
m 2-0 
a
§
.rr
i : 160 1:320 1:6401:801:10 1 :20NEAT 1
Antiserum dilution (initial)
125Pig. 3.13 : G-oat antiserum dilution curves using sulthiame- I-TME.
Pigs. 3» 12 & 3*^3 show typical dilution curves of treated rabbit and goat 
sera, with those produced by sera from normal animals superimposed.
However^the sheep sera did show specific binding of the label,compared
with normal sheep serum. Using fraction 33 of the label whose elution pattern
|
and chromatographicelectrophoretograms have already been illustrated (fig.3.7
!
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Fig. 3*14 : G-/S/3 - Variation of antibody titre with time and booster
125immunisations using sulthiame- I-TME.
and fig.3.8), it was possible to construct antiserum dilution curves with 
all the sera obtained from sheep G-/S/3 and to plot a graph showing the 
variation of antibody titre with time over the period of treatment (fig.3.14.)• 
The increase in titre following the booster injections indicates that anti­
bodies, capable of specific binding of’the label^have been produced.
However, sulthiame standard curves using this antiserum and the same 
protocol and procedure as were used for phepytoin, were unsuccessful in that
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sulthiame. Experiments were therefore carrier out to exa the nature of 
the binding.
(a) Eight antiserum dilution curves were constructed using the antiserum 
G/S/3~VIHa. To four of these (curves 1 to 4) was added- unlabelled sulthiame 
(30 ng/100 ^ l), while the same volume of buffer was added to the rest (curves
3 to 8). Pre-incubation periods of 24 h (curves 1,2,5 & 6) and 48 h (curves 
3,4,7 & 8) were employed.
After the pre-incubation periods, the label was added for 5 niin 
(curves 1,3,5, & 7) or 30 min (curves 2,4,6 & 8) before the addition of the 
DGC suspension. Five minutes later, the tubes were centrifuged at 2000 rpm 
and 4°0 for five min and 200 jal aliquots of the supernatants counted on a 
gamma counter. The tubes were placed in iced-water for the last fifteen 
minutes of the pre-incubation period, during the incubation period with the 
label and during phase separation.
The resulting antiserum dilution curves were all virtually superimpos- 
able, as can be seen from fig. 3.15, irrespective of either the pre-incubation 
period or the time in contact with the label. This suggested that the label 
was bound to the antiserum immediately it was added to the system and that 
all the avaiable binding sites are occupied. The results also suggested that 
the antiserum must have a much higher avidity for the label than for the 
unlabelled drug.
(b) A series of antiserum dilution curves was contructed with the same
antiserum and either unlabelled sulthiame (10 nmole/100 ul), TME (10 nmole/
100 pi), non-iodinated sulthiame-TME complex (10 nmole/100 ^ il) or buffer
(100 jil) added per assay tube. The solutions were prepared in buffer
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Fig* 3*15 : Antiseruih dilution curves to illustrate the effects of
pre-incubation with unlabelled sulthiame.
and the antiserum diluted with 1:6 FNP; approximately 1 pmole of sulthiame- 
"^I~TME was added per tube.
The resulting antiserura dilution curves (fig. 3*16) show that neither 
sulthiame nor TME would displace the label from its binding sites. The
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Antiserum: G-/S/3-Villa .• Label .-sulthiame-"' ^ I-TME, 1 pmole/tub.e
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Fig.‘3*16 : Sulthiame antiserum dilution curves for label assessment.
dilution curves in the presence of these two compounds are the same as that 
produced by the label alone* in fact only one curve has been drawn in 
fig. 3.16 to avoid confusion. The addition of non-iodinated sulthiame-THE 
complex did succeed in displacing the bound label completely.
These results suggest that the antiserum is specific for the chemical 
linkage between sulthiame and TME, which is thought to be the same as that 
between sulthiame and BSA, and cannot recognise either of the two compounds
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3iii. Using H-sulthiame.
3H-sulthiame was used to screen all the sera from immunised animals 
hut failed to show the presence of -antibodies. Since all the animals had 
been immunised frequently with sulthiame-BSA conjugates, this suggested either 
that the conjugates must be non-immunogenic with regards to the production 
of specific sulthiame antibodies, or that the tritiation process had 
rendered the sulthiame molecule non-immunoreactive.
3d. PISCUSSION.
The conjugation of sulthiame to BSA indicated that^ in the presence 
of a coupling agent, a sulphonamide group will react in a similar way to 
a primary amino group^producing a peptide bond. In contrast, the conjugation 
of HFftS to sulthiame in aqueous solution^without the aid of a conjugating 
agent, suggests that the sulphonamide group is not as reactive as a free 
amino group, probably because of the electron withdrawing properties of 
the benzene ring.
Chromatographicelectrophoretograms of the iodinated drug-tag complexes 
indicate that these do not behave in the same way as radioiodinated 
proteins. In the latter case^the peak occuring at the origin on the elect- 
rophoretogram repesents the pure- iodinated material, while the second peak 
is the'’damaged'component and the third peak is free iodide. With drug-tag 
complexes, it appears that the material that reacts with the serum does 
not remain at the origin but migrates slightly towards the anode. A similar 
effect has also been shown in the chromatoelectrophoretograms of other 
iodinated drug-tag complexes (Robinson et al.. in press; see appendix).
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the antibodies produced against the sulthiame-BSA conjugates are specific
for the molecular linkages betv/een the drug and the tag, which are thought
to be the same as those found in the immunogens. The antibodies were not
capable of recognising either sulthiame or TME even when present in large
excess of the amount of label, and the binding of the label could only be
reduced by unlabelled sulthiame-TME complex. It is possible that antibodies
are present that are capable of recognising these two compounds but the
avidity of the antiserum for the linkage is greater than that for either
sulthiame or TME. The antibodies would then bind to the'label in preference.
However^ the antibodies failed to recognise tritiated sulthiame when this
was used as the label, confirming that the antibodies are specific for the
molecular linkage.
A similar problem was recently described by Cameron, Morris, Scaris-
brick and Hillier (1973) with regard to steroid radioimmunoassays. Using
the iodohistamine method of Nars and Hunter (1973) to label various steroids,
they compared these labels with the corresponding tritium labelled steroids.
Cameron jst al. also investigated the effects of this type of labelling on
the specificities of the various antisera. Their results indicated that
when the hapten used to prepare the immunogen was identical to that used to 
125.synthesise the I-labelled antigen^the binding of this label was normally
3
higher than that for the H-labelled steroid. In some cases the binding was 
so high that ” substantial quantities of unlabelled steroid added to the 
antibody-labelled ligand mixture were incapable of displacing appreciable 
amounts of radioactivity1’.
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1 25the steroid nucleus of the I-antigen and the immunogen differed, the 
binding of antigen to antibody was less avid and sensitive standard curves 
resulted. In this system,it was also noted that the cross-reactivity
tended to increase for steroids resembling the relevant antigen, ie. the
. \ r .
antiserum lost some of its specificity.
From these results it is clear that the same coupling reaction should
not be used to prepare both the immunogen and the label. The insertion of
a different chemical grouping, a spacer group, between the drug and the tag
may help overcome this problem if the same type of chemical linkage as
found in the immunogen is avoided.
The largest radioiodination tag that has been successfully used in
drug radioimmunoassays consisted of a random synthetic copolymer of
glutamic acid, lysine, alanine and tryosine (&LAT) in the ratios $6:24:35:5*
and was used to provide a radioiodine label for morphine (Van Vunakis,
Wasserman & Levine, 1972). These workers found the iodine label to be 
1ksuperior to C-morphine for use in a morphine radioimmunoassay. However, 
the success of Van Vunakis et al. (19/2) was not paralleled by Teale (1974) 
in his radioimmunoassay for tetrahydrocannabinol^ using GLAT as the radio­
iodination tag. The results reported by Teale (1974) are similar to those 
described here using TME as the iodination tag, in that the binding to the 
antibody could not be reduced by the addition of unlabelled drug. Again? 
the same type of conjugation reaction, was used to prepare both the immunogen 
and the label^  resulting in the antibody recognising the linkage as well as 
the drug.
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been carried out during the development of other drug radioimmunoassays.
The results of these studies are outlined in ’’Problems encountered in the 
use of radioiodination tags in radioimmunoassays for drugs” (Robinson et al., 
1974, in press; see appendix).
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Chemical structure of morphine. t
Summary.
In view of the apparent lack of immunogenic ity of the sulthiame-BSA 
conjugates and the failure of the phenytoin conjugates to induce antibodies 
in more than one animal, it was decided to examine some of the factors that 
might be expected to influence the immunogenicity of drug-carrier complexes.
For this purpose the morphine radioimmunoassay developed at the University 
of Surrey (Morris et al. t 1974: Aherne et al., in press)' was used to assess 
methods for increasing the immunogenicity of the conjugates and the specificity 
of the antisera produced. Since this would involve the production of a large 
number of different morphine-3SA conjugates and would necessitate the use of 
large numbers of experimental animals, it was thought that rats would be more 
suitable than guinea-pigs, rabbits, sheep or goats. Large numbers could be kept 
at low cost in a samll space, and in addition, several rats could be treated 
with the same conjugates to give a better assessment of the iramunogenicity of 
the conjugate and reduce the effects of individual variation. Immunisation 
schedules that-would result in the production of antibodies in a relatively 
short time could also be employed.
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produced having different degrees of derivatisation and different length 
"spacer” groups between the drug and the carrier. Each conjugate was injected 
.into six rats and the antisera examined for titre and, where possible, for 
avidity and specificity.-Two of the conjugates were also injected into sheep.
From the experiments it was concluded that the succinyl spacer group 
with a degree of derivatisation between 14 and 28, was the most successful 
in invoking antibodies to morphine.
Morphine was the first non-steroid drug for which a radioimmunoassay 
was developed (Spector & Parker, 1970), More recently a similar assay has 
been developed in the Biochemistry Department of the University of Surrey 
(Morris et al., 1974; Aherne et al. , in press) using antiserum raised in 
rabbits and goats against a 6-succinyl-morph.ine-BSA conjugate. This assay, 
capable of detecting less than 1 ng morphine per ml of serum, was used to 
study the factors affecting the immupogenicity of drug-protein conjugates. 
i.Materials and Methods.
The protocol for the morphine radioimmunoassay is. shown in table 4.1.
TOTAL MSB A/S DILN. S!iCANDARD CURVE
P1 pi
CURVE
pi
MB
pi
ZERO STD.
pi
Diluent 500 500 500 400 400 400
Std./buffer 100 100 - - 100 100
Label 10 10 10 10 10 10
Antiserum - - 100 200 100 100
DCC - 100 100 100 100 100
Buffer 100 - - - - -
Aliquot for 
liquid
scintillation
counting
200 200 200 200 200 200
Table 4.1 : Protocol for morphine radioimmunoassay.
The buffer used in this radioimmunoassay was 005 M phosphate buffer,
7  7
pH 7*4. It was used to dilute the label ( H-dihydromorphine(/H-DHM), Radio­
chemical Centre, code = TRK450, specific activity 74 Cd/mraole) and the 
various antisera produced. A 1:6 dilution of FFP was used as the diluejit 
throughout the assay. A DCC suspension containing 5 /w/v Norit A charcoal and
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measured by liquid scintillation counting.
The opiates examined for cross-reactivity with the rat antisera were 
'morphine, diamorphine and codeine (Maefarlane Smith). In addition^the sheep 
antisera were screened with etorphine (Reckitt and Sons), morphine-3- 
glucuronide ( gift from Dr.T.Moffat, Home Office Research Laboratories, 
Aldermaston), 6-monoacetylmorphine ( gift from the Laboratories of the 
Government Chemist, via Dr.R.G-.Twycross, St. Christopher1 s Hospice, 
Sydenham, London), Nalorphine ("Lethidone”, Wellcome) and ethyl morphine 
(May and Baker). Standard solutions containing 0*1 mg/ml of these compounds 
were prepared and diluted for use in the assay in the same y/ay as the 
phenytoin standards (section 2d).
After addition of the reagents to the assay tubes in the order and
quantities indicated in the protocol, the contents were mixed and incubated
at room temperature for 50 min. After a further 10 min incubation with the
tubes in iced-water, cold (4°C) DCC was added and the tubes left for 10 min
in iced-water. This was followed by centrifugation at 2000 rpm and 4°C for
%
5 min; aliquots of the supernatants were taken for liquid scintillation 
counting.
4b. EFFECT OF SPACER GROUPS.
In affinity chromatography work, Cuatrecasas (1970) has shown that, 
for full ligand interaction, a spacer group of 4-6 carbon atoms should be 
inserted between the hapten and its support. It is possible that a similar 
approach may be advantageous in antiserum production by allowing the hapten 
to be more easily recognised by the circulating lymphocytes.
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of different lengths inserted between the hapten and the carrier. These 
were injected into rats and after seven weeks the animals were bled out 
and the sera examined for antibodies to morphine.
As there have been no previous reports of the successful use of rats 
for the production of antibodies to morphine,.it was decided also to use a 
conjugate of proven immunogenicity as a control. A 6-succinyl-morphine-BSA 
•conjugate was chosen, as it had proved extremely immunogenic in all guinea- 
pigs, rabbits, sheep and goats into which it had been injected.
i. Preparation of Immunogens.
The control conjugate of 6-succinyl-morphine-BSA was prepared by 
Mr.B.A.Morris, following the method of Simon, Dole & Hiller (1972), during 
the course of the development of the morphine radioimmunoassay. This 
involved refluxing morphine with three equivalents of succinic anhydride 
in a minimum volume of benzene for three hours. After cooling^the benzene 
was decanted off and the residual solvent evaporated under a stream of 
nitrogen. The solid material was dissolved in distilled water and the pH 
adjusted to 2 to remove free acid. After centrifugation^ the supernatant was 
made alkaline (pH 9) with 2N.NaOH to remove free morphine and the pH re­
adjusted to 5 with 2N.HC1. The 6-succinyl-morphine was slowly precipitated 
overnight at 4°C. Conjugation to BSA was achieved by carbodiimide (CMC) 
condensation and purification was by dialysis against distilled water.
The antibodies produced against this conjugate however, lacked the 
specificity required (Spector & Parker, 1970; Aherne et al., in press) in 
that they reacted almost as wel3. with codeine and diamorphine as with morphine
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positions to the carrier also lacked the required specificity (Spector &
Parker, 1970; Spector et al. 1973)* S'0** this reason the effects of spacer 
groups were examined, by coupling them to the cyclic nitrogen of morphine in 
order to allow the hydroxyl groups at positions 3 a c^L 6 to exert their full 
antigenic effects.
As the methyl group attached to the cyclic nitrogen atom is unreactive, 
normorphine (N-demethylated morphine) was used as the hapten (Morris et al. 
1974). Four derivatives of normorphine were prepared : normorphine-BSA, 
N-succinyl-normorphine-BSA, N-adipyl-normorphine-BSA and N-sebacyl-nor- 
morphine-BSA, these having chains of 0, 4, 6, and 10 carbon atoms respectively.
The normorphine-B3A conjugate was prepared by Mr.B.A.Morris and 
contained 90 residues of normorphine per BSA molecule. For this conjugate 
an excess of normorphine was mixed overnight with BSA and carbodiimide (CMC) 
in aqueous solution, followed by purification by dialysis against distilled 
water. •
In a typical conjugation reaction incorporating a spacer group, 
normorphine (27*4 nig) dissolved in dimethyl foimiamide (DMP)(1*0 ml) y/as 
added to a solution of succinic anhydride (11 • 7 nig) in distilled water (2*0 
ml). The carbodiimide EDO (52*4 mg) was then added and the solution stirred 
at room temperature for 20 h. The material was purified by gel filtration 
on a S sphadex G--10 column (40 x 1 cm), the succinyl-noraorphine being 
eluted first. The fractions v/ere scanned on a SP800 spectrophotometer and 
those containing the N-succiryl-normorphine pooled, giving a total volume 
of 35 rnl.
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Pig. 4.1 : U.V. calibration curve for normorphine.
The U.V. absorbance of this solution was measured at 237 nm on a SP300 
spectrophotometer and by comparison with a normorphine U.V. calibration 
curve (Pig. 4.1) the concentration of normorphine equivalents calculated 
(525* 9 ^ g/nil). The amount of BSA required to give a hapten: carrier ratio of
N
approximately 20:1 was calculated (assuming 100 % conjugation) to be 237 mg. 
BSA (237*7 mg) was stirred into the succinyl-normorphine solution follov/ed 
by CMC (220*3 mg) as the coupling agent. After stirring overnight at room 
temperature, the solution was purified by dialysis against distilled water 
(2 changes, 1 1 each). U.V. analysis of the dialysates failed to indicate 
the presence of free succinyl-normorphine., indicating that all the hapten had 
been conjugated to the carrier.
A similar procedure was employed for the production of the N-sebacyl-
shown in table 4.2. The reaction scheme is outlined in fig 4.2.
N-SUCCINYL -
M/i-BSA
mg/ral
N-ADIPYL-
NM-BSA
mg/ml
N-SEBACYL-
NM-BSA
mg/ml
NM-GHJT-
BSA
mg/ml
Noi*morphine 27-4 27*2 26*7 4-0
DMF 1*0 1*0 1-5 1*0
Acid 11*7 15-0 20*3 -
H2°
2*0 4-0 2*0 . 4-0
EDO 52-4 51-2 49-9 -
NM-Spacer 18*4 2*9 7-4 -
BSA 237-7 37-4 95-8 50*0
CMC 220*5 102*1 199*6 -
h 20 35-0 37-0 ' 43-0 -
2 %' Glutar- 
aldehyde. - - -■ 1*0
Ratio 14:1 13:1 12:1 21:1
Table 4.2 : Quantities of reagents used in preparation of normorphine 
spacer-BSA conjugates.
NORMORPHINE + ■ SUCCINIC ACID---— ^ --► N-SUCCINYL-NOBMORPHINE
+ ■
BSA-NH2
BSA
EDC
Fig 4.2 : Reaction scheme for preparation of N-succinyl-norraorphine-BSA.
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prepared using glutaraldehyde as the coupling agent. In this reaction
normorphine (4*03 mg) in dimethylformamide (1*0 ml) was added to BSA (50*0 mg)
in distilled water (4*0 ml) and a, 2 f* y?/v glutaraldehyde solution (1*0 ml)
>
added dropwise. After shaking, the mixture was allowed to stand at room 
temperature for three hours, purified by dialysis against distilled water 
and freeze dried. Examination of the U.V. spectra of the dialysates suggested 
that all the normorphine had reacted with the BSA to give a hapten:carrier 
ratio of 21:1. Fig. 4*3 shows the reaction that is thought to have taken 
place. .
The proposed chemical structures of the immunogens are illustrated 
in fig. 4*4*
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0=C— (CH2)— G=0 +  NH2— BSA
NORMORPHINE GLUTARALDEHYDE
HO
HO
H
■> H H 
I I
H
■Cr C-( CK2)—  C=N— BSA
I OH H)
 V
H H H
1 1 ■ , \ IN—  C = C —  ( CH2) —  C «*N— BSA.
Fig. 4.3 i Postulated reaction mechanism for conjugation of normorphine to 
BSA using glutaraldehyde.
171
/ \
6-SUCCIKYL- MORPHINE-'BSA
0
o— c —  ( CH 9 ) C — N— BS A
2 2 I 
H
BSA
I
H— N 
I
C=0
( k } 4
C=0
I
OHHO
N-SUCCINYL-NOHMOHPHINE-BSA
N-ADIPYL - NORM ORPHI HE -BSA
N-SEBAC YL -NORivIORPHII'IE -BSA
BSA
I
H— N 
I
C =  0
( f 2>2
OHHO'
BSA
I
H— N 
J
C = 0
(CH2)g
C=0
I
Pig. 4*4 * Proposed chemical structures
for nonnorphine-spacer-BSA and 
6-succinyl-morphine-BSA ^ djnraunogens OHHO
; ■ ■ r
The five normorphine-BSA immunogens describee^ together with the 
control preparation, 6-succinyl-morphine-BSA, were each injected into 
groups of six Wistar-Albino rats, each of 100 g average weight. The animals 
were injected subcutaneously into the fore-limbs and intramuscularly into 
the hind limbs; over the course of treatment they received a total dose of 
270 fig of conjugate given in almost equal amounts. The conjugates were 
prepared in aqueous solution and emulsified with two volumes of Marcol 52 
adjuvant; 0*1 ml of this emulsion was injected per site. The primary 
injection also included 3 rag SCO vaccine per animal. The rats were immunised 
at weekly intervals for four weeks and after a two week rest period were 
given a further two injections-, one week apart. Seven days after the last 
injection, the animals 'were anaesthetised with a 1:10 solution of Nembutal 
(Abbott) in NaCl (0«9/o)0 ml/100 mg body weight) and bled out by cardiac 
puncture. The serum was collected and stored at 4°C,
iii. Screening Procedure;
Using the procedure already described,the serum from each animal was 
examined for the presence of antibodies to morphine at neat and 1:5 
dilution. Those sera showing more than 40 % binding in neat serum were 
further examined for avidity and specificity. The cross-reactivity of the 
sera with four opiate alkaloids, morphine, normorphine, codeine and 
diamorphine, was examined and the avidity determined from a modified 
Scatchard plot of the results of the morphine curve.
iv. Results and Discussion.
In these experiments, binding of greater than 2 fo of the added label
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than 1 %. In terms of the numbers of animals responding to each drug-spacer- 
BSA conjugate, it was clear that N-succinyl-normorphine-BSA was as immunogenic 
as the 6-succinyl-morphin -BSA conjugate ( table 4*3) • The N-3ebacyl-nor- 
morphine-BSA was more immunogenic than either N-adipyl-normorphine-BSA or 
n ormorphine-glu ta raldehy de-BSA.
CONJUGATE DEGREE OP DSRIV. RESPONSE
6-succinyl-morphine-BSA 30:1 5/5
Normorphine-BSA 10:1 * k/6
N-succinyl-normorphine-BSA 14:1 6/6
N-a dipyl-norm orphine-BSA 13:1 0/6
N-s ebacyl-normorphine-BSA 11:1 5/6
N0 rmorph in e -glu ta ral de hy de -BSA 21:1 3/6
Table 4.3 : Effect of bridge length on number of rats producing 
morphine antibodies.
(* the results for this conjugate are reported in preference to those 
for the normorphine-BSA conjugate containing 90 residues to facilitate 
direct comparison between inmunogens of similar degree of deriv- 
atisation. The results for the 90 residue conjugate are reported 
later.)
Pig. 4.3 shows that the antisera binding the highest percentage of the 
added label were those produced against the 6-succinyl-morphine-BSA 
immunogen. In addition, the percentage binding at a 1:5 dilution was almost 
the same as that at neat, although the antibody concentration in the two sera 
examined, as determined by modified Scatchard plots, were different. Fig. 4.5 
also shows that the binding of those antisera to N-succinyl-normorphine-BSA 
was only slightly lower and table 4.4 shows that the antibody concentrations 
are comparable. The avidities of almost
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Fig. 4.5 : Effect of bridge length on percentage binding of ^H-DHM by
neat serum from rats immunised with various morphine immunogens, .
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order of magnitude suggesting that in this respect, all the conjugates have 
comparable immunogenicity (table 4*4)*
CONJUGATE EAT No. AVIDITY, Ka 
10"8 x B.M71
Ab. Cone, n.
9 -1 
107 x M.L.
6-3uccinyl-morphine-BSA 2 0*74 0*96
4 15*40 9*10
N-succinyl-normorphine-BSA 4 4*19 4*36
3 6*80 4*73
6 2*19 3*76
N-s ebacyl-normorphine-BSA 3 5*35 4*33
Table 4*4 • Antibody characteristics of various rat antisera to 
morphine-BSA immunogens.
None of the antisera to those conjugates of normorphine to BSA which 
were examined (ie. the N-succinyl and N-sebacyl-normorphine-BSA conjugates) 
showed any cross-reactivity with codeine, and that with normorphine and 
diamorphine, with reference to morphine, seemed to vary with individual 
animals (fig. 4.6 to fig. 4.8^ This indicates that, although the rats were 
all of the same age, breed and strain, there was still a great deal of 
individual variation in the specificity of the antisera produced to the 
same immunogen. The response of the rats immunised with 6-succinyl-morphine- 
BSA is interesting in that both the antisera examined appear to be much 
more specific for diamorphine and are able to discriminate between the 
other three opiates. This contrasts markedly with the antisera produced 
against this conjugate in sheep, goats and rabbits, in which there is little
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cross-reactivity curves of goat antiserum raised against 6-succinyl-morphine- 
BSA with morphine, codeine and diamorphine.
The lack of immunoreactivity of the N-adipyl-normorphine-BSA conjugate 
was probably due to the fact that the adipyl spacer group is not a straight 
chain projecting from the normorphine molecule, but curves back on itself 
(Dr. G-. Court, personal communication). In such a case, the normorphine would 
be 'facing the BSA molecule, or at least only protruding slightly from 
the surface of the carrier, and would not be readily accessible to the 
circulating lymphocytes..
Thus?it can be concluded that the insertion of a succinyl (4C) spacer 
group between the hapten and carrier 'was effective in increasing 
the immunogenicity of the morphine conjugates. In addition^the length of 
the spacer group appeared ta have little effect on the specificity and 
avidity of the resulting antisera.
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Fig, 4.9 i Cross-reactivity curves for goat antiserum against 6-succinyl- 
morphine-BSA,
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Although James and Jeffcoate (1974) have stated that, with steroids, 
there is no evidence that the titre is dependent upon the degree of 
derivatisation, it is generally accepted that this does, influence the 
immunogenicity of drug-protein complexes. However, it is not clear whether 
the hapten:carrier ratio should be low or high. Several workers,including 
Kantor, Ojeda and Benacerraf (1963) a*id Taylor and Iverson (1971) consider 
that the fewer the number of haptenic residues per mole of carrier, the 
better. In contrast, Spector (1973) a^d Hurn (1974) have stated that a high 
degreeof derivatisation is preferable. Rubin (1972) has Shown that once 
a minimal number of residues, 11, has been conjugated to the carrier, the 
inclusion of further haptens does not increase the immunogenicity. Landsteiner 
(1943) suggested that the optimal number of residues was 10, and that too 
high or too low a degree of derivatisation impaired immunogenicity. Taylor 
and Iverson (1971) calculated that if a hapten-albumin complex consisted of 
more than 12 haptenic molecules per albumin molecule, the reaction of these 
12 haptenic residues with 12 univalent antibody molecules would completely 
occupy the surface of the albumin molecule.
To clarify the situation v/ith regard to morphine antibody production, 
several conjugates of normorphine to BSA were prepared having different 
degrees of derivatisation. In the first series of experiments, the nor­
morphine was linked directly to the carrier, and then, on the basis of the 
results obtained v/ith spacer groups, a second series of conjugates v/ith 
different degrees of derivatisation was prepared,incorporating a succinyl 
spacer group between the hapten and the carrier.
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Direct linkage to BSA.
It has already been shown (Morris et 41., 1974-) that it is possible 
to conjugate 133 haptenic residues to BSA if the amino groups on the hapten 
are coupled to free carboxyl groups on the BSA. In practice, as many as 90 
normorphine residues ^ ave been coupled directly to BSA in the presence of 
excess normorphine. Cheng et al. (1973) have also used the carboxyl groups 
of BSA in the preparation of their amphetamine immunogens. By limiting the 
amount of normorphine present, it was possible to prepare a series of 
conjugates having 3, 10, 20 and 40 residues per mole of'BSA. The conjugate 
already prepared by Mr.B.A.Morris having 90 residues per mole was also used.
The quantities of the various reactants used are recorded in table
4.4. The conjugation was effected by dissolving the BSA in distilled water
and stirring in the carbodiimide (CMC). Normorphine was dissolved in
dime thy ljformamide and added to the BSA/carbodiimide solution. After stirring
*
overnight at room temperature,purification of the conjugate v^ as effected by 
dialysis against distilled water (two changes of 1 1 each), and the conjugate 
solutions freeze-dried.
d)
mg/ml
(2)
mg/ml
(3)
mg/ml
(4)
mg/ml
BSA
h 2°
CMC
Normorphine
DMF
30*1
4*0
100*0
4*0
1*0
30*0
4*0
100*0
2*0
1*0
30*1
4*0
100*0
1*0
1*0
30*1
4*0
100*0
8*0
1*0
Ratio 20:1 10:1 5:1 . 40:1
Table 4.4 : Quantities of reagents used in preparation of normorphine- 
BSA conjugates.
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had been coupled to-(he BSA and the molar ratios of the conjugates were as 
shown in table 4/4* The chemical reaction thought to have taken pihice is 
illustrated in fig. 4.10.
OH
CMC >
BSA
HO OH
Fig. 4*10 : Direct conjugation of normorphine to BSA.
Linkage to BSA through a spacer group.
A preparation of N-succinyl-normorphine was produced, by the same 
method as already described (section 4«a*i). ^or this conjugation,
normorphine (135*0 mg) was reacted with succinic acid (59*4 nig) in the 
presence of CMC (200 mg). Purification was by gel filtration on a Sephadex 
G—10 column (40 x 1 cm) and the concentration of N-succinyl-normorphine in 
the pooled fractions calculated by reference'to the U.V. calibration curve 
for normorphine. The solution was found to have an absorbance equivalent
185
normorphine /ml.
Aliquots of the N-succinyl-normorphine solution were taken and the 
volumes.made up to 15 ml with distilled water. Varying amounts of BSA, 
calculated to give the molar ratios required,assuming 100 fa conjugation, and 
carbodiimide were added; table 4.5 shows the amounts of the various reagents 
used . The procedure for the purification of the N-succinyl-normorphine-BSA 
conjugates was the same as that already described (section 4 b.i).
U.V. analysis of the dialysates showed unconjugated normorphine to be 
present in two of the Preparations By comparison with the U.V. absorption 
curve for normorphine and correction for the differences in molecular weighty 
it was possible to calculate the concentration of free material. Prom 
this the molar ratios of hapten:carrier for the conjugates were calculated; 
the values are shown in table 4*5. The conjugates containing 7, 14, 28, and 
50 normorphine residues/BSA molecule were used in the experiment.
The immunisation schedule and screening procedure were the same as 
those used in the experiments to study the effect of spacer groups, except 
that the antisera were not assessed for cross-reactivity with codeine, 
diamorphine or normorphine.
0)nig (2)mg %
N-suc ciny1-NM 1-6, 3*6{• 7-8 21*9
H^O to total 14*0 ml 12«7 ml 10*0 ml 1* 0n3
of 15 ml
BSA 35-9 45*2 50-0 40-3
CMC 74-8 100*3 100.0 100*3
Ratio 7:1 14:1 28:1 50:1
Table 4.5 : Quantities of reagents used in preparation of normorphine - 
spacer-BSA conjugates.
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Table Zj.. 6 shows that all the normorphine-BSA conjugates successfully 
elicited the production of antibodies to a varying extent, and suggests 
that those conjugates containing 20,40, and 90 haptenic residues/mole were the 
most immunogenic. However^ the percentage binding of label produced by the 
antisera to these conjugates w^s 107/, only one, that produced against the 
conjugate having Z*0 residues per mole of carrier, binding more than 50 % 
of the added label (fig. 4.11)*
DEGREE OP DERIV. RESPONSE
5:1 4/6
10:1 4/6
20:1 6/6
40:1 5/6
90:1 6/6
Table 4*6 : Effect of degree of derivatisation on number of rats
. producing morphine antibodies to normorphine-BSA conjugates.
Of the N-succinyl-normorphine-BSA conjugates, those containing 14,
28, and 50 haptenic residues per mole appear to be the most immunogenic in 
terms of the number of animals responding (table 4*7).
DEGREE OP DERIV. RESPONSE
7:1 3/6
14:1 6/6
28:1 5/6.
50:1 6/6
Table 4*7 : Effect of degree of derivatisation on number of rats
producing morphine antibodies to N-succinyl-normorphine- 
BSA conjugates.
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Pig. 4.11 : Effect of degree of derivatisation on percentage binding 
x
of H-DHM by neat serum from rats immunised with nor­
morphine-BSA conjugates,
A. Normorphine-BSA direct.
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successful in eliciting antibodies to morphine. Antiserum shov/ing high binding 
of the label (60-70 %) was produced in one rat immunised with the N-succinyl- 
normorphine-BSA conjugate having seven residues per mole, but the total response 
v/as not as good as that against the 14 and 28 residue conjugates. These 
results also indicate that a high degree of derivatisation impaired the 
immunogenicity of the conjugate and elicited only low binding antibodies, as 
can be seen from the results of the conjugate having 50 residues per mole.
The advantage of using a succinyl spacer group to separated the drug 
from the carrier is clearly seen in fig, 4**13* The antisera showing the 
highest binding were elicited by the conjugates incorporating the spacer group, 
while the antisera against the conjugates lacking the spacer group show only 
low binding of the added label, .
Table 4.8 lists the antibody characteristics of the rat antisera to 
N-succinyl-normorphine-BSA conjugates that were examined, and shows that there 
was no correlation between the degree of derivatisation and the avidity of 
the antisera produced. The antiserum with the highest avidity was produced 
against a conjugate having 28 residues per mole, while that with the lowest 
avidity was produced against a conjugate having 14 residues, the most 
immunoganic conjugate in terms of numbers of animals responding. The effective 
binding site concentration, however, was slightly higher in the two antisera 
to the 28 residue conjugate that were examined.
Pig. 4.14 shows that the cross-reactivity of an antiserum in which the 
hapten is linked directly to the carrier is comparable to that raised
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Pig. 4.12 : Effect of degree of derivatisation on percentage binding by 
neat serum from rats immunised with various normorphine 
conjugates.
B. N-succinyl-normorphine-BSA.
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Fig, 4.13* Effect of succinyl spacer group on percentage binding of H-DHM 
by neat serum from rats immunised with nomorphine conjugates 
various degrees of derivatisation.
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the spacer group acts by influencing the immunogenicity of the conjugate 
but does not appreciably alter its specificity.
CONJUGATE RAT No. AVIDITY, Ka
10~8 x l .m71
Ab.CONC,n.
108 x m.l71
NM-SUC-3SA 7:1 2 11*1 0-43
5 13-4 0*24
NM-SUC-BSA 14:1 1 3-3 1*60
2 3-7 0-37
5 0*8 1*36
6 8*9 0-37
NM-SUC-BSA 28:1 4 4-9 3-23
5 40*0 1*40
NM-SUC-BSA 30:1 3 10*3 0-27
Table 4.8 : Antibody characteristics of various rat antisera to 
N-succinyl-normorphine-BSA immunogens.
Rat 3
s 30
(see p. 180 for key)
60 70 100 ng/ml10 200 40 8050 90
fig. 4.14 : Crossreactivity curves for rat antisera against normorphine-BSA
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The N-succinyl-normorphine-BSA (20:1) and normorphine-glutaraldehyde-BSA 
conjugates were also injected into two sheep, G-/S/7 and G-/S/10 respectively. 
The amounts of the immunogens and the time intervals betv/een treatments 
are illustrated in table 4*9. The conjugates were dissolved in distilled 
water (1*0 ml) and emulsified with Freund’s "complete'’ adjuvant (2*0 ml) 
for the initial immunisation and with Marcol 52 adjuvant for the booster 
immunisations. Blood samples were collected after each booster injection 
and the serum collected as before. The sera were screened for morphine 
antibodies using the procedure already described, 
i. Results and Discussion.
The N-succinyl-normorphine-BSA conjugate proved to be immunogenic in 
the sheep, but only weakly so. After four monthly immunisations with large 
amounts of immunogen^low titre antibodies were seen. Subsequent boosts, 
however, did not increase the titre . Booster injections^after a rest 
period that followed a large dose of immunogen^also failed to increase the 
titre c The antibody titres are illustrated in table 4.9.
Using the antiserum &/S/7-VIIIa-1:60. the cross reactivity with other 
opiates was investigated (fig. 4*15)• The antiserum showed approximately 
5 c/o cross-reactivity with codeine and only 2*5 fo cross-reactivity with 
diamorphine. Thus? in contrast to the rat antisera to this conjugate, the ' 
sheep antibodies seem to be more specific for morphine and can discriminate 
against codeine, diamorphine and even normorphine. Other compounds that do 
not show any cross-reactivity with this antiserum include etorphine, ethyl 
morphine, morphine-3-glucuronide and 6-mono-acetyl-morphine.
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sshum No. V/t of IMMUNOGEN 
rag
TITRE 
1 :x
SERUM No. V/t. of IMMUNOGEN 
mg
TITHE 
1 :x
5/10/73 1*0 - 1*0 -
2/11/73 0*5 - 0*5 ~
9/11/73 Ia - - Ia. - -
30/11/73 0*5 - 0*5 -
10/12/73 Ila - - Ila - ' -
11/1/74 0*1 - 0*1 -
21/1/74 Ilia - 60 Ilia - -
15/2 74 0*1 - 0*1 -
25/2/74 IVa - 18 IVa - -
15/3/74 IVb 2*0 54 IVb - -
25/3/74 Ya - - 90 Va 2*0 -
18/4/74 1*0 -
25/4/74 Via - 60
25/5/74 2*0 -
3/6/74 Vila - '48
21/6/74 5*0 -
1/7/74 Villa - 42 . Vb - 30
29/7/74 2*0 60
6/8/74 Vlllb - 6 Via - 60
23/8/74 Vlb - 60
3/9/74 VIIIc - 6 Vic - -
20/9/74 2*0 - ■ 2*0 -
30/9/74 IXa - . 30. Vila — 30
Table 4.9 : Immunisation schedules and antibody titres in sheep immunised with 
normorphine-spacer-BSA immunogens.
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/tube
MB = 80*0 /T
, V  D, O--
50 *
20 «
10
100 ng/ml10
Fig, 4,15 : Cross-reactivity curves for sheep antisera against N-succinyl- 
normorphine-BSA (see p.180 for key).
G/S/10-Yla-1 :60 Label:- 0-5 pmole/
tube
70-
50-
MB = 88*2 /T 
KS3 = 13*4 yf
I I  t  , H I T . i m  K  I I  
20 30 40 30 60 90 100 ng/ml8070100
Fig, 4.16 : Cross-reactivity curves for sheep entiserum against nor' 
morphine-glutaraldehyde-BSA,(see p.180 for key),
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but was found to be more immunogenic in the sheep. The antibodies to this 
immunogen appeared after a five-month rest period and without the animal 
receiving a booster injection. Subsequent boosters have only succeeded'in 
producing a small increase in titre (table 4.9). The cross-reactivity of 
G/S/10-Vla-1:60 with opiate alkaloids showed the antiserum to be even more 
specific for morphine than the G/S/7-VIIIa antiserum. The cross-reactivity 
with codeine and diamorphine was negligible, as was that with 6-mono-acetyl- 
morphine. Normorphine and nalorphine, however, did cross-react to almost the 
same extent as morphine .(fig. 4.16). Thus, it appears that the antiserum will 
cross-react with morphine analogues that differ from morphine only at the Im­
position.
4e. GENERAL DISCUSSION AND CONCLUSIONS.
The results of the studies on the effects of spacer groups and degree of 
derivatisation demonstrate that a 4-carbon spacer group, such as that of a 
succinyl derivative, and between 14 and 28 residues per mole, have the greatest 
beneficial influence on increasing the immunogenicity of morphine-BSA conjugates
* N
In the absence of a spacer group, i.e. by linking the normorphine 
directly to BSA using a carbodiimide, the highest binding of added label was 
seen in the antiserum from one of the rats immunised with the conjugate 
having 40 residues per mole of carrier. This may be an individual response 
in that particular rat, or it may suggest that even though the surface of 
the immunogen may be overcrowded in such a way that the haptens cannot be 
recagnise individually by the lymphocytes, the immunogenicity of the conjugate 
is not impaired. If the latter is the case, it contrasts with the reports
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all suggest that a high degree of derivatisation impairs . immunogenicity. 
However, the specificity of the antiserum raised against the highly 
derivatised conjugate is comparable with that of antisera to less derivatised 
conjugates. This suggests that the antigenic determinants are able to exert 
a similar effect to that exerted when they are coupled via a spacer group 
and are more easily accessible to the circulating lymphocytes.
The insertion of a spacer group has the effect of increasing the 
immunogenicity of the conjugates but appears to have very little influence 
on the specificity of the resulting antiserum. Cheng et al. (1973) commented 
that the extra bridge length in their amphetamine immunogens "actually 
enhanced the affinity and specificity of the antibody", and suggested that 
this type of effect would explain the high affinity and specificity of 
their phenobarbiturate antibody (Chung et al,, 1973)*
In the work reported here with spacer groups, it appears that a 
lower degree of derivatisation is optimal for maximal interaction than in 
the absence of a spacer group. One explanation for this difference is that
• *v
when the haptens protrude further from the carrier, they are more easily 
recognised by the lymphocytes and can be almost completely surrounded by the 
antibody molecules. When the hapten is linked directly to the carrier it is 
possible that the lymphocytes . react only with those haptens on the out­
side surface of the folds of the BSA molecule and that, from examination of 
the modified Scatchard plot's, only low avidity antibodies are produced to 
the other haptens^ if produced at all. In both cases it appears that it is 
the same region of the morphine molecule that acts as the antigenic
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raised against the normorphine-BSA conjugates are not generally sensitive to 
changes in the groups attached to the cyclic nitrogen atom of morphine.
The normorphine-glutaraldehyde-Bsa conjugate was weakly immunogenic, but 
produced a more specific antiserum than that raised against normorphine-succ- 
inyl-BSA, reacting only with those alkaloids differing from morphine at the Im­
position. It is difficult to explain this effect, since the immunogen differs 
from the N-succinyl-BSA immunogen only in the length on the spacer group, that 
of the glutaraldehyde conjugate having 5 carbon atoms. This may be due to the 
individual response of the sheep or the influence of the double bond in the 
bridge coupling the hapten to the carrier, producing a less flexible linkage.
Rats have been shov/n to be veJcy useful experimental animals in which to
screen conjugates for immunogenicity. The immunisation schedule was chosen
such that,if the conjugates were immunogenic, antibodies would be produced
in a very short time. The most immunogenic conjugates could then be selected
for immunisation of larger animals. It is possible that if a different
immunisation schedule is employed, rats could be used to produce high titre
%
antisera. The low avidity of the antisera produced in the rats, may be a 
function of the low titres produced, since it has been shown that, with the 
phenytoin immunogens, as the titre increased, so too did the avidity of the 
antiserum.
The lack of high titre antibodies in rats is not necessarily 
indicative of non-immunogenicity of the conjugate, as has been shown with 
the glutaraldehyde conjugate. This complex was only weakly immunogenic in 
rats but succeded in eliciting ’’useable" antibodies in the sheep. Again, it
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resulted in the production of antibodies to this immunogen* Alternatively, 
this may demonstrate a species difference in the response to the same immunogen.
The slight variation in the specificity of the antisera raised to the 
normorphine-BSA conjugates in the rats and sheep is probably due to an 
individual variation in response. Insufficient experiments have been carried 
out on too few animals for it to be demonstrated that there is a definite 
species difference in the response to hapten-carrier immunogens.
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RADIOIMMUNOASSAY FOR ETOREHINE.
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HO
|H3
C— CH— CH— QH^ 
OH
Chemical structure of
CH^ etorphine.
Summary,
The information gained from the experiments with morphine conjugates 
in rats regarding the optimal chain length of the bridging group and 
optimal degree of derivatisation^was applied to the development of a 
radioimmunoassay for etorphine. Etorphine is a potent analgesic for which 
no sensitive method for measuring the drug in biological fluids was 
available. The basic structure of etorphine is closely related to that of 
morphine^ having a substituted phenenthrene nucleus. The etorphine-3-hemi- 
succinate derivative was prepared, coupled to BSA and the conjugate 
injected into two rabbits. A radioimmunoassay for etorphine was developed 
using antiserum collected from one of the rabbits.
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i. Production of Immunogens.
Etorphine-3-hemisuccinate (Et-3-HS) was prepared following the 
method used by Wainer, Fitch, Rothberg and Fried (1972a) for the production 
of morphine-3-hemisuccinate. Etorphine hydrochloride (44*2 mg)(Reckitt& 
Sons) was refluxed for four hours with succinic anhydride (30*7 nig) in 
pyridine (3 ml). The solvent was evaporated under reduced pressure and 
the residue washed with hot ethanol (5 x 10 ml). The product was finally 
recrystallised from hot 60 % ethanol^ resulting in a yield of 14*1 mg 
Et-3-HS.
The Et-3-HS (2*3 mg) was conjugated to BSA (18*0 mg) in aqueous 
solution (3*0 misusing a carbodiiraide condensation reaction (EDO, 40*0 mg). 
The resulting solution of the conjugate (Et-3-HS-BSA) was purified by 
dialysis, over a period of 48 h, against two changes of distilled water 
(300 ml each). U.V. analysis of the dialysates failed to show the presence 
of free Et-3-H3 and it was assumed that all the derivative had been coupled
7
to the BSA. This resulted in a conjugate containing 16 moles Et-3-HS per mole 
of BSA. The conjugate solution was frozen and stored at -10°C.
ii. Characterisation of Et-3-HS.
The U.V. spectrum of Et-3-HS proved to be the same as that for 
etorphine hydrochloride solution (fig. 3*1)> indicating that the U.V. 
absorbing groups and the overall structure of the molecule had not been 
disrupted during the reaction. Comparison of the infra-red (i.R.) spectra 
of etorphine and 2t-3-HS (fig. 3*2) shor/ed the latter to have new C=0 
stretching peaks at approximately 1700 cm , -C-0-C- stretching peaks at
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a* phenolic-OH group. This confirmed that the hemisuccinate grouping had 
been produced at the 3 position in the etorphine nucleus. The chemical 
structure postulated for the Et-3-HS-BSA conjugate is shown below in
fig. 5.3.
.CH
CH
CH— CH
OH
CH
NH
BSA.
Fig. 5*3 i Structure of Etorphine-3-hemisuccinate-BSA.
iii. Immunisation Schedule.
One female Dutch rabbit (G/r/34) was immunised with Et-3-HS-BSA 
(1*0 mg) in distilled water (0*3 ml) emulsified with Marcol 52 adjuvant 
(1*0 ml) containing BCG- vaccine (3*0 mg). The emulsion was administered 
by intramuscular injection into the fore (0*25 ml) and hind (0*5 ml) limbs.
A second female Dutch rabbit (g/r/3 1) was similarly treated,but 
received only 100 jug conjugate in the same volume of emulsion.
After three months each animal was given a booster injection (i) 
containing the same quantities of conjugate and adjuvant as the initial 
injection; the BCG was not included. The second (il) and third (i'll) booster
207
samples were collected seven days after each booster injection,
iv. Assay Procedure,
Tritiated etorphine (^H-Et) (Reckitt & Sons, specific activity 
0*44 Ci/mmole) was used as the label for this radioimmunoassay. The ^H-Et 
was dissolved in ethanol (9*0 ml) to give the first stock solution (Et Stock 
1; 200 nmole/ml). An aliquot (20 ^ ul) of Et Stock 1 was diluted to 10 ml with 
ethanol to give the second stock solution (Et Stock 2; 400 pmole/ml).
The stock solutions were stored at -20°C and Et Stock 2 was diluted 1:10 
v/ith buffer before use in the assay.
0*05 M phosphate buffer, pH 7*4, was used to dilute the antiserum and 
label, and as the assay diluent. For the antiserum dilution curves, the 
sera were initially diluted 1:5 and then double diluted with buffer. For the 
standard and cross-reactivity curves, aliquots of a stock solution (0*1 mg/ml) 
were diluted to 100 ng/ml and then double diluted to 1*57 ng/ml to give the 
series of standards used in the assay. The compounds examined for cross­
reactivity with the etorphine antiserum were morphine,codeine, nalorphine, 
normorphine, diamorphine and morphine-3-glucuronide.
The procedure for the radioimmunoassay, using the quantities of reagents 
illustrated in Table 5.1*was the same as that employed for the phenytoin 
radioimmunoassay, under equilibrium conditions. An incubation time of 50 min 
at room temperature, followed by 10 min in iced-watery was allowed before the 
addition of DCC (0*625 % w/v charcoal with 0*062 % w/v dextran T-70 in 
buffer). After a further. 10 min in iced-water, the DCC was precipitated by 
centrifugation at 2000 rpm and 4°C for 5 min. 200 ^ ul aliquots of the
208
pi pi pi
JdD
P1
XilUJXU
pi
oxu
pi
Diluent 300 300 200 100 100 100
Std/buffer - -* - - 100 100
Antiserum - 100 200 100 100
Label 100 100 100 100 100 100
DCC - 200 200 200 200 200
Buffer 200 - - - -
Aliquot for
liquid
scintillation
counting
200 200 200 200 200 200
Table 5.1 : Protocol for etorphine radioimmunoassay.
supernatants were counted by liquid scintillation counting techniques.
v. Calculations.
After correction for NSB values, the results of 'the antiserum dilution 
curves were plotted as percentage of T otal and those for the standard curves 
as the percentage of MB.
5b. .RESULTS.
Of the two rabbits treated with Et-3-HS-BSA, only G-/R/34 produced anti­
bodies. Table 5*2 and fig 5*4 show the increase in percentage binding of the 
label in this animal with successive booster injections. .
SSHJM SMAPLE WEEKS AFTER 
INITIAL DOSE
JoTOTAL
Preimmunisation 0 4.9
la 13 32*8
Ila •- 18 48*9
Ilia 28 75-9
Table 5*2 : The degree of binding of ^H-Et in a 1:4 final dilution of 
antiserum collected after each booster injection.
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90*
Antiserum G/r/34 
2
Label “H-Et, 4 pmole/tube.70'
Bleed : 1=1 Preimmunisation 
a ia
60 *
Ila
a Ilia
0
Neat 1:10
Antiserum dilution.(initial)
Pig. 5.4 : Antiserum dilution curves for G/R/34.
The slow appearance of antibodies and the low titres that were, reached, 
indicate that the Et-3-HS-BSA was only weakly immunogenic in the two rabbits 
immunised. The titre of the antisera could possibly be increased by using a 
smaller amount of label ag.0*5 pmole/tube. However^-this was not convenient 
with the low activity label used here^ as the count rate would have been too 
low to be practicable. A standard curve using G/R/34-II&--1 :4 is shown in
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found to be 0*88 £ 0*04 ng/ml. With doses of 1 /ig/kg in man, assuming 100 %
availability of the drug, the maximum blood levels that can be expected
are approximately 14 ng/ml; hence the assay should be sensitive enough to
detect etorphine in clinical samples.
AScatchard plot (fig5.5) of the results of this standard curve
indicates that there ..-were two populations of antibody present. The high
9 -1avidity antibodies have a K value for etorphine of 1*82 x 10 L.M. at an
- 9 - 1
effective binding site concentration of 2«33 x 10 M.L. ; for the low
7 - 1avidity antibodies, K = 1.04 x 10 L.M. .
The cross-reactivity studies indicated that, over the range 0-100 ng/ml, 
the anti serum did not cross react with any of the compounds examined. As 
etorphine has been used clinically in conjunction with diamorphine (Blane 
& Robbie, 1970}, it is important that the antiserum should not cross react 
with this opiate or any of its congeners. Thus the assay is applicable to 
the analysis of sera from patients receiving opiate analgesics in combined 
therapy with etorphine.
5c. EFFECT OF PROTEIN CONCENTRATION OH. ETORPHINE STANDARD CURVES.
Since the plasma etorphine levels in clinical samples can be expected 
to be near the present detection limits of the etorphine radioimmunoassay, 
the samples cannot be diluted before analysis. Thus, it was necessary to 
determine the effects that serum proteins might have on the assay.
Two standard curves were set up in quintuplicate; in one, the standards 
were prepared and diluted with buffer, and in the othei^  with undiluted 
FFP. In both cases, the antiserum ( G-/R/3 4-IIIa-1 :5) and label were diluted
211
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Anti serum G/P/3 4~IiIa-*1 i5 
Label ^H-Et, 4.0 pmole/tube
▲ Buffer 
a  FFP
60 -
50*
20*
Fig. 5.6 : To show the effects of serum protein on the etorphine
standard curve. *
with buffer and buffer was used as the assay diluent. All other conditions 
were the same as those employed in the previous etorphine standard curves.
The resulting curves were plotted as percentage binding of zero and 
are shoT/n in fig. 5*6. In both cases the NSB values were high (10*6 / T 
with buffer and 14*3 /^ T with FFP) and the zero values were low (6*6 foil with 
buffer and 9*0 with PPP) indicating that the antiserura had been used at 
too high a dilution. The two standard curves suggest that protein does have 
an effect on the assa^ by increasing the binding of label in the presence 
of high concentrations of protein.
The assay characteristics, determined from modified Scatchard plots of the 
results of these two curves (fig. 5.7), suggest that there is little 
difference in the behaviour of the antiserum under these conditions. For,the
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8 —1high avidity binding sites was 1*12 x 10 L.M. at an effective binding site
-9 -1concentration of 3*57 x 10 M.L, ; the sensitivity of this curve is
7 - 11 • 58 ng/ml. When the standards were prepared in FFP, K = 8*03 x 10 L.M.
—9 —1and n = 6*00 x 10 M.L. ; the sensitivity of this curve was 1*59 ng/ml.
These results indicate that protein has an effect in the assay, 
increasing the amount of label bound;but not affecting the sensitivity of 
the assay. Thus, by keeping the protein content of the system constant 
during an assay, ie. by preparing the standards in normal serum, the assay 
could be used to measure the drug in clinical samples. *
5d. DISCUS3I0N.
Etorphine was coupled to BSA by preparing the 3~^eraisuccinate 
derivative and coupling this to BSA. The method followed was that of Yfainer 
et al. (1972a) for the production of morphine-3-hemisuccinate. However, it 
was later stated that the morphine derivative they had produced by this 
method was the 6-hemisuceinate and not the 3-hemisuccinate (Wainer et al..
1972b)Etorphine does not have a reactive alcoholic group at the 6- position 
and it is unlikely that etorphine-6-hemisuccinate will have been produced. 
This is confirmed by the I.R. spectrum of the hemisuccinate which shows 
that the peak characteristic of a phenolic-OH group has disappeared. Thus, 
it was inferred that the derivative produced was, in fact, etorphine-3-hemi­
succinate.
Of the two animals immunised with Et-3-HS-BSA, only one (g/r/34) 
produced antibodies, and these were of low titre. This animal received ten 
times the weight' of conjugate that was given to G-/R/31. The lack of anti-
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to the small amount of immunogen injected.
Until the development of this radioimmunoassay, no method was 
available that was capable of measuring the low levels of etorphine in 
biological fluids. The experiments described here show that high concenti>- 
ations of protein increase the binding of the label to the antibody; they 
do notjhowever, influence the sensitivity of the assay, so confirming its 
applicability to the analysis of clinical samples.
In the experiments to illustrate the effects of protein, the standard 
curves were less sensitive than those produced with G/R/34-Ha. This may be 
caused by the antiseru'm being used at a’higher dilution in. the assay, and 
may also reflect differences between bleeds from the same animal.
In serum G/R/34-IIIa, neat serum binds a higher proportion of the total label 
added than does, serum IIa» however, the avidity of the a,ntibodies for 
etorphine in Ila and the effective binding site concentration, remained the 
same. This indicates that serum Ilia is not as suitable for use in an assay 
as serum Ila, confirming; that each serum sample from the animals should be 
screened for titre, sensitivity, avidity and cross-reactivity before being 
used in a radioimmunoassay for clinical samples.
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CHAPTER 6
FINAL DISCUSSION AND CONCLUSIONS.
present at low concentrations in biological fluids and has only recently 
been applied to the determination of blood drug levels. This thesis has 
described the successful development of radioimmunoassays for phenytoin 
and etorphine and has examined the problems encountered during the 
developmental work of an assay for sulthiame. Using morphine as a modely it 
was possible to study factors that influence the immunogenicity of drug- 
protein conjugates and to propose ways in. which this may be increased.
One of the first problems encountered during the developmental work 
was that of raising specific antibodies to the drugs. Phenytoin, sulthiame, 
morphine and etorphine are all low molecular weight compounds (253-4S8) 
and are not -'usually immunogenic. To invoke an immune response against 
these drugs it was necessary to couple them as haptens to the carrier protein 
BSA. Conjugation of the haptens to the carrier was achieved by several 
different coupling reactions.
Carbodiimides usually result in the formation of a peptide bond 
between the hapten and the carrier, and are normally used to couple primary 
amino groups on the carrier to carboxylic acid residues on the hapten. The 
work reported here has described the use of carbodiimides in the coupling 
of secondary amino and sulphonamide groups on the hapten to carboxylic acid 
groups on the carrier. Activation of one of the secondary amino groups in 
the bydantoin ring of phenytoin to facilitate this type of reaction was 
achieved by the use of the sodium salt of the drug. Under alkaline 
conditions phenytoin sodium dissociates, activating one of the two nitrogen 
atoms. The proximity of the electron-donating phenyl groups to the nitrogen
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activated. Carbodiimide condensation to the carrier through this part of the 
phenytoin molecule is then more likely to take place.
A similar situation occurs with the secondary amino group, of nor- 
morphine, except that, in this case, activation is not accomplished by 
dissociation of a sodium salt. The electron-donating properties of part of 
the phenanthrene nucleus enable the 7r-electron cloud of the phenyl ring 
to be delocalised over the whole molecule. The electronegative N atom 
becomes more negatively charged and the molecule is polarised.
Conjugation of the hapten to carrier by a carbodiimide condensation 
reaction is efficient; for example, there is a maximum of 133 carboxylic 
acid residues on the BSA molecule that can be utilised, and as mai^ y as 90 
residues of norraorphine have been coupled directly to BSA by this method.
By limiting the amount of normorphine and carbodiimide- present in the reaction 
mixture, it was possible to control the degree of derivatisation of the carrier. 
With less than 30 haptens per mole of carrier, the conjugations 7/ere 100 % 
efficient. The conjugation reactions involving the coupling of N-succinyl- 
normorphine derivatives to BSA were also efficient. There are 59 lysine 
residues, in the BSA molecule that can be used for this type of reaction 
(Erlanger, 1973; Morris et al., 1974)> and the maximum number of 
N-succinyl-normorphine residues that 7/ere conjugated by carbodiimide 
condensation was fifty. In both this reaction and the one involving the 
carboxylic acid residues of BSA, it was more difficult to attain high 
degrees of derivatisation; to do this, a large excess of hapten had to be 
used.
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sulphonamide group of the drug. In the absence of a coupling agent; it was 
found that four molecules of sulthiame became attached to each BSA molecule; 
by using a carbodiimide, seventy sulthiame residues were coupled to the BSA.
This confirms that the sulphonamide group was reacting in a similar way
/- •
to a primary amino group and was coupled to the carboxylic acid residues of 
BSA. Further evidence for this type of reaction is provided by the sulthiame 
conjugations in which glutaraldehyde was used as the coupling agent. This 
compound normally acts to couple two primary amino groups, although it 
will react with phenolic, and other chemical groups. The successful coupling 
of sulthiame to BSA by this method showed that the sulphonamide group would 
act like an amino group.
However, when the conjugation labelling method of-Bolton and Hunter 
(1972) was used to produce a radioiodine label for sulthiame, it was found 
that the final coupling reaction, ie. peptide bond formation, did not 
occur. In this situation the sulphonamide group did not react as expected 
and no peptide bond was formed. Thus it appeared that the sulphonamide 
group of sulthiame was capable of reacting as a free amino group only in 
the presence of an active conjugating agent.
The ability of glutaraldehyde to couple to a secondary amino group 
was demonstrated by the conjugation of normorphine to BSA. The possibility 
that the glutaraldehyde had reacted with the phenolic or alcoholic groups 
could be excluded, as the specificity of the resulting antiserum was such 
that conjugation could only have taken place through the cyclic nitrogen 
atom. The glutaraldehyde bridge between the normorphine and the carrier had
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sation reaction^, with the subsequent formation of a double bond between two 
of the carbon atoms. The bridging group so formed was either a heptan-1-ol 
(-CH0H-CH2-CH2-€H2-CH=) or heptan-1-ene (-CH=GH-CH2-CH2-CH=).
Glutaraldehyde could not be used to couple phenytoin to BSA. Although 
phenytoin could be activated to react with a carbodiimide, the same type of 
activation did not facilitate a reaction with glutaraldehyde. With this 
reagen^ the hydantoin -Mi groups would not react in the same way as 
secondary amino groups. The difference between the hydantoin- and normorphine 
NH groups is the other atoms to which they are attached. The electron with­
drawing and donating properties of the rest of the molecules-are such that 
both are activated to carbodiimide condensation, but only the normorphine 
is activated to react with glutaraldehyde. It would appear that the :required 
type of activation is provided by a phenenthrene but not a hydantoin nucleus
Evidence that conjugation has taken place was obtained by two methods. 
Firstly, U.V. spectral analysis of the dialysates showed the presence of 
unconjugated drug. By measuring the quantity of free material and subtract­
ing from the weight of drug added at the start of the reaction, the amount 
of conjugated drug was determined. Secondly, the U.V. spectum of the conjugate 
solutions showed that the structure of the BSA had been modified in some 
way by the introduction of U.V. absorbing groups. The spectra observed for 
all the drug-BSA conjugates were the same, showing two absorbance peaks, a
v
strong peak at 220 run and a smaller, though broad peak, at approximately 
280 nm. At the concentrations used in the reactions and at v/hich the 
conjugate spectra were examined,neither the drugs nor the carrier show
individual reactants.
Once satisfactory conjugates have been produced^the next important 
factor to be considered in the development of a radioimmunoassay is the 
choice of an immunisation schedule. Most of the antisera raised against 
protein hormone immunogens were elicited by the administration of micro­
gram amounts of material; following these procedures, rabbits were 
immunised with microgram amounts of sulthiame and phenytoin conjugates.
Initially, many of the rabbits were immunised using the low dose, multi-site, 
intradermal method of Vaitukaitis _et al. (1971), using Freund* s "complete"
adjuvant. This immunisation method resulted in ulceration at the site of
(in press)
injection, an observation also made by Lynch and Shirley/when they used 
this immunisation technique. The animals were obviously under stress, even 
though they continued to feed and drink. For this reason the Marcol 52 
adjuvant described by Marks, Morris and Teale (1974) was used. Marcol 52 
is a pharmaceutical grade oil produced by the Esso Petroleum Company, and 
was used to replace the Bayol F component of Freund* s "complete" adjuvant.
• N
The use of this oil eliminated ulceration at the injection sites and so 
reduced the stress to the animals. However, this intradermal immunisation 
schedule failed to result in the required antisera to the drug-protein 
conjugates being produced, and subsequent immunisations of these and other 
animals were by sub-cutaneous or intra-muscular routes. These schedules, 
again using microgram amounts of conjugate, also failed to invoke the 
required immune response.
The rats used during the experiments to investigate the immunogenicity
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less than 500 pig over a period of two months. Those animals receiving the 
more immunogenic conjugates produced low titre, low avidity antibodies to 
morphine.
Of the two rabbits immunised with the etorphine-3-hemisuccinate-BSA 
conjugate, only that receiving 1 mg doses of conjugate produced any anti-, 
bodies to etorphine; the other showed no positive response.
Of the published radioimmunoassays to drugs, approximately half have 
involved the immunisation of animals with large (1 mg and more) amounts 
of immunogen. The highest titre antisera were also produced in those animals 
receiving large doses of immunogen; for example the phenytoin antiserum of 
Cook jet al. (1973)> useable at a final dilution of 1:14000, was raised in 
rabbits immunised with 2*5 mg conjugate, with 1*0 mg amounts being given in 
the boosters; the LSD antibody of Taunton-Rigby et al. (1973)(final: dilution 
1:500,000) used 0*5 mg doses of immunogen; the pentazocine antibody 
(Williams & Pittman, 1974; final dilution = 1:7300) was raised against 
1 mg doses of immunogen. The phenytoin and sulthiame antibodies described 
here were eventually raised in sheep after milligram doses of immunogen 
had been injected intramuscularly.
From these results, it can be concluded that in order to invoke an 
immune response against hapten-protein conjugates of low molecular weight 
compounds, resulting in antibodies capable of reacting with the hapten, it 
is necessary to immunise with large'amounts of conjugate. Since conjugates 
normally have approximately twenty residues of hapten per mole of carrier, 
the total amount of hapten injected in 1 mg of conjugate is small, of the
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therefore received a negligible amount of hapten against which to produce 
specific antibodies.
Eisen and Siskind (1964) have demonstrated.that excessive amounts of 
conjugate can have an adverse effect on antibody production. The minimum 
amount of conjugate that they used was 5 mg and the maximum 250 mg, injected 
in a single dose. The rabbits receiving the small amounts of immunogen 
produced the high titre^high avidity antibodies, while .those injected with 
large amounts produced low titre antisera of low avidi-iy.
A recent paper by Lynch and Shirley (in press) has demonstrated that 
it is possible to raise high titre antisera, using the intra-dermal method 
of Vaitukaitis et al.(1971), ie* against low doses of immunogen. The compounds 
they used were large molecular weight protein hormones which are extremely 
immunogenic. Colburn (1974)> raising antisera against a prednisolone-BSA 
conjugate, found that frequent (bi-weekly) immunisation with 0*5 mg 
conjugate produced only low titre antisera. After eleven months of frequent 
boosting^ the titres remained low and the animals were then immunised intra­
venously with an aqueous solution of the conjugate and the titres increased 
twenty fold. Colburn1 s experiences with antiserum production seem to closely 
parallel those reported here^ in the rabbits immunised with phenytoin and 
sulthiame conjugates. By analogy, it seems possible - that an intravenous 
administration of the conjugates into these animals could result in the 
production of antisera of measurable titre.
The experiments with morphine conjugates have demonstrated that the 
immunogenicity of drug-protein conjugates can be improved b3>- controlling
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optimum degree of derivatisation was dependent on the way in which the hapten 
v/as linked to the carrier. When the drug was linked directly to the carrier 
through the cyclic nitrogen atom, the antiserum binding -the highest 
percentage of added label was produced in a rat immunised with a conjugate 
having 40 residues per mole of carrier. If the drug was linked to the 
carrier by means of a succinyl spacer group, the optimum degree of derivat­
isation was found to lie between 14 and 28 residues per mole of carrier.
The immunogenicity of the morphine-BSA conjugates was also improved 
by the insertion of a spacer group between the drug and the carrier. 
Experiments showed that the succinyl (40) spacer group had the greatest 
effect, with the sebacyl (8C) spacer also increasing the immunogenicity. The 
use of an adipyl (6c) spacer group failed to have any beneficial effect on 
antibody production; in fact, the conjugate employing this group was non- 
immunogenic. As has already been described (section 4b iv), this was 
probably due to steric folding of the adipyl chain.
From these experiments it was concluded that the insertion of a 
succinyl spacer group and a degree of derivatisation between 10 and 30 
would result in the most immunogenic hapten-protein conjugate. This 
hypothesis was tested during the development of the radioimmunoassay for 
etorphine. Etorphine-3-hemisuccinate-BSA,having 16 moles of etorphine-3- 
hemisuccinate per mole of carrier, was produced and injected into two 
rabbits. It is' thought that the lack of antibodies to etorphine in one of 
the rabbits was the result of immunising with too low a dose of immunogen,, 
rather than the non-iinmunogenicity of the conjugate.
225
carrier increased the immunogenicity of the conjugate, it did not appear 
to appreciably affect the specificity or avidity of the antisera. Cheng ejb
U ; i :/ ^
al»('5 973) stated that the extra bridge length used in their radioimmunoassay 
for amphetamine did enhance the specificity and avidity of the anti­
amphetamine antibodies, but did not provide any experimental evidence to 
support their conclusions. These workers also commented that a similar 
effect had been observed in the production of antibodies for a phenobarb- 
iturate radioimmunoassay (Chung et al, ,1973) • In the morphine radioimmuno­
assay, it v/as the point of attachment to the carrier that influenced the 
specificity of the antiserum and not the spacer group. The antibodies 
raised against normorphine conjugates proved to be the most specific, as 
the -OH groups at positions 3 and 6 were free to act as antigenic 
determinants.
The effect of the point of attachment on the specificity of an anti­
serum is demonstrated in the phenytoin radioimmunoassays. The assay of 
Tigelaar et al.(l973) used an antiserum raised against a conjugate produced 
by coupling the phenolic -OH group of the metabolite, HPPH, to the carrier. 
The resulting antiserum failed to distinguish between the drug and its 
metabolite. In both the assay of Cook et al. (1973) and that reported here, 
the carrier was attached to the hydantoin ring at a site remote from the 
phenyl groups. Both of these antisera showed little cross-reactivity with 
HPFH, and neither showed any cross reactivity with any of twelve compounds 
having a chemical structure closely related to that of phenytoin.
As the titre of the phenytoin antiserum increased,so did the
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as the titre increased to 1:1600, the cross-reactivity with HFPH fell to
less than 4*0 x *i0"^  %. The increase in titre was accompanied by a
8 -1corresponding increase in avidity, from 4*49 x 10 L.M. to 
10 -11«25 x 10 L.M. . This increase in both specificity and avidity contrasts 
with the findings of Smith, Butler and Haber (1970), who reported that as 
the avidity of their anti-digoxin antiserum increased, the cross-reactivity 
also increased and the assay became less specific. Eisen and Siskind (19&4) 
suggested that the increase in avidity with time could account for the 
observation that the specificity of the antiserum decreases with progressive 
immunisations, since high avidity antibodies should be more capable of 
displaying a wider variety of cross-reactions than low avidity antibodies. 
Hooker and Boyde (1941) have made simi3.ar observations.
The explanation put forward by Eisen and Siskind (19&0 for the hapten- 
binding heterogeneity was that (a) antibody-producing cells are functionally 
heterogenous, each cell or group of cells producing antibody molecules of a 
uniform and distinctive avidity; and (b) fluctuations in the biosynthetic 
mechanisms are of such magnitude that even a single cell secretes antibodies 
with different avidities for any given antigen.
Pauling (1940) stated that antibodies of exceptionally high avidity 
for the antigen would be infrequent since, during biosynthesis, their 
dissociation from hypothetical antigen-templates would be improbable, 
whereas the antibodies of low affinity would dissociate leaving the 
template free to react again.
Eisen and Siskind (1964). suggested that the increase in average
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characteristic of the immune response in general. Their work would suggest 
that the highest titre antibodies, normally appearing 7-10 days after an 
immunisation, do not necessarily have the highest avidity. Other workers 
(Talamange and Maurer, 1953; Parr, 1958), however, have observed that the 
antiserum avidity increases with progressive immunisationsj the avidities 
of the antisera to the drug-protein conjugates used in this work have, in 
general, agreed with these findings. The low avidity of the rat antisera 
to normorphine conjugates is probably due to the low titres at which the 
antibodies were produced. There have been no reports of low titre, high 
avidity antisera and the increase in avidity of the antisera reported here 
.is accompanied by a corresponding increase in titre and specificity.
The results presented have shown that the higher the titre of the 
antiserum, the higher the avidity and the greater the specificity of the 
fesulting radioimmunoassay. The increased titre and avidity also lead to 
an increased assay sensitivity, which results in a reduction of the effects 
that protein concentrations may have on the assay. As the assay is more 
sensitive, the samples may be assayed at higher dilutions and so the non­
specific binding of the drug to the serum proteins becomes less significant, 
and more precise and accurate assays result.
Another factor influencing the sensitivity of a radioimmunoassay
is the specific activity of the radiolabelled antigen. In general, high
specific activity labels result in more sensitive assays. This is
demonstrated in the radioimmunoassay for phenytoin described here. The low 
1A
activity C-DPH label was suitable for detecting antibodies to phenytoin
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count rate (250 cpin), it was necessary to add at least 0*1 ninole (25 ng) of
this label to produce an assay capable of detecting 5 ng phenytoin per ml
3of serum. With the higher activity H-DHi it was necessary to add only 
0*5 pmole (126*1 pg) of label per assay tube to achieve a count rate of 
1000cpm and an assay sensitivity of 300 pg/ml. The use of the higher activity 
label enabled low titre antibodies to be detected in sera that had shown
A }
negative reactions with C-DPH.
11
For sulthiame^ neither tritium nor C labelled forms were available 
and experiments to label the drug with radioiodine were carried out. A 
radioiodination tag, TME, was attached and the complex radioiodinated by 
the chloramine-T method. The resulting labels werefbund to be capable of 
reacting with the antisera^ but the problem v/as then one of displacing the 
label with unlabelled drug. Once bound to the antiserum.^  the label could not 
be displaced by the addition of a large excess of either sulthiame or TME, 
and could only be displaced by adding uniodlnated sulthiame-TME complex.
The production of a tritium-labelled form of sulthiame failed to show 
the presence of any specific sulthiame antibodies, assuming that the sulthiame 
molecule had not been damaged by the tritiation reaction. It was concluded 
that the binding of the sulthiame-TME complex was not directed against the 
sulthiame part of the molecule. Since the immunogen was not sulthiame-TME 
and the binding could not be reduced by the addition of TME, the antibodies 
must have been specific for the chemical linkage between the drug and the 
tag. As the same conjugation reaction was used to couple the drug to BSA 
and to TME, the same type of molecular bridge would have been produced. In
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the sulthiame antisera were directed against the bridge portion of the 
immunogen. A similar observation was made by Cameron et al. (1973) in steroid 
radioimmunoassays. These workers used histamine as the radioiodination tag 
and observed that the histamine side chain closely resembles that of lysine/ 
to which the hapten molecules had been attached in the production of the 
conjugate to BSA. Hence,the steroid and bridge portions were so similar 
in the immunogen and the label that the binding of the label exceeded that 
of the free steroid.
Of the published radioimmunoassays for non-steroid drugs only four 
use radioiodine to label the drug molecule*, these are the digoxin (Lader 
fit al., 1972), L.S.D. (Taunton-Rigby et al.. 1973)> cotinene (langone et al. 
1973) and morphine (Van Vunakis fit al., 1972) radioimmunoassays. The 
majority of the remainder of the drug radioimmunoassays use a tritium 
labelled antigen.
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Prom the work presented here^  it has been shown that drug radioimmuno­
assays are valuable research tools capable of high sensitivity, accuracy 
and precision. In setting up such an assa^ several important factors should 
be taken into account:-
i.The immunogenicity of a drug-protein conjugate can be increased 
by inserting a succinyl spacer group between the hapten and carrier, and 
restricting the number of haptenic residues, to between 10 and 30 Per nioie
of carrier.
ii. The point of attachment of the carrier to the hapten will 
influence the specificity of the resulting antiserum. By examining the 
chemical structure of the drug and its metabol!tes/ the point of attachment 
that is likely to result in the specificity required, can be chosen.
iii. The immunisation schedule will influence the production 
of antisera. Por rapid screening experiments, weekly (or more frequent) 
injections into small animals are sufficient to indicate the more immuno­
genic drug-protein conjugates. Por the production of high titre, high 
avidity antisera, a large initial dose ( of the order of milligrams), two 
or three booster injections at monthly intervals with approximately half 
•the amount of conjugate, followed by a rest period of several months and then 
further boosters,'seems to produce the required antiserum. Since drugs are 
low molecular weight compounds, large amounts of drug-carrier conjugate 
must be administered to incorporate microgram amounts of drug.
iv. Large numbers of drug-protein conjugates may be rapidly 
screened for immunogenicity and possible specificity by using rats as the
231
v, A high specific radioactivity label is necessary for a
\
sensitive radioimmunoassay; tritium appears to be the most suitable isotope 
•with which to label small drug molecules.
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3Preparation of 5,5-Bis (plienyl-4- H)hydantoin 
J. A. Kepler 
Research Triangle Institute
Br
C=0
T2, 10% Pd/C 
   ^KCN + (NH4)2C03 HN HN
1Preparation of 5,5-Bis-(4-bromophenyl)hydantoi
A 1.30 g (3.8 mmol) sample of 4,4’-dibroinobenzophenone (Columbia 
Organic Chemicals) was dissolved in 16 g of acetamide with stirring and 
heating. Potassium cyanide (0.342 g, 5.26 mmol) was added and the stir­
ring and heating continued until solution was complete. Ammonium carbo­
nate (1.09 g, 11.3 mmol) was added and the solution immediately sealed
in a Paar bomb (40- ml capacity) with glass liner. The seaJ.ed' bomb was
$
kept in an oven at 120° for 20 hours. After cooling, the contents of 
the bomb were suspended in water and the suspension acidified with hydro­
chloric acid. The mixture was filtered and the residue stirred with 50 
ml of 5% sodium hydroxide and filtered. The filtrate was acidified, the 
•precipitate collected and crystallized from ethyl acetate to give 973 mg 
(63%) of 5,5-bis-(4-bromophenyl)hydantoin. m.p. 308-309°, C^H^ qB^^O^, 
Required m/c 409.909; Found m/e 409.911.
^It is essential that the entire bomb be heated uniforml}r, otherwise the 
ammonium carbonate sublimes from the solution and greatly reduced yields 
are obtained. '
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'3Preparation of 5,5-Bis(phenyl-4- H)hydantoin
t
To a solution of 10 mg (0.025 mmol) of 5,5-~bis(4--broinophenyl)hydantoin 
and 10 pi (0.07 inmol) of triethylamine in 1 ml of dioxane was. added 10 mg 
of 10% Pd/C. The mixture was stirred in an atmosphere of tritium gas 
until no more tritium was absorbed (ca« 3 hr). The catalyst was removed by 
filtration and the labile tritium removed in vacuo using ethanol as solvent. 
The residue was dissolved in 5 ml of ethyl acetate, washed with 3 x 1 ml of 
water and the ethyl acetate solution filtered through sodium sulfate. The 
ethyl acetate solution was chromatographed on a 20 x 20 ChromAR 1000 sheet 
using carbon tetrachloride-acetone (8:2) as solvent. The radioactive zone 
was cut from the chromatogram and eluted with ethanol. The residue 
obtained after removal of the ethanol was further purified by sublimation 
(180°/0.05 mm). The sublimate (1.5 mg) had a specific activity of 233 
mCi/mg (56 Ci/ramol). Isotoptic dilution analysis (crystallized from ethanol 
and water) indicated that the radiochemical purity was greater than 98%.
The material was stored in 10% ethanol-benzene solution at about 4°.
After storage in this manner for 18 months no decomposition could be 
detected by radio tic (silica gel HF, acetone-chloroform, 3:7).
1. H. R. Henze and L. M. Long, J. Amer. Chem. Soc. , JE13, 1941 (1941).
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5,5-Bis (phenyl-4- II) hy dan to in
Specific activity: 56.5 Ci/mmole
Concentration 500 pCi ml in
HN NH
10% ethanol:benzene
Stability and storage recommendation: decomposition has been <1% upon
storage for 1 year at 5°C in 10% ethanol:benzene solution. Purity 
should be checked at least once a month.
Radiochemical purity: >98% determined by radiochromatography using 7:3
chloroform:acetone on silica gel F-254.
Quality control: radiochemical purity last checked on January 2, 1974.
Preparative procedure: 5,5-Bis(phenyl-4- K)hydantoin is obtained by
^reductive tritiation of 5,5-Bis-(p-bromophenylhydantoin) (1).
*
Reference: (1) C. E. Cook, John A. Kepler and H. Dix Christensen, Res.
Commun. Chem. Path. Pharm., _5, 767 (1973).
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in Radioimmunoassays for Drugs
J.D. Robinson, G.W. Aherne, J.D. Teale, B.A. Morris and V. Marks 
Department of Biochemistry, University of Surrey, Guildford, Surrey
One of the main reagents in a radioimmunoassay is a suitable radioactively 
labelled form of the antigen. Since the sensitivity of the radioimmunoassay is affected 
by the specific activity of the label, in general the higher the specific activity, the 
greater the sensitivity of the assay. In some cases the maximum sensitivity is not 
required. An excellent illustration of this is the radioimmunoassay for phenytoin 
developed in this laboratory (Robinson et al., 1974). This assay is capable of detecting 
as little as 300 pg/ml of plasma and as the therapeutic level of phenytoin is 10-20yug/ml, 
the samples must be diluted at least 500 times to bring them within the range of the assay.
In this case the sensitivity of the assay is an "added extra" enabling estimations to be 
made on microsamples of blood (5yul), such as those obtained by a finger-prick.
In developing assays for the more potent drugs which are used in much smaller
doses, it becomes necessary to take full advantage of the sensitivity potential of the
radioimmunoassay. In many cases tritium labelled forms of the drugs can be obtained
having specific activities of the order required. However, for the efficient detection
of the low energy beta particles emitted by this isotope, liquid scintillation counting
must be used. This method is both time consuming and costly in the use of scintillants
and solubilisers. Many of the inconveniences encountered in the use of tritium can be
125 1 14overcome by the use of radioiodine. The relative advantages of I over °H or C are 
shown in Fig. 1. This indicates that in order to obtain the same number of counts per
■I n r  O  ^
unit time as are obtained from one atom of °I, 52 atoms of II and 37, 000 atoms of C
would be required, taking into account the differences in half-lives and detection efficiencies. 
125Thus on this basis I would seem to be the isotope of choice.
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The chemistry of radioiodination is essentially the chemistry of substitution 
into phenolic groups (Hughes, 1957) such as those of tyrosine. Iodine substituted in 
this way constitutes a chemically stable tracer and the iodination conditions can be 
arranged so as to favour the substitution. Five methods have been described for direct 
radioiodination to high specific activity: -
1. The Iodine Monochloride method (Samols and Williams, 1961),
2. The Chloramine-T method (Hunter and Greenwood, 1962 and Greenwood,
Hunter and Glover, 1963),
3. The Electrolytic method (R o s a e ta l., 1964),
4 . Enzymic iodination (Marcolonis, 1964)
5. The Hypochlorite method (Redshaw and Lynch, 1974).
125The chloramine-T method has been successfully used to introduce I  into the 
tetrahydrocannabinol (THC) molecule, probably at the positions ortho and para to the 
phenolic -OH group. The resulting label was found to be immunoreactive but was very  
unstable, each preparation having a shelf half-life of only two or three days. This 
instability can be attributed to the effect of introducing large atoms such as iodine into 
the nucleus of THC. When the radioiodine decays the molecule to which it is attached 
experiences a shock or decay catastrophe and may either dissociate or undergo other 
structural changes.
The overall molecular thickness of the benzene molecule is 3.2oX units while 
the Van der Waals radius of iodine is 2 .15 il. The covalent radius of iodine is 1. 33&, 
which means that the influence of the Van der Waals forces of iodine when attached to a 
benzene nucleus are exerted 3.48X from the benzene ring. Thus not only does the energy 
released by the decaying radioiodine disrupt the molecule, but the atom may also cause 
changes in the overall shape of the molecule tending to reduce both its stability and 
immunor e act iv ity .
2$if
One way of overcoming the problems of steric hindrance is to attach a compound 
that can be radioiodinated to the antigen in such a way that the antigen is altered as little  
‘as possible. Such compounds are known as "radioiodination tags". The smallest 
molecule that can be used for this purpose is an (-^^iodophenol group. Three compounds 
that contain this grouping and that have been used for radioiodination tags are tyrosine 
methyl ester, histamine and a copolymer of glutamic acid, lysine, alanine and tyrosine 
(GLAT, M .W ’ = 30, 000) in the ratios indicated (Fig. 2).
Since antisera are generally indifferent to changes in substituents attached to the 
antigen at the point of attachment used in the immunogen (Hunter, 1974), this would seem 
to be the best site for conjugation of the tag.
The largest radioiodination tag that has been used in this laboratory is GLAT.
The tag was coupled to THC using the same techniques as were used to couple THC to 
bovine serum albumin (BSA) for production of the immunogen (Teale, Forman, King and 
Marks, 1974) (Fig. 3). Radioiodine was then introduced into the tyrosine residues of 
the complex using the chloramine-T method. This label was incubated with the THC 
antiserum and the bound fraction precipitated using ammonium sulphate. Although the 
label was found to bind to the antibody, the binding seemed to be irreversible since the 
label could not be displaced by the addition of unlabelled THC. However, unlabelled 
THC-succinyl-GLAT complex did reduce the binding of the label. It seems likely that 
the antiserum recognises not only the THC molecule but also part of the linkage, suggesting 
that the avidity of the antiserum for THC and linkage is greater than that for THC alone.
A sim ilar problem has arisen with the radioimmunoassay for sulthiame.
Sulthiame is a fa irly  unreactive molecule; the immunogen was prepared using a w ater-
soluble carbodiimide to couple the drug to BSA. A sim ilar technique was used therefore, to
couple sulthiame to tyrosine methyl ester for radioiodination. Fig. 4 shows the type of
reaction envisaged with these reactants, the complex containing the same type of molecular
255
JLinKage as mat tnougnt to oe touna in tne immunogen.
This complex was successfully radioiodmated by the chloramine-T method 
and purified on a Sephadex G10 column, the elution pattern of the label is shown in Fig. 5. 
Fractions from peaks 17 and 33 were incubated with sera from immunised animals.
Using Dextran-coated charcoal to effect phase separation it was found that the material 
in fraction 17 did not bind to antibodies, while that in fraction 33 did.
Samples of both the iodination mixture before purification and of various fractions 
after purification were subjected to chromatoelectrophoresis. Fig. 6 shows the 
chromatoelectrophoretogram of the iodination mixture. By drawing comparisons with 
the radioiodination of protein hormone solutions it might be expected that the peak at the 
origin represents the pure, labelled material, the second peak is the "damaged" fraction  
and the third peak would be free, radioiodine.
Similar treatment of fraction 17 showed this to be relatively impure (Fig. 7).
This fraction did not react with the antiserum. Chromatoelectrophoresis of the fraction
that did bind to the antisera, fraction 33, indicated (Fig. 8) that the peak of activity occurred
not at the origin as expected but had migrated. This effect has been found on the chromato-
125electrophoretograms of other I-drug-tag complexes.
The radioiodinated sulthiame-tyrosine methyl ester was used to screen sera from  
all the animals immunised with conjugates of sulthiame. One animal in particular showed 
high binding with this labeT and an assay including all the serum samples obtained from  
this animal during the course of immunisations showed a definite variation in titre  over a 
period of time (Fig. 9). This animal is also producing antibodies to phenytoin and the prod­
uction of these antibodies follows a sim ilar pattern. This indicates that the original 
conjugate was immunogenic and that the label was immunoreactive.
Unfortunately when unlabelled sulthiame was added to the incubation mixture the 
binding of the iodinated-sulthiame tyrosine methyl ester was not reduced. Dilution
various non-labelled compounds. Fig 10 shows that one curve could be drawn to 
illustrate the effects of tyrosine methyl ester and sulthiame on the binding of 
sulthiame-tyrosine methyl ester. Similarly an equimolar solution containing both 
sulthiame and tyrosine methyl ester did not have any effect. However, the addition 
of non-iodinated sulthiame-tyrosine methyl ester complex to the system results in 
the displacement shown, indicating that this compound reacts with the antibody.
Incubation of this antiserum with a tritium labelled sulthiame failed to indicate the 
presence of specific sulthiame antibodies. These results suggest that the antiserum is 
specific for the linkage between the drug and the tag, which is thought to be the same 
as that between the drug and BSA in the immunogen.
In an attempt to overcome some of these problems it was decided to increase 
the distance between the drug molecule and the tag by inserting a spacer group. This 
technique has been successful in the radioimmunoassays for digoxin (Oliver et a l.,  1968; 
Lader et a l., 1972) and cyclic GMP (Steiner et a l . , 1970), and was applied to our radio­
immunoassay for morphine using a histame tag.
One of our antisera to morphine was raised against a morphine-6-succinyl-BSA  
conjugate and the antiserum does not appear to be too sensitive to changes in this part 
of the drug molecule. A carbodiimide reaction was used to couple histamine to 6-succinyl 
morphine. The complex was successfully radioiodinated by the chloramine-T method 
and purified on a Sephadex-GlO column. Chromatoelectrophoresis of the fractions 
produced results sim ilar to those obtained with the sulthiame-tyrosine methyl ester complex.
The label was incubated with the antisera and was found to be immunoreactive. 
Although the label bound to and could be displaced from the antibody with unlabelled 
morphine, the binding was low, neat serum binding only 8% of this label. (With tritiated
O
dihydromorphine ( H -D IIM ) the antiserum is useable at a final dilution of 1 :1200). It  was
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immunoreactivity of the drug.
3Using H-DHM, antiserum dilution curves were set up in the presence of the 
various intermediates produced during the preparation of this label. Fig. 11 shows the 
results obtained and indicates that while the unconjugated morphine is extremely 
immunoreactive, the attachment of succinyl and then histamine groups progressively 
reduces the affinity of these compounds for the antibody. The conditions of the iodination 
reaction decrease the immunoreactivity even more (6-SM-Hist. (I)). It would appear 
that this antiserum is specific for the morphine part of the complex and can discriminate 
against large chemical groupings attached to the molecule.
In an attempt to overcome the effects of the iodination conditions on the drug 
molecules, we looked at the conjugation labelling technique of Bolton and Hunter (1972). 
This method involves the radioiodination, by the chloramine-T method, of the N-hydroxy- 
succinimide ester of 3 (p-hydroxyphenyl) propionic acid (HPHS) (Fig. 12). The iodinated 
ester is then extracted into benzene and evaporated to dryness. The addition of an 
aqueous solution of the antigen to this residue results in an immediate condensation 
reaction whereby the iodinated acyl groups are linked to the antigen through a peptide bond.
This technique has been applied to the labelling of pheneturide using acylating agent 
kindly supplied by D r. Rildinger. Fig. 13 indicates the condensation reaction that is 
thought to have taken, place. Separation of the labelled pheneturide complex from other 
labelled products of the reaction, such as 3-(4-hydroxyphenyl) propionic acid was achieved 
by passing the mixture down a 40 cm Sephadex G10 column. The elution pattern of the 
label shows two distinct areas of radioactivity (Fig. 14). Chromatoelectrophoresis of 
samples from the peaks suggested that the material in the firs t peak might be immuno- 
reactive. Fractions from both peaks were incubated with antisera but failed to show any 
binding. Unfortunately no other labelled form of the drug is available and it is not clear 
whether the lack of binding of the iodine label was due to non-immunore activity of the label
or the absence of antibodies.
This method of labelling was also applied to the production of a different 
morphine label. Using normorphine, N-demethylated morphine, as the antigen 
linkage to HPHS was carried out as before resulting in a labelled .morphine complex.
On purification, again using Sephadex, this label showed sim ilar elution and chromato- 
electrophoretic patterns to those of the pheneturide label. Incubation of this label 
with two morphine antisera, raised against different morphine-BSA conjugates, failed 
to show any binding. Thus it can be assumed that the normorphine-HPHS complex was 
not immunoreactive.
In conclusion, it can be stated that, in our experience, radioiodine has not 
proved to be a suitable label for use in drug radioimmunoassays, whether introduced 
by direct iodination methods or by the use of iodination tags.
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Fig. 2. ' RADIOIODINATION TAGS
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Fig. 3. THC-Succinyl-GLAT Conjugate
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THE EFFECT OF BRIDGE LENGTH AND DEGREE OF DERI VAT I SAT I ON 
ON THE PRODUCTION OF ANTIBODIES TO MORPHINE
The Use of Rats in the Screening of Drug-Protein 
Conjugates for Immunoreactivity
J.D. Robinson, B eA. Morris-, E.M. Piall, G.W. Aherne, V
Division of Clinical Biochemistry, 
Department of Biochemistry,
University of Surrey, Guildford, Surrey.
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As Professor Marks has already mentioned in his introductory 
paper this morning (p. ) small molecules, such as drugs, are not
normally immunogenic. In order to make them so, it is necessary to 
conjugate them to large molecular weight carrier proteins. Some 
of the factors which might be expected to influence the immunogenicity 
of the conjugate, i.e. to increase the titre of the anti serum produced 
are: '
(a) the nature of the carrier protein used:
(b) the distance separating the hapten from its
carrier, and
(c) the average number of hapten molecules 
coupled to each carrier molecule, often 
referred to as "the degree of derivatisation".
The influence of the chemical nature of the carrier protein has 
not been studied critically, although bovine serum albumin (BSA) appears 
to be the protein most often used. There are reports, however, that 
BSA is only weakly immunogenic compared with haemocyanin (Steiner & 
Eisen, 1967) and ovalbumin (Mitchison, 1967).
The reason for considering that the length of the bridge 
between the hapten and its carrier may have some effect on the 
immunogen?city of the conjugate stems from the fact that Cuatrecasas 
(1970) has shown, in affinity chromatography, that spacer groups of 
4-6 carbon atoms are necessary for full ligand interaction. It could 
be argued that they might play a similar beneficial role in antiserum 
production byallowing the hapten to be more easily recognised by the 
circulating lymphocytes.
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With regard to the optimum number of hapten residues which one 
should aim to couple to a carrier molecule in order to obtain maximum 
immunogenicity, opinion is divided as to whether one should have as few 
or as many as possible. Some workers, among them Kantor, Ojeda & .
Benacerraf (1963) and Taylor & Iverson (1971) consider that the fewer 
the number of haptenic residues per mole of carrier the better, whilst 
both Spector (1973) and Hurn (197*0 have advocated a high degree of 
substitution. James & Jeffcoate (197*0 have stated that there is no 
evidence, with steroids at least, that the titre is dependent upon the 
degree of derivatisation, whilst Rubin (1972) has shown that once a 
minimal number of residues, have been conjugated to BSA, the inclusion 
of a higher number does not increase the titre. It was decided, 
therefore, to study the effect that the last two factors might have on 
the immunogenicity of drug conjugates.
To investigate and optimise all these variables properly would 
require the production of a large number of conjugates and the use of 
an even larger number of animals. Traditionally, rabbits and guinea- 
pigs have been used for this purpose, but due to the cost of their 
purchase, upkeep and the limitation on the space available in most 
animal houses, it was decided to investigate the feasibility of using 
rats for rapidly screening drug-protein conjugates to find the most 
immunogenic for injecting into larger animals.
One of the groups of compounds in which we are interested is 
the opiate alkaloids, in particular morphine and its congeners, heroin 
(diamorphine) and codeine (Fig.l)• The morphine molecule is 
essentially a phenanthrene derivative with a phenolic hydroxyl group
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at position 3, a secondary alcoholic hydroxyl group at position 6 and 
a methyl group attached to the cyclic nitrogen. Codeine is 3-methyl- 
morphine and heroin is 3,6-diacety1-morphine.
It is apparent from examination of these structures that the 
point of attachment of the drug to the carrier protein will determine 
the specificity of such antibodies that are produced. Codeine and 
heroin differ from morphine at the 3 position; therefore, to immunise 
with a conjugate of the drug attached to the protein through this 
position, as Spector & Parker (1970) initially did, will produce an 
antibody which reacts equally well with all three alkaloids.
In our own laboratory, it was found that an extremely immunogenic 
conjugate of morphine could be produced by coupling the drug to BSA 
through the 6-hydroxyl group. However, it has already been shown 
(Aherne, Piall, Robinson, Morris & Marks, 197*0 the antibodies produced 
to it unfortunately lacked the specificity that was required for our 
studies, in that they reacted almost as well with codeine and diamorphine 
as with morphine itself. It was, therefore, decided to conjugate 
morphine through the cyclic nitrogen atom in order to allow the two 
hydroxyl groups to exert their full antigenic effect.
Because there have been no previous reports of the successful 
use of rats for producing antibodies to morphine, the 6-succinyl morphine- 
BSA conjugate was used as a control since this compound proved to be 
extremely immunogenic in all rabbits, guinea pigs, goats and sheep into 
which it had been injected. -
2?8
-  II -
Preparation of conjugates
In view of the fact that the methyl group attached to the cyclic
nitrogen is fairly unreactive, it was decided to use normorphine as the 
(Morris, Robinson, Piall, Aherne & Marks, 197*0 
starting material.'; this compound is N-demethylated morphine (Fig.2).
The normorphine was conjugated directly to BSA using 1-ethyl-3-(3"
dimethylaminopropyl) carbodiimide hydrochloride (EDC) (Goodfrrend, Levine
& Fasman, 196*0. However, when injected into both goats and rabbits,
the conjugate was found to be only weakly immunogenic. Methods o f
improving its immunogenicity were then considered and the effect of the
factors ,already mentioned investigated.
The first part of this investigation was a study of the effect that 
the distance between the drug and the carrier protein had on the immuno- 
genicity of the conjugate, by using spacer groups of various lengths 
(Table 1). The following derivatives of normorphine were prepared:
N-succinyl-normorphine, N-adipyl-normorphine and N-sebacyl-normorphine by 
condensing succinic, adipic and sebacic acids respectively to the 
secondary amino group of normorphine using 1-cyclohexyl- 3 " (2-morpholinyl-
■v
(*»)-ethyl) carbodiimide metho-p-toluenesul phonate (Morpho CD I) (Goodfriend 
e £  aj_, 196*i), as shown in Fig.3. These were purified by gel filtration 
on Sephadex G-10. The fractions containing the N-derivatised normorphine 
were pooled and the normorphine equivalent concentration determined by U.V. 
spectroscopy. The appropriate amount of BSA was then added together with 
ethyl carbodiimide. After condensation was complete, the conjugate was 
purified by dialysis and then freeze-dried.
In addition, normorphine was also coupled to BSA using g 1u t a r a 1dehyde 
(Reichlin, Schnure & Vance, 1968; Abraham & Grover, 1971). This
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condensing agent is normally used to link two primary amino groups with 
a five carbon spacer group between them.
Immunisation Procedures
Groups of six Wistar~Albino rats, each of 100 g average weight, 
were immunised at weekly intervals for four weeks with the normorphine 
conjugates and 6-succinyl-morphine-BSA. They received subcutaneous 
injections into the forelimbs and intramuscular injections into the 
hind limbs. After a rest of two.weeks they were given a further two 
injections a week apart and bled out seven days later. Over the period 
of treatment each rat received a total of 270 yg of conjugate in almost 
equal amounts. Frequent immunisation with Freund's adjuvant at such 
short time intervals results in ulceration at the sites of injection.
For this reason we used an adjuvant consisting of Marcol 52 and Arlacel A 
in the ratio of 9:1, which we have shown does not produce ulceration 
'(Marks, Morris S Teale, 197**; Morris, in preparation). The aqueous 
solution of the conjugate was emulsified with two volumes of the 
adjuvant and 0.1 ml of this emulsion was injected per site. The primary 
injections also contained 3 mg of BCG vaccine per animal.
The serum from each animal at the end of the experiment was 
examined for the presence of antibodies to morphine at neat and a 1:5 
dilution. If the binding of the neat serum was >**Q%, the antiserum was 
examined further to determine its avidity and specificity.
Table 2 shows the number of rats in each group which produced 
antibodies to morphine. From it one can see that the N-succinyl 
normorphine conjugate is the most immunogenic followed by the conjugate
uwith the sebacyl spacer group,. In terms of the number of animals 
responding’, N-succinyl normorphine is as immunogenic as the control 
preparation, 6-succinyl-morphine-BSA. Although the conjugates 
contain different degrees of derivatisation, the variation is within 
the range that will not affect the result of this study.
However, if one examines the response of each animal to its 
conjugate in terms of its titre, measured by the X binding of the 
neat serum, as is shown in Fig.4-, it becomes immediately apparent that 
the 6-succinyl-morphine-BSA conjugate is more immunogenic than N- 
succinyl-normorphine-BSA. Although the conjugate with the sebacyl 
spacer group showed an overall response in five out of the six animals 
immunised, it is apparent from the histogram that only low titres were 
produced. The glutaraldehyde conjugate did not appear to be as 
immunogenic as that of normorphine linked direct to BSA.
Those antisera which exhibited a high enough binding of label 
were then compared in terms of their avidity and antibody concentration. 
As can be seen from Table 3, they are all more, or less comparable with 
the exception of the two antisera to the control preparation, £- 
succinyl-morphine-BSA, one of which was appreciably better and the 
other inferior to the antisera produced to the normorphine conjugates.
Fig.5 shows the specificity of one of the anti sera produced to 
the N~succinyl-normorphine-BSA conjugate. Whilst diamorphine c r o s s ­
reacted appreciably, codeine was completely unreactive, a feature which 
contrasts markedly with the goat antiserum to 6-succinyl-morphine-BSA, 
which has been described by Aherne ejt aj_ (197*0* This complete lack 
of cross-reactivity with codeine was shown by all four antisera to
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this conjugate which were examined in this way, and also by that to 
N-sebacyl-normorphine-BSA, suggesting that the length of the bridge 
does not appear to affect the specificity.
Effect of Degree of P e r ?vatisat ion
The second part of this investigation was a study of the effect 
that the degree of derivatisation had on the immunogenicity of the 
conjugate. It has already been shown (Morris, Robinson, Piall, Aherne 
& Marks, 197*0 that it is theoretically possible to conjugate 133 
haptenic residues to BSA if the amino group on the hapten is coupled 
to the free carboxyl groups on the albumin-molecule. In practice, we 
were able to couple an average of 90 residues of normorphine directly 
to BSA, if an excess of the drug was present in the reaction mixture.
By 1 imiting the quantity of normorphine present, it was possible, by 
the method already described, to produce a tseries of conjugates of 
normorphine to BSA having 5, 10, 20, ^0 and 90 residues/mole. These 
were then injected into rats, the quantities of immunogen and the 
immunisation schedule being the.same as that for the study of the 
effect of the spacer group.
At the end of the experiment, the animals were bled out and 
the sera screened for the presence of antibodies to morphine. As 
one can see from Table h t all the conjugates elicited antibody 
formation to a varying extent when expressed in terms of the total 
number of animals responding.
However, if the response is examined quantitatively as before, 
(Fig.6), i.e. by grouping the animals according to the percentage
282
binding by neat serum of the dihydromorphine label, it is apparent 
that the conjugate containing AO residues/mole was the most 
immunogenic - but only marginally - the overall response in terms 
of antibody production being very poor.
V/e therefore repeated this experiment, but this time utilising
the information we had obtained on spacer groups. A series of 
conjugates of N-succinyl-normorphine to BSA were prepared having 7,
1A, 28 and 50 haptenic residues/mole. These conjugates were injected 
into rats as before and the sera at the end of the experiment examined 
for the presence of antibodies to morphine.
Table 5 shows the total number of rats producing morphine
antibodies in each group. From this data it could be concluded that
between 1A and 50 residues/mole were optimal for eliciting antibody 
production. V/hen these results were expressed in the form of a 
histogram as before (Fig.7), it became apparent that conjugates 
containing between 1A and 28 N-succinyl-normorphine residues/mole BSA 
w e r e  the most successful in producing antibodies to morphine. It 
should be noted that antisera produced against the conjugate 
containing 7 residues/mole were as good as the best antisera produced 
against those containing 1A and 28 residues/mole, but the total 
response was not as good. It is also apparent from this histogram 
that over derivatisat ion can impair the immunogenicity of the conjugate, 
as is shown by the results for the conjugate containing 50:1 residues/ 
mole.
If the results of those animals showing a 5/6 or greater 
response with the normorphine-BSA conjugates are combined with those .
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showing a similar degree of response to the N-succinyl-normorphine 
conjugates (Fig.8), the beneficial effect of the succinyl spacer 
group on immunogenicity is very obvious.
Species Specificity
The N-succinyf-normorphine BSA conjugate having 28 residues/ 
mole was selected for immunisation into a sheep, and after boosting 
at monthly intervals with 1 mg of the conjugate, antibodies to 
morphine were obtained. The specificity of these antibodies was 
examined as before.
Fig.9 shows the specificity of the sheep anti serum to the same 
conjugate. Codeine does cross-react with the ovine antibody though 
only to the extent of 5% and diamorphine is even less cross-reactive 
than codeine. V/hether this is an individual or species variation is 
not yet known.
In conclusion, it has been shown that rats may be used for 
the rapid screening of drug-protein conjugates prior to their injection 
into larger species of animal. in the case of morphine, antibodies 
were detected within nine weeks. The insertion of a spacer group, 
in particular a succinyl, between the hapten and the carrier protein, 
enhanced the immunogenicity of the conjugate. The length of the 
spacer group did not appear to affect the specificity of the antiserum 
produced. The degree of derivatisat ion has also been shown to 
influence the immunogenicity of the hapten-carrier conjugate.
Between 1A and 28 residues per mole of carrier were found to be 
optimal for morphine. A higher degree of incorporation was found to 
impair the immunogenicity.
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Antisera raised in four rats against a N-succinyl-normorphine- 
BSA conjugate showed no cross-reactivity with codeine in each case, 
whereas diamorphine was almost as cross-reactive as morphine. When 
this conjugate was injected into a sheep, antibodies were produced 
which showed 5% cross-reactivity with codeine, diamorphine being even 
less cross-reactive than codeine. It is not known whether this is 
an individual or a species difference on account of the small number 
of animals involved.
We wish to.acknowledge-the generous financial support given 
by the Cilag-Chemie Stiftung fllr Therapeutische Forschung of 
Switzerland.
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Development of a Radioimmunoassay for Etorphine 
(Preliminary Communication)
J.D. Robinson, B.A. Morris and Vincent Marks
Department of Biochemistry - 
Division of Clinical Biochemistry,
University of Surrey, Guildford, Surrey, England..
ABSTRACT
A radioimmunoassay for etorphine has been developed using
antibodies raised in a rabbit against an etorphine-3~hemisuccinate-
bovine serum albumin conjugate. Using tritiated etorphine as the
label, the antiserum could be used at a final dilution of 1 :*l and had
-1an avidity of 1.8 x 109 L.M. i The sensitivity of the assay was
0.88 ± 0.0*1 ng etorphine per ml of serum and there was no cross­
reactivity with any of the six opiate alkaloids examined over the 
range 0-100 n g / m l . -
INTRODUCTION
Etorphine is one of the most potent analgesics described to 
date but also acts as a depressant on the respiratory centres of the 
brain. V/hen given sub-cutaneously etorphine is 1,000 to 80,000 times 
as potent as morphine, and its ability to cause catatonia at very low 
dose levels has resulted in its use for the immobilisation of game 
animals (King S Carter, 1965; Harthoorn, 1965; 1967).
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The drug is a clinically efficacious analgesic at doses of 1 yg/kg, 
having a-rapid onset and moderately short duration of action.
Etorphine, often in combination with other analgesics, was the 
preferred drug in eighteen out of thirty-two patients with intractable 
pain due to tumours (Blane & Robbie, 1970).
The low dose levels at which etorphine is used demands a 
sensitive measurement technique if blood level determinations are to 
be made for studies on its pharmacokinetics and metabolism. Radio­
immunoassay is both sensitive and specific enough to meet this 
requirement and eliminates the need for complex extraction procedures. 
This paper describes the development of a radioimmunoassay for etorphine 
suitable for clinical application and capable of detecting as little as 
1 ng etorphine per ml of serum.
M E T H O D
1. Production of immunogen
Etorphine is a small molecule (molecular weight bbS) and is
"V
not naturally immunogenic. It can be made so by covalent linkage to 
a carrier molecule. An immunogenic conjugate of etorphine to bovine 
serum albumin (BSA) was prepared using the 3 ”hemisuccinate derivative 
of etorphine. This intermediate was made by refluxing, for four 
hours, three equivalents of succinic anhydride with one equivalent of 
etorphine in pyridine. The pyridine was then evaporated under reduced 
pressure and the residue washed with hot ethanol. The resulting
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etorphine~3~hemisuccinate was recrystal 1 ised from hot 60% ethanol 
.before characterisation by U.V. and I.R. analysis.
The etorphine-3-hemi succinate was coupled to BSA using 1- 
ethyl-3”diisopropylamino-carbodiimide HC1 (EDC) as the conjugating 
agent (Erlanger, 1973)* The resulting etorphine-3-hemisuccinate-BSA 
was purified by a dialysis against two changes (1 L each) of d em in e ra l ­
ised water. Since no free etorphine-3“hemisuccinate was found in the 
dialysates it was assumed that it had all been conjugated to the BSA. 
This suggests that each mole of BSA bound 16 moles of e to rphine-3“ 
hemisuccinate.
2. Immunisation techniques
One female Dutch rabbit (A) was immunised with 1 mg etorphine- 
3“hemisuccinate-BSA in 0.5 ml demineralised water - emulsified with 
1.0 ml adjuvant consisting of Marcol 5 2 ^  with 10% Arlacel A ^ ,  and 
3 mg BCG vaccine. The emulsion was administered by intramuscular 
injection to the fore and hind limbs.
A second female Dutch rabbit (B) was similarly treated but 
received only 100 yg conjugate in the same volume of emulsion.
After three months each animal was given a booster of similar 
composition to the initial injection except that BCG was excluded.
^ M a r c o l  52 (Esso Petroleum Co. Ltd.)
(2)Arlacel A (Hilltop Research Inc., Ohio)
Second and third booster injections were given one month and four months 
•later. Venous blood samples were collected seven days after each 
booster injection.
3* Assay Procedure
Tritiated etorphine (specific activity 2.23 yCi/mmole, purity 
>98% by thin-layer chromatography) was used to screen the sera for a n t i ­
bodies. k p mole of labelled etorphine was incubated for one hour with 
each antiserum. All dilutions were made with 0.05M phosphate buffer 
pH 7 . k .  After incubation dextran-coated charcoal (DCC) was added to 
separate the free and antibody-bound fractions. Following centrifugation, 
aliquots of the supernatant containing the antibody-bound tracer were 
taken for liquid scintillation counting (Table 1).
TABLE 1 
Assay Protocol
"Total" "Non-Specific Bind i ng"
Ant i serum 
Dilution 
Curve
Standard
Curve
Buffer 0.2 0.2 0.1 0.1
Standard/ 
Norma] Serum 0.1 0.1 0.1 0.1
Ant i serum - - • 0.1 0.1
3H-Etorp'ni ne 0.1 0.1 0.1 0.1
DCC - 0.2 0.2 0.2
Buffer 0.2 - - -
A1i quot for 
Count i ng 0.2 0.2 0.2 0.2
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The values refer to reagent volumes in ml. All dilutions were made 
with phosphate buffer. The 3H-ethorphine was stored in ethanol and an 
aliquot diluted with buffer before use. The dextran-coated charcoal 
(DCC) contained 2.5% Nor it A charcoal with 0.25% Dextran T 70 in buffer.
Serum from rabbit A  collected after the second booster 
injection was used to measure the decrease in tracer binding produced 
by increasing amounts of unlabelled etorphine. For this a stock 
solution of 100 ng etorphine per ml was double diluted to give a series 
of standard solutions. Aliquots of the standards were incubated with 
the anti serum and the label in buffer as above to give a standard curve.
The cross-reactivity of the antiserum with opiate alkaloids 
was checked by incubating the anti serum wi th increasing amounts of the 
opiates as for the standard curve.
RES U L T S
Table 2 shows the degree of binding of the 3H-etorphine 
exhibited by serum collected after each booster injection from rabbit A. 
The results are expressed as the percentage of tracer present in the anti- 
body-bound fraction (% bound) after correction for non-specific binding.
TABLE 2
The degree of binding of 3H~etorphine of a 1:4 final dilution of a n t i ­
serum taken after booster injections
No. of Boost % Bound Counts
1 32.8
2 48.9
3 75.9
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A standard curve obtained using an etorphine antiserum 
collected after the second booster injection is shown in Fig.1.
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FIG.1: Inhibition of tracer a n t i b o d y 'binding by the addition
of increasing amounts of etorphine to the assay system
Similar standard curves (not shown) were obtained when the etorphine was 
dissolved in neat human serum, indicating the-applicability of the assay 
to the clinical situation.
- Scatchard plots based on the results of standard curves gave 
an avidity for the antiserum of 1.8 x 109 L.M. 1 . The sensitivity of
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the assay, calculated by the method of Albano and Ekins (1970) is
0.88 ± 0.04 ng etorphine per ml.
The cross-reactivity of the antiserum with opiate alkaloids 
is negligible and is summarised, in Table 3, cross-reactivity with other
oripavine derivatives has still to be examined.
TABLE 3 
Cross-Reactivity Studies
% Bound Concent rat i on ng/ml
Counts 0. 00 1 .57 3 .14 6. 25 12. 50 25..00 50. 00 100. 00
Etorph i ne 66. 00 58 .60 54,.09- 47. 77 40. 35 35.-75 26. 72 22. 15
Morph i ne 66. 00 57 .00 56,.74 62. 33 58. 95 60..26 62. 15 59. 33
Codei ne 66. 00 61 .43 64 .31 63. 52 59. 53 65..30 63. 11 72. 08
Nalorphine 66. 00 77 ,70 59 .91 63. 58 56. 54 57..44 58. 17 61. 60
Diamorph i ne 66. 00 66 .84 54,.73 69. 20 63. 78 64..69 68. 75 70. 54
Normorph i ne 66. 00 60 .44 68 .82 67. 39 61. 48 63..11 65. 09 65. 21
Morph i ne~3“ 
G1ucuroni de 66. 00 59 .36 62 .45 66. 78 62. 39 62..33 63. 06 71. 44
D I S C U S S I O N
Until the development of this radioimmunoassay no method 
for measuring etorphine in biological fluids was available. Full 
experimental details including data on the specificity, precision, 
reproducibility and the results of studies on etorphine blood levels 
will be reported in a later publication.
Of the two rabbits immunised only the one receiving the 
larger dose of 1 mg etorphine-3“ hemisuccinate-BSA produced usable
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antiserum. This enabled a radioimmunoassay to be developed which was spec­
ific for etorphine when tested against other commonly used opiate alkaloids.
The low titre at which the antiserum must be used is not 
uncommon. Other investigations have reported low titre high avidity 
radioimmunoassays for drugs (Tigelaar, R.E. 1973; Spector, S. and
Parker, C.Wi, 1970), this contrasts with the high titre anti sera usually 
obtained against polypeptide hormones.
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Radiolnnnurioassay3 are being developed for two of the more
4 .
commonly prescribed anticonvulsant drugs, sulthlame and phenytoln.
The drugs, having low molecular weights, are not themselves naturally 
Immunogenic and one of the problems encountered in this w o r k  has been 
the production of specific antibodies against the compounds. This has 
been overcome by coupling the drugs as haptens to the carrier protein 
bovine serum albumin. Several conjugates have been produced using 
carbodiImides as the coupling agent and these have been Injected into 
various animals for the production of antisera,
A  further requirement for the development of a radioimmunoassay 
Is the availability of a radloactIvely labelled form of the drugs 
having a high specific activity. Unfortunately such labeis are not 
commercially available for sulthlame and phenytoln, although a low 
specific activity carbon-lA labelled phenytoln is prepared by the 
Radiochemical Centre. In the case of sulthlame a label has been 
produced by conjugation of the drug to the lodination n tag“ tyrosine 
methyl ester using the same techniques as were used to couple the drug 
to Its carrier protein. The resulting complex has been radiolodinated 
by the chloramlr.e-T method and the label checked for reactivity with 
serum samples from Immunised animals. This has enabled the presence of 
antibodies to be demonstrated but presents a further problem in that 
onee bound to the ant I serum the label cannot be displaced w i t h  cold 
sulthlame. Work is now In progress to overcome this problem,
* Not members of the Society for Endocrinology
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A  high specific activity 6rltlurn-labelled phenytoln hss been 
provided by Or* Kepler, of the Research Triangle Institute In North 
Caroline, who prepared the label by reductive trltlation of the 
dl-bromo salt of phenytoln. Using this label antibodies have been 
produced that can bo used at a final dilution of 1:2000. Scatchard 
plots, constructed from standard curves with this anti serum show the 
avidity constant to be 1.25 x 10*® and the assay to be capable
of detecting approximately 750 ng. L.~* phenytoln. Twelve other a nt i ­
convulsant drugs having a chemical structure resembling that of 
phenytoln have been screened for cross-resetivIty and found not to 
Interfere with the assay. Similarly the cross-reactlv!ty with the 
p-hydroxy metabolite of phenytoln has been found to be less than 1%.
A  comparison of the radioimmunoassay with the currently used GLC 
method Indicates a good correlation between the two assays as shown 
by the Students paired n tn test, and shows no significant difference 
between the results.
The radioimmunoassay has recently been used in a study of the
%
pharmacokinetics of a single oral dose of phenytoln in five normal 
subjects. The results of this experiment Indicate that two points of 
maximum concentration occur at three and ten hours after admlnistratIon 
The overall half-life of the drug appears to he 9.75 hrs. The results 
from this study will be presented at* the meeting.
The development of a radioimmunoassay for inorphj.no 
having ininiinal cross-reactivity with codeine
by B.A. MORRIS, J.D. ROBINSON, EVELYN PIALL, G. WYNNE AHERNE $ V. MARKS 
Department of Biochemistry, University of Surrey, Guildford, Surrey.
Morphine was the first non-steroid drug for which'a radioimmuno­
assay (RIA) was developed (Spector § Parker, 1970). The antiserum was 
raised in rabbits to a 3-carboxymethylmorphine-bovine serum albumin 
(BSA) conjugate. However it reacted equally well with morphine and 
its related analogues, heroin (diacetylmorphine), codeine (methylmorphine) 
and normorphine. This lack of specificity also occurred with an anti­
serum to 6-succinyl-morphine-BSA, the conjugate prepared independently
ef
by Simon, Dole § Hiller (1972) and Wainer et_ al_ (1972). Spector A(1973) 
reported an antiserum raised against 2-(p-aminophenylazo)-morphine-BSA 
which allowed all three side chains on the morphine molecule to act as 
antigenic determinants. However, its cross-reactivity with codeine was 
still 83.3%, probably due to the shielding of the 3-hydroxyl by the 
aminophenylazo bridge.
In developing a RIA for morphine for use in clinical and pharma­
cological studies, it was necessary to produce an antiserum that would 
not react with either its principal metabolite, morphine-3-glucuronide, 
or with codeine, particularly in view of the recent report by BUrner § 
Abbott (1973) that, in man, morphine may undergo 3-0-methylation to 
codeine.
It was therefore decided to conjugate morphine to carrier through 
its heterocyclic nitrogen, thus allowing the two hydroxyl groups (at 
positions 3 and 6) to exert their maximum effect as antigenic determinants. 
On account of the low reactivity of the N-methyl group in morphine, nor- 
morphinc was chosen as the hapten for conjugation to BSA.
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Although Erlangcr (1973) listed all the aminoacid residues■on 
BSA that can be used for conjugation purposes, no mention was made 
of the 133 free carboxyl groups on the 52 aspartic and 81 glutamic 
acid residues (Schultze fT Heremans, 1966). Normorphine was conjugated 
through the secondary amine directly to the carboxyl groups on BSA 
using l-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) 
(Goodfriend, Levine Fasman, 1964). It is thought that this is the 
first time that the carboxylic acid groups on.BSA have been used for 
this purpose. Antisera to this conjugate were raised in rabbits.
Using a high specific activity, tritiated dihydromorphine label 
(Radiochemical Centre Ltd, Amersham, Code no. TRK 450) a standard curve 
for morphine was obtained using antiserum G/R/18. The cross-reactivity 
with heroin was 87.5% while'that of codeine was only 5.5%. Despite 
the fact that the antiserum was raised a normorphine-BSA conjugate, 
normorphine itself showed- negligible cross-reactivity with the anti­
body.
The principal disadvantage of this antiserum was its low titre. 
This was increased by inserting a spacer group between the hapten and 
the carrier protein. N-succinyl-normorphine was prepared from nor­
morphine and succinic acid using l-cyclohexyl-3-(2-morpholinoethyl) 
carbodiimide meta-p-toluenesulphonate, and after purification on 
Scphadex G-10, was conjugated to BSA using EDC. Both rabbits and 
sheep were immunised with this conjugate. The sheep antiserum, G/S/134, 
had the same cross-reactivity with codeine (4.8%) as G/R/18, while the 
cross-reactivity with heroin was only 2.3%. Normorphine, however, was 
12.8% cross-reactive and morphinc-3-glucuronide < 0.1%. The avidity 
of this antiscrum for morphine was 3.99 x 109 litres/mole.
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When this N-succinylnormorphine-BSA conjugate was injected 
into rats, antibodies to morphine, showing no cross-reactivity with 
codeine, were produced in four of the six animals immunised.
The authors gratefully acknowledge financial assistance from 
the Cilag Chemie Stiftung flir Therapeutische Forschung of Switzerland.
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TWO APPLICATIONS OF A RADIOIMMUNOASSAY FOR
MORPHINE
G. Wynne Aherne, Evelyn M. Piall, J. D. Robinson, B. A. Morris 
and V. Marks, Department of Biochemistry, University of Surrey, 
Guildford, Surrey.
Morphine is probably one of the earliest drugs known to man.
It is a powerful analgaesic narcotic and is addictive. Morphine 
is essentially a phenanthrene derivative (Fig. 1) with a phenolic 
hydroxyl group at position 3, an alcoholic hydroxyl group at 
position 6 and a methyl group attached to the cyclic nitrogen.
Another opiate alkaloid is codeine, which differs frcm morphine 
in that it has an O-methyl group at position 3 i.e. it is methyl 
morphine. Heroin (Diamorphine) has acetyl groups at position 3 and 
6.
The metabolism of these three drugs is closely related 
(Fig. 2). Morphine is metabolised by i) conjugation with ^glucuronic 
acid to form the major metabolite, morphine-3-glucuronide, Which is 
excreted in the urine, ii) by N-demethylaticn to form normorphine 
and iii) by O-methylation to codeine (Bomer and Abbott, 1973).
Heroin is successively deacetylated first to monoacetylmorphine then 
to morphine. Codeine is metabolized by i) conjugation with glucuronic 
acid ii) by N-demethylation to norcodeine and iii) about 10% by 
O-demethylation to morphine.
Sensitive assay techniques for these drugs are required' for
detailed metabolic studies, for monitoring drug levels during treatment
as well as for screening for drug abuse. For the latter, it is
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essential that the method is absolutely specific for the drug in 
question. This communication describes the development of a 
radioimmunoassay for morphine and two applications of that assay.
The first radioimmunoassay for morphine was described in 
1970 by Spector and Parker. Various other immunoassays have 
followed using such techniques as enzyme labelling (Rubenstein 
et al, 1972), spin labelling (Leute et al., 1972), and haemagglutination 
inhibition (Adler and Liu, 1971). All these methods depend on the 
presence of a suitable anitserum to morphine. Morphine, though not 
normally immunogenic can be made so by coupling it to a carrier protein 
i.e. it acts as an hapten.
Spector and Parker produced the 3-carboxymethyl derivative 
which is carboxy codeine. It is hardly surprising that the antibody 
to this derivative coupled to bovine serum albumin does not distinguish 
between morphine, codeine and heroin. So that the 3 position could 
remain free to act as an antigenic determinant Simon, bole & Hiller 
and Wainer and his colleagues independantly in 1972 produced 6~succinyl 
morphine. However, there was considerable cross reactivity with 
morphine, heroin, codeine and wTith irorphine-3-glucuronide. Spector et al 
(1973) attempted to leave all three side chains free and synthesised 
the 2-para-aminophenyl azo derivative by utilising the active hydrogen 
at position 2. The high cross reactivity of the antibody with morphine , 
codeine and heroin is probably explained by the fact that the amino- 
phenyl azo side chain may be shielding the 3-hydroxy group from 
recognition as a determinant. The cyclic N position has also been used 
for conjugation purposes (Morris et al., 1974).
- 3 -
6-succinyl morphine was prepared by refluxing morphine with 
excess succinic anhydride in benzene (Simon et al., 1972) and 
conjugated to BSA using the water soluble carbodiimide l-ethyl-3- 
(3-dime thy laminopropyl) carbodiimide hydrochloride (EDC). The 
conjugate was purified by dialysis and the concentration of 
free 6-succinyl morphine determined spectrophotcnetrically at 
285 nm. The iirraunogen had an average 30 residues of morphine per 
BSA molecule and was found to be immunogenic in rats, guinea pigs, 
rabbits, goats and sheep. However, the goat antiserum proved to be 
the most suitable for developmental work as it could be used at 
high dilutions and was available in large quantities.
Fig. 3 shews the protocol which has been developed for both 
antiserum dilution curves and for assays. 0.05 M phosphate 
buffer pH 7.4 is used as the basis of the buffers. Originally, 
fibrinogen-free plasma was diluted six times for the assay buffer. 
Because of the inconsistency of this material, phosphate buffer 
containing 0.5 g/100 ml BSA and 0.6g/10Cml NaCl has been selected as the 
assay buffer. This change meant that a lower dilution of antiserum 
had to be used probably because certain antibodies recognising both 
BSA and morphine would be adsorbed by the addition of BSA.
However, the average affinity constant as determined by Scatchard
9plots (Scatchard, 1949) was not altered considerably being 3.30 x 10 L/M 
in diluted plasma at a final antiserum dilution of 1:540 compared with 
2.04 x 109 L/M at a dilution of 1:360 in BSA buffer. The sensitivity of 
the assay was not altered either. Both standard dilutions and sample 
dilutions were made in 4 g/100 ml BSA and 0.6 g/100 ml NaCl in 
phosphate buffer.
3 ta
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Assay tubes were set up with the volumes shown depending 
on whether an antiserum dilution curve or a standard curve was 
being setup. Tritiated [l,7,8 (n)-3H] dihydrcmorphine (DHMorphine) 
of specific activity 74 Ci/nmole obtained frcm the Radiochemical 
Centre (Code No TEK 450) was used as the label. lOyl of an 
ethanolic dilution equivalent to 0.5 pnole DHMorphine was added to 
each tube, the tubes mixed. After one hour*s incubation phase 
separation was achieved using dextran coated charcoal at 4°C.
After centrifugation, 200yl aliquots of supernatant were taken for 
liquid scintillation counting. The non specific binding to buffer 
constituents is less than 4% of total amount of activity present.
A suitable antiserum dilution for use in standard curves is 
calculated from the antiserum dilution curves and is that dilution 
which binds 50% total label present.
The results for a standard curve (Fig. 4) are expressed as a
percentage of the maximum label bound in the presence of excess
anitbody. The antiserum for this curve was of a later date and
could be used at a final dilution of 1:6000. The. average affinity
9
constant was 9 x 10 L/M and the concentration of antibody binding 
sites 5.2 x 10 M/L - these figures being obtained frcm a 
Scatchard plot of the data. Sensitivity was 300 pg/ml and was 
calculated by the slope of the dose response curve at zero divided 
by the standard deviation at zero (Albano & Ekins, 1970).
The specificity of the antisera was investigated with structurally 
related compounds and with other commonly used drugs. An antiserum 
(G/R/6) raised in a Dutch rabbit, cross reacted almost equally with
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morphine, codeine and heroin (Fig. 5). Morphine arid heroin cross 
react so closely that only one curve has been drawn for clarity.
Cross reactivity of this antiserum with morphine-3-glucuronide i.s 
50% calculated on the basis of the ratio of the amounts of morphine 
and morphine-3-glucuronide required to inhibit the binding of label 
by 50%. The goat antiserum (G/G/l) cross-reacts almost equally with 
morphine, codeine and heroin (Fig. 6). Monoacetyl morphine although 
not shown also cross reacts to the same extent as morphine in both 
antisera. Because of this high cross reactivity with closely 
related drugs results can only be expressed as "morphine equivalents".
In contrast with the antiserum G/R/6, only 10% morphine-3- 
glucuronide is recognised by the antiserum G/G/l. Normorphine does not 
react with this antiserum. Other drugs tested have all failed to cross 
react with the antiserum and include salicylate, methadone, naloxone, 
arrphetamine sulphate, phenobarbitone, phenytoin, tetracycline, 
tetrahydrocannabinol, lignocaine hydrochloride, sulthiame, nicotine 
hydrogen tartrate, promazine hydrochloride, ephydrine and 
amitrypty line.
Morphine and Diamorphine are used in the treatment of pain in 
terminal cancer patients and work is being undertaken by 
Dr. R. G. Twycross at St. Christopher's Hospice, London to examine 
the comparative effectiveness of these drugs in these patients.
The radioimmunoassay has been used to measure morphine levels in 
60 such patients. The drug is given orally five or six times daily 
in doses dependent upon each individual and varies between- 5 mg and 
60 mg per dose.
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Fig. 7 shows the results obtained with seven patients talcing 
oral morphine or diamorphine, all samples except patient M.G. being 
taken just prior to the 9 a.m. dose. The sample frcm patient 
M.G. was taken following the 9 a.m. dose. These results indicate 
that free drug is present in the blood 4 hours after oral administration. 
Morphine levels measured with the rabbit antiserum are frcm 3-6 times 
higher than those measured with the goat antiserum demonstrating the 
presence of large amounts of morphine-3-glucuronide.
This data is currently being correlated with the clinical effectiveness 
of the two drugs-and it is proposed to measure morphine levels in serial 
samples from selected patients receiving oral doses of morphine and 
diamorphine.
Because of the close, cross reactivity of the antiserum to both 
morphine and codeine it is possible to measure codeine if - codeine 
standards are used and the results are expressed as codeine equivalents.
The Radiochemical Centre now produce [l(n)-3H] codeine, specific 
activity 22 Ci/mmole (Code No. TRK 448) and it was hoped to use this as 
a labelled tracer. N .
Two codeine standard curves are shown in Fig. 8 one obtained with 
3H-DHMorphine and the other with 3H-codeine. Because of the lower 
specific activity of the codeine preparation 1.0 pmole/tube as 
opposed to 0.5 pmole/tube of DHMorphine was added. Despite this the 
titre of the antiserum for the codeine label was twice that for the 
morphine label. During the course of some weeks it was found necessary 
to progressively decrease the titre of the antiserum because of the 
low percentage bindings that were being attained. Thin layer 
chromatography of the stock label solution which had been stored in
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liquid nitrogen did not shew any deterioration of the label.
The average affinity for the codeine label was 1.27 x 109 L/M, 
four times less than that for morphine and the concentration of 
antibody sites was 6.7 x lcf10 M/L. The sensitivity of the assay 
using 3H-codeine was only 820 pg compared with 300 pg with 3H- 
DHMorphine. Because of the higher sensitivity obtainable with 
labelled morphine it was decided to continue using it for codeine 
studies.
Codeine is a milder analgaesic than morphine and is often 
taken with other drugs such as aspirin. Although widely used 
little is known of its pharmacokinetics in man.
Two 'Codis' tablets, each tablet consisting of 500.mg salicylate 
and 8 mg codeine phosphate equivalent to 5 mg codeine, were taken by 
4 normal healthy volunteers. Various blood samples were taken at 
intervals over 24 hours. The subjects ate light breakfasts 1 hour 
before the zero hour. The serum was assayed for codeine, expressed 
as codeine equivalents - the samples from each subject being assayed 
in the same assay. Various dilutions for each sample were prepared 
in triplicate.
The codeine disappearance curves for the four subjects (Fig. 9) 
were very similar in shape although not identical and probably reflect 
individual variations in absorption and metabolism. No codeine was 
detected at 24 hours.
The time taken to reach peak plasma concentration (Fig. 10) 
varied from 1.0 to 3.0 hours with a mean value of 2.1 hours. The
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half life of codeine was estimated from a' log-linear plot of 
the results after the peak concentration and varies from 1.9 to 
3.0 hours. These figures are similar to ones quoted in the literature 
for animal studies (Woods et al 1956) but no reference could be found 
for figures for man. The total plasma clearance was calculated by 
dividing the dose in yg/kg by the area under the curve.
The plasma salicylate concentration was measured using Trinderf s 
reagent (Trinder, 1954). The example (Fig 11 ) shows the salicylate 
levels in one subject and these closely follow the codeine disappearance 
curve.
The relative concentrations of salicylate and codeine are the same 
as in the original dose. It is proposed to conduct further- experiments 
to compare the metabolism of these two drugs and to establish the 
efficacy of various preparations of codeine.
In conclusion, a radioimmunoassay for morphine has been developed 
using an antiserum raised against 6-succinyl morphine. The assay has 
been applied to the measurement of morphine levels in patients receiving 
oral administration of narcotic analgaesics - free morphine being 
present 4 hours after the last dose. The assay has been used in a 
preliminary study to measure codeine blood levels in normal subjects 
after a single oral dose of "Codis".
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